Amedeo Smart

Free Medical Literature Service


 

Amedeo

COVID-19

  Free Subscription

Articles published in
J Med Virol
    September 2022
  1. GUNELL M, Rantasarkka K, Arjonen R, Sanden A, et al
    Clinical evaluation of an automated, rapid mariPOC(R) antigen test in screening of symptomatics and asymptomatics for SARS-CoV-2 infection.
    J Med Virol. 2022 Sep 30. doi: 10.1002/jmv.28189.
    >> Share

  2. YEO YH, Wang M, He X, Lv F, et al
    Excess risk for acute myocardial infarction mortality during the COVID-19 pandemic.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28187.
    >> Share

  3. SRIRAMAN K, Shaikh A, Vaswani S, Mestry T, et al
    Impact of COVID-19 vaccination on transmission risk of breakthrough infections: Lessons from Adapted N95 Mask Sampling for Emerging Variants and Interventions.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28188.
    >> Share

  4. NAGASAWA M, Kato T, Yamaguchi Y, Sugita Y, et al
    Rapid decrease of nasopharyngeal SARS-Co-V2 antigen in an outbreak of the Omicron strain.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28179.
    >> Share

  5. YANG J, Song H, Hao X
    Whole-transcriptome sequencing data reveals a disparate cognitive and immune signature in COVID-19 patients with and without dementia.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28177.
    >> Share

  6. SU J, Shen S, Hu Y, Chen S, et al
    SARS-CoV-2 ORF3a inhibits cGAS-STING-mediated autophagy flux and antiviral function.
    J Med Virol. 2022 Sep 26. doi: 10.1002/jmv.28175.
    >> Share

  7. ZHOU J, Liu Z, Zhang G, Xu W, et al
    Development of variant-proof SARS-CoV-2, pan-sarbecovirus and pan-beta-coronavirus vaccines.
    J Med Virol. 2022 Sep 25. doi: 10.1002/jmv.28172.
    >> Share

  8. HANAFUSA M, Nawa N, Goto Y, Kawahara T, et al
    Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: a hospital-based observational study.
    J Med Virol. 2022 Sep 23. doi: 10.1002/jmv.28168.
    >> Share

  9. MESSALI S, Bugatti A, Filippini F, Caruso A, et al
    Emergence of S gene-based quasispecies explains an optimal adaptation of Omicron BA.5 subvariant in the immunocompetent vaccinated human host.
    J Med Virol. 2022 Sep 22. doi: 10.1002/jmv.28167.
    >> Share

  10. SILVA MFS, Pinto ACMD, Oliveira FCE, Caetano LF, et al
    Antibody response six months after the booster dose of Pfizer in previous recipients of CoronaVac.
    J Med Virol. 2022 Sep 22. doi: 10.1002/jmv.28169.
    >> Share

  11. FAVRESSE J, Gillot C, Bayart JL, David C, et al
    Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster.
    J Med Virol. 2022 Sep 21. doi: 10.1002/jmv.28164.
    >> Share

  12. DURAND GA, Amroun A, Grard G, Badaut C, et al
    Positive SARS-CoV-2 RT-qPCR of a nasal swab spot after 30 days of conservation on filter paper at room temperature.
    J Med Virol. 2022 Sep 21. doi: 10.1002/jmv.28165.
    >> Share

  13. VEGA-RODRIGUEZ W, Ly H
    GETTING AHEAD OF MONKEYPOX: Learning from the COVID-19 pandemic experience to prevent the potentially new monkeypox pandemic.
    J Med Virol. 2022 Sep 21. doi: 10.1002/jmv.28146.
    >> Share

  14. KONG W, Zhong Q, Chen M, Yu P, et al
    Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.
    J Med Virol. 2022 Sep 20. doi: 10.1002/jmv.28163.
    >> Share

  15. KRISHNAMOORTHY S, Li GH, Cheung CL
    Transcriptome-wide Summary Data based Mendelian Randomization analysis reveals 38 novel genes associating with Severe COVID-19.
    J Med Virol. 2022 Sep 20. doi: 10.1002/jmv.28162.
    >> Share

  16. TAN Y, Lu S, Wang B, Duan X, et al
    Single-cell transcriptome atlas reveals protective characteristics of COVID-19 mRNA vaccine.
    J Med Virol. 2022 Sep 19. doi: 10.1002/jmv.28161.
    >> Share

  17. QIU X, Liu Y, Sha A
    SARS-CoV-2 and Natural Infection in Animals.
    J Med Virol. 2022 Sep 19. doi: 10.1002/jmv.28147.
    >> Share

  18. BOYTZ R, Slabicki M, Ramaswamy S, Patten JJ, et al
    Anti-SARS-CoV-2 Activity of Targeted Kinase Inhibitors: Repurposing Clinically Available Drugs for COVID-19 Therapy.
    J Med Virol. 2022 Sep 18. doi: 10.1002/jmv.28157.
    >> Share

  19. CECCARELLI G, d'Ettorre G, Russo A, Fabris S, et al
    SARS-CoV-2 pandemic, influenza, and influenza-like illness epidemics: Allies or enemies?
    J Med Virol. 2022 Sep 17. doi: 10.1002/jmv.28148.
    >> Share

  20. DESINGU PA, Nagarajan K
    Unveiling HERV-K113-ENV as SARS-CoV-2 severity admissible biomarker by mining transcriptome data.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28149.
    >> Share

  21. LI Z, Yong H, Wang W, Gao Y, et al
    GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2-R671 di-methylation.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28158.
    >> Share

  22. CENAT JM, Noorishad PG, Moshirian Farahi SMM, Darius WP, et al
    COVID-19 Vaccine Hesitancy and Related Factors in Canada: A Systematic Review and Meta-analysis.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28156.
    >> Share

  23. LI XK, Tu B, Zhang XA, Xu W, et al
    Dysregulation of glutamine/glutamate metabolism in COVID-19 patients: a metabolism study in African population and mini meta-analysis.
    J Med Virol. 2022 Sep 16. doi: 10.1002/jmv.28150.
    >> Share

  24. KLOPFENSTEIN T, Gendrin V, Zayet S
    "Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: The ANOSVID study": Author's reply.
    J Med Virol. 2022 Sep 15. doi: 10.1002/jmv.28151.
    >> Share

  25. LAN Q, Wang L, Jiao F, Lu L, et al
    Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.
    J Med Virol. 2022 Sep 13. doi: 10.1002/jmv.28143.
    >> Share

  26. CALABRETTO M, D'Alisa R, Faraone S, Mazzuti L, et al
    DETECTION OF SARS-COV-2 RNA AND ANTIBODIES IN BREAST MILK OF INFECTED MOTHERS.
    J Med Virol. 2022 Sep 13. doi: 10.1002/jmv.28142.
    >> Share

  27. FRYE CJ, Shine M, Makowski JA, Kensinger AH, et al
    Bioinformatics Analysis of the s2m Mutations within the SARS-CoV-2 Omicron Lineages.
    J Med Virol. 2022 Sep 13. doi: 10.1002/jmv.28141.
    >> Share

  28. ZHOU Y, Zhi H, Teng Y
    The outbreak of SARS-CoV-2 Omicron lineages, immune escape and vaccine effectivity.
    J Med Virol. 2022 Sep 12. doi: 10.1002/jmv.28138.
    >> Share

  29. LIANG LG, Zhu MJ, He R, Shi DR, et al
    Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, Influenza A and B.
    J Med Virol. 2022 Sep 11. doi: 10.1002/jmv.28139.
    >> Share

  30. QUEROMES G, Frobert E, Bouscambert-Duchamp M, Oblette A, et al
    Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: the example of SARS-CoV-2 and monkeypox virus.
    J Med Virol. 2022 Sep 11. doi: 10.1002/jmv.28126.
    >> Share

  31. JIANG W, Johnson D, Adekunle R, Heather H, et al
    COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity.
    J Med Virol. 2022 Sep 10. doi: 10.1002/jmv.28134.
    >> Share

  32. LI Y, Yang J, Shen S, Wang W, et al
    SARS-CoV-2-encoded Inhibitors of Human LINE-1 Retrotransposition.
    J Med Virol. 2022 Sep 9. doi: 10.1002/jmv.28135.
    >> Share

  33. MARCHI L, Vidiri A, Fera EA, Pallottini M, et al
    SARS-CoV-2 IgG "heritage" in newborn: a credit of maternal natural infection.
    J Med Virol. 2022 Sep 7. doi: 10.1002/jmv.28133.
    >> Share

  34. CELIK E, Ozcan G, Vatansever C, Paerhati E, et al
    Alterations in Vaginal Microbiota among Pregnant Women with COVID-19.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28132.
    >> Share

  35. RZYMSKI P, Kasianchuk N, Sikora D, Poniedzialek B, et al
    COVID-19 Vaccinations and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28131.
    >> Share

  36. FAIZO AA, Qashqari FS, El-Kafrawy SA, Barasheed O, et al
    A Potential Association between Obesity and Reduced Effectiveness of COVID-19 Vaccine-Induced Neutralizing Humoral Immunity.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28130.
    >> Share

  37. ABDALLA M, El-Arabey AA, Gai Z
    Hypertension is still a moving target in the context of COVID-19 and post-acute COVID-19 syndrome.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28128.
    >> Share

  38. AKASH S, Rahman MM, Islam MR, Sharma R, et al
    Emerging global concern of Langya Henipavirus: Pathogenicity, Virulence, Genomic features, and Future perspectives.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28127.
    >> Share

  39. SCARPA F, Sanna D, Azzena I, Giovanetti M, et al
    On the SARS-CoV-2 BA.2.75 variant: a genetic and structural point of view.
    J Med Virol. 2022 Sep 4. doi: 10.1002/jmv.28119.
    >> Share

  40. NICOT F, Tremeaux P, Latour J, Nicolas J, et al
    WHOLE GENOME SEQUENCING OF SARS-CoV-2: COMPARISON OF TARGET CAPTURE AND AMPLICON SINGLE MOLECULAR REAL TIME SEQUENCING PROTOCOLS.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28123.
    >> Share

  41. ARISH M, Qian W, Narasimhan H, Sun J, et al
    COVID-19 immunopathology: From acute diseases to chronic sequelae.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28122.
    >> Share

  42. WETTSTEIN L, Immenschuh P, Weil T, Conzelmann C, et al
    Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28124.
    >> Share

  43. YU T, Liu F, Yi N, Yin H, et al
    Evaluating agreement in different diagnosis methods is necessary.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28117.
    >> Share

  44. WANG C, Liu B, Zhang S, Huang N, et al
    Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: a world-wide review.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28118.
    >> Share

  45. WANG Q, Ye SB, Zhou ZJ, Li JY, et al
    Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28116.
    >> Share

    August 2022
  46. KAYA Y, Gulcu O, Aksakal E, Kalkan K, et al
    A Significant Predictor of In-Hospital and Long-term Mortality and Progression In COVID-19 Patients: The End-Stage Liver Disease (MELD) Score Model.
    J Med Virol. 2022 Aug 31. doi: 10.1002/jmv.28109.
    >> Share

  47. BARANOVA A, Cao H, Zhang F
    Causal Effect of COVID-19 on Alzheimer's Disease: A Mendelian Randomization Study.
    J Med Virol. 2022 Aug 30. doi: 10.1002/jmv.28107.
    >> Share

  48. GENG Y, Wang Y
    Stability and transmissibility of SARS-CoV-2 in the environment.
    J Med Virol. 2022 Aug 30. doi: 10.1002/jmv.28103.
    >> Share

  49. YAO Y, Song H, Zhang F, Liu J, et al
    Genetic predisposition to blood cell indices in relation to severe COVID-19.
    J Med Virol. 2022 Aug 29. doi: 10.1002/jmv.28104.
    >> Share

  50. COLSON P, Gautret P, Delerce J, Chaudet H, et al
    The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the fate of RNA virus epidemics and obeys the Mistigri rule.
    J Med Virol. 2022 Aug 28. doi: 10.1002/jmv.28102.
    >> Share

  51. LIU S, Cai J, Li Y, Ying L, et al
    Outbreak of acute respiratory disease caused by human adenovirus type 7 and Human Coronavirus-229E in Zhejiang Province, China.
    J Med Virol. 2022 Aug 28. doi: 10.1002/jmv.28101.
    >> Share

  52. XIE J, Klemsz MJ, Kacena MA, Sandusky G, et al
    Inhibition of MEK signaling prevents SARS-CoV2-induced lung damage and improves the survival of infected mice.
    J Med Virol. 2022 Aug 28. doi: 10.1002/jmv.28094.
    >> Share

  53. GHANG B, Kim S, Kim J
    Autoimmune rheumatic disease after SARS-CoV-2 vaccination.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28092.
    >> Share

  54. CAO H, Baranova A, Wei X, Wang C, et al
    Bidirectional causal associations between type 2 diabetes and COVID-19.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28100.
    >> Share

  55. SALIMIAN J, Ahmadi A, Amani J, Olad G, et al
    Safety and Immunogenicity of a Recombinant Receptor Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine) Against COVID-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28097.
    >> Share

  56. ALI AM, Tofiq AM, Rostam HM, Ali KM, et al
    Disease Severity and Efficacy of Homologous Vaccination Among Patients Infected with SARS-CoV-2 Delta or Omicron VOCs, Compared to Unvaccinated using Main Biomarkers.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28098.
    >> Share

  57. LIU H, Chang S, Chen S, Du Y, et al
    Highly sensitive and rapid detection of SARS-CoV-2 via a portable CRISPR-Cas13a-based lateral flow assay.
    J Med Virol. 2022 Aug 27. doi: 10.1002/jmv.28096.
    >> Share

  58. PATERSON C, Davis D, Roche M, Bissett B, et al
    What are the long-term holistic health consequences of COVID-19 among survivors? An umbrella systematic review.
    J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28086.
    >> Share

  59. MENG Y, Zeng F, Sun H, Li Y, et al
    Clinical characteristics and outcomes of patients with COVID-19 and psoriasis.
    J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28085.
    >> Share

  60. DING C, Ni S, Zhang X, Xie J, et al
    Evaluation of humoral immune responses induced by different SARS-CoV-2 spike trimers from wild-type and emerging variants with individual, sequential, and combinational delivered strategies.
    J Med Virol. 2022 Aug 19. doi: 10.1002/jmv.28081.
    >> Share

  61. DE MICHELENA P, Olea B, Torres I, Gonzalez-Candelas F, et al
    SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2.
    J Med Virol. 2022 Aug 19. doi: 10.1002/jmv.28079.
    >> Share

  62. MA Z, Mao Y, Wang Y, Duan Z, et al
    Suicidal ideation and attempted suicide among cancer patients during the COVID-19 pandemic.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28076.
    >> Share

  63. ALI MA, Zhang GF, Hu C, Yuan B, et al
    Ultra-Rapid and Ultra-Sensitive Detection of SARS-CoV-2 Antibodies in COVID-19 Patients via A 3D-Printed Nanomaterial-Based Biosensing Platform.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28075.
    >> Share

  64. LIU H, Li Q, Xiang Y, Li H, et al
    An Outbreak of Acute Respiratory Disease Caused by HAdV-55 in Beijing, China, 2020.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28074.
    >> Share

  65. CUI A, Xie Z, Xu J, Hu K, et al
    Comparative analysis of the clinical and epidemiological characteristics of human influenza virus vs. human respiratory syncytial virus vs. human metapneumovirus infection in nine provinces of China during 2009-2021.
    J Med Virol. 2022 Aug 18. doi: 10.1002/jmv.28073.
    >> Share

  66. TAO SS, Wang XY, Yang XK, Liu YC, et al
    COVID-19 and inflammatory bowel disease crosstalk: from emerging association to clinical proposal.
    J Med Virol. 2022 Aug 16. doi: 10.1002/jmv.28067.
    >> Share

  67. MOHEBI L, Karami H, Mirsalehi N, Ardestani NH, et al
    A delayed resurgence of respiratory syncytial virus (RSV) during the COVID-19 pandemic: An unpredictable outbreak in a small proportion of children in the Southwest of Iran, April 2022.
    J Med Virol. 2022 Aug 12. doi: 10.1002/jmv.28065.
    >> Share

  68. YU W, Guo Y, Zhang S, Kong Y, et al
    Proportion of asymptomatic infection and non-severe disease caused by SARS-CoV-2 Omicron variant: a systematic review.
    J Med Virol. 2022 Aug 12. doi: 10.1002/jmv.28066.
    >> Share

  69. GEISEN UM, Rose R, Neumann F, Ciripoi M, et al
    The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFalpha blockade.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28063.
    >> Share

  70. THAKUR N, Das S, Kumar S, Maurya VK, et al
    Tracing the origin of Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): A systematic review and narrative synthesis.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28060.
    >> Share

  71. JIA M, Wang X, Gong W, Zhong J, et al
    Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort study.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28055.
    >> Share

  72. CHEUNG PH, Ye ZW, Lui WY, Ong CP, et al
    Production of single-cycle infectious SARS-CoV-2 through a trans-complemented replicon.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28057.
    >> Share

  73. INFANTINO M, Manfredi M, Alessio MG, Previtali G, et al
    CLINICAL UTILITY OF CIRCULATING CALPROTECTIN TO ASSIST PREDICTION AND MONITORING OF COVID-19 SEVERITY: AN ITALIAN STUDY.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28056.
    >> Share

  74. KUMBHAKAR R, Neradilek M, Barnabas RV, Stewart J, et al
    Using Time Weighted Average Change from Baseline of SARS-CoV-2 Viral Load to Assess Impact of Hydroxychloroquine (HCQ) as Post-exposure Prophylaxis and Early Treatment for COVID-19.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28054.
    >> Share

  75. WANG H, Guo S, Yang H
    Rapid quantitative monitoring of SARS-CoV-2 spike protein mediated syncytia formation using split NanoLuc.
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28053.
    >> Share

  76. ELBAYIYEV S, Simsek GK, Ceran B, Akin MS, et al
    Could red cell distribution width be used for predicting cardiac injury in neonates with COVID-19?
    J Med Virol. 2022 Aug 8. doi: 10.1002/jmv.28050.
    >> Share

  77. ZOU L, Zhang H, Zheng Z, Jiang Y, et al
    Serosurvey in SARS-CoV-2 inactivated vaccine-elicited neutralizing antibodies against authentic SARS-CoV-2 and its viral variants.
    J Med Virol. 2022 Aug 5. doi: 10.1002/jmv.28049.
    >> Share

  78. ZHANG H, Ding Q, Yuan J, Han F, et al
    Susceptibility to mice and potential evolutionary characteristics of porcine deltacoronavirus.
    J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28048.
    >> Share


  79. Corrigendum.
    J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28046.
    >> Share

  80. SUNTRONWONG N, Kanokudom S, Auphimai C, Assawakosri S, et al
    Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
    J Med Virol. 2022 Aug 4. doi: 10.1002/jmv.28044.
    >> Share


  81. Corrigendum.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28043.
    >> Share

  82. LIM CC, Leeu JJ, Mok IY, Tan HZ, et al
    Influenza Vaccine Awareness and Acceptance in Kidney Disease during the Corononavirus Disease 2019 pandemic.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28039.
    >> Share

  83. KOJIMA Y, Nakakubo S, Kamada K, Yamashita Y, et al
    Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28037.
    >> Share

  84. LIANG W, Wang S, Wang H, Li X, et al
    When 3D genome technology meets viral infection, including SARS-CoV-2.
    J Med Virol. 2022 Aug 2. doi: 10.1002/jmv.28040.
    >> Share

    July 2022
  85. PENG P, Deng H, Li Z, Chen Y, et al
    Distinct immune responses in the early phase to natural SARS-CoV-2 infection or vaccination.
    J Med Virol. 2022 Jul 29. doi: 10.1002/jmv.28034.
    >> Share

  86. MURPHY H, Ly H
    What are the levels of risk of humans contracting SARS-CoV-2 from pets and vice versa?
    J Med Virol. 2022 Jul 29. doi: 10.1002/jmv.28035.
    >> Share

  87. ALEXIEV I, Giovanetti M, Cella E, Ivanov I, et al
    Initial Introduction and Spread of the SARS-CoV-2 AY.4.2.1 Delta Variant in Bulgaria, a Genomic Insight.
    J Med Virol. 2022 Jul 28. doi: 10.1002/jmv.28033.
    >> Share

  88. ZHANG GF, Meng W, Chen L, Ding L, et al
    Neutralizing Antibodies to SARS-CoV-2 Variants of Concern Including Delta and Omicron in Subjects Receiving mRNA-1273, BNT162b2 and Ad26.COV2.S Vaccines.
    J Med Virol. 2022 Jul 28. doi: 10.1002/jmv.28032.
    >> Share

  89. KOJIMA N, Desai V, Klausner JD
    Distributing Effective SARS-CoV-2 Medicines in a Timely Manner.
    J Med Virol. 2022 Jul 26. doi: 10.1002/jmv.28030.
    >> Share

  90. POURAKBARI B, Mirbeyk M, Mahmoudi S, Sadeghi RH, et al
    Evaluation of response to different COVID-19 vaccines in vaccinated healthcare workers in a single center in Iran.
    J Med Virol. 2022 Jul 26. doi: 10.1002/jmv.28029.
    >> Share

  91. JANG EJ, Choe YJ, Yun GW, Wang S, et al
    Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study.
    J Med Virol. 2022 Jul 25. doi: 10.1002/jmv.28026.
    >> Share

  92. DU Y, Li W, Guo Y, Li L, et al
    Epidemiology and genetic characterization of human metapneumovirus in pediatric patients from Hangzhou China.
    J Med Virol. 2022 Jul 24. doi: 10.1002/jmv.28024.
    >> Share

  93. LIU R, Lin X, Chen B, Hou Z, et al
    The mutation features and geographical distributions of the surface glycoprotein (S gene) in SARS-CoV-2 strains: a comparative analysis of the early and current strains.
    J Med Virol. 2022 Jul 24. doi: 10.1002/jmv.28023.
    >> Share

  94. PENG H, Zheng B, Yang S, Du J, et al
    A soluble DR5-Fc chimeric protein (sDR5-Fc) attenuates inflammatory responses induced by coronavirus MHV-A59 and SARS-CoV-2.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28021.
    >> Share

  95. WANG X, Zhao X, Cui Y, Qiao R, et al
    Neutralization of Distinct Omicron Sublineages by Longitudinal Vaccination Sera.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28017.
    >> Share

  96. OSTERDAHL MF, Christakou E, Hart D, Harris F, et al
    Concordance of B and T cell responses to SARS-CoV-2 infection, irrespective of symptoms suggestive of COVID-19.
    J Med Virol. 2022 Jul 21. doi: 10.1002/jmv.28016.
    >> Share

  97. LIANG Y, Gong Z, Guo J, Cheng Q, et al
    Spatiotemporal analysis of the morbidity of global Omicron from November 2021 to February 2022.
    J Med Virol. 2022 Jul 21. doi: 10.1002/jmv.28013.
    >> Share

  98. WANG Y, Wang X, Luu LDW, Li J, et al
    Single-cell transcriptomic atlas reveals distinct immunological responses between COVID-19 vaccine and natural SARS-CoV-2 infection.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28012.
    >> Share

  99. YANG Y, Zhao R, Wang Y, Song D, et al
    Rapid and universal detection of SARS-CoV-2 and influenza A virus using a reusable dual-channel optic fiber immunosensor.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28015.
    >> Share

  100. CHEEMA HA, Shahid A, Aziz H
    Severe acute pediatric hepatitis: the undue emphasis on adenovirus needs to be reassessed.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28014.
    >> Share

  101. DE VITO A, Colpani A, Bitti A, Zauli B, et al
    Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: a real-life experience.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28011.
    >> Share

  102. HUANG D, Lin S, He J, Wang Q, et al
    Association between COVID-19 and telomere length: a bidirectional Mendelian randomization study.
    J Med Virol. 2022 Jul 19. doi: 10.1002/jmv.28008.
    >> Share

  103. MONARI C, Pisaturo M, Maggi P, Macera M, et al
    EARLY PREDICTORS OF CLINICAL DETERIORATION IN A COHORT OF OUTPATIENTS WITH COVID-19 IN SOUTHERN ITALY: A MULTICENTER OBSERVATIONAL STUDY.
    J Med Virol. 2022 Jul 19. doi: 10.1002/jmv.28007.
    >> Share

  104. HUANG N, Wang C, Han B, Zhao T, et al
    Change in willingness to COVID-19 vaccination in China: two online surveys during the pandemic.
    J Med Virol. 2022 Jul 18. doi: 10.1002/jmv.28004.
    >> Share

  105. BAUER G, Struck F, Staschik E, Maile J, et al
    Differential avidity determination of IgG directed towards the receptor-binding domain (RBD) of SARS-CoV-2 wild-type and its variants in one assay: Rational tool for the assessment of protective immunity.
    J Med Virol. 2022 Jul 18. doi: 10.1002/jmv.28006.
    >> Share

  106. CHEN J, Liu X, Liu W, Yang C, et al
    Comparison of the respiratory tract microbiome in hospitalized COVID-19 patients with different disease severity.
    J Med Virol. 2022 Jul 15. doi: 10.1002/jmv.28002.
    >> Share

  107. JASIM SA, Mahdi RS, Bokov DO, Najm MAA, et al
    The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update.
    J Med Virol. 2022 Jul 14. doi: 10.1002/jmv.28000.
    >> Share

  108. VAIRA LA, De Riu G, Boscolo-Rizzo P, Hopkins C, et al
    In response to: Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: The ANOSVID study.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27999.
    >> Share

  109. FERRAVANTE C, Arslan-Gatz BS, Dell'Annunziata F, Palumbo D, et al
    Dynamics of nasopharyngeal tract phageome and association with disease severity and age of patients during three waves of COVID-19.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27998.
    >> Share

  110. FILHO FFD, Chaves EBM, D'Avila KG, Neyeloff JL, et al
    Clinical characteristics and outcomes of healthcare workers with COVID-19 pre- and postvaccination.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27997.
    >> Share

  111. RAHMATI M, Keshvari M, Mirnasuri S, Yon DK, et al
    The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis.
    J Med Virol. 2022 Jul 13. doi: 10.1002/jmv.27996.
    >> Share

  112. CHEN J, Song J, Dai L, Post SR, et al
    SARS-CoV-2 Infection and Lytic Reactivation of Herpesviruses: a Potential Threat at Post-pandemic Era?
    J Med Virol. 2022 Jul 12. doi: 10.1002/jmv.27994.
    >> Share

  113. FARHEEN S, Araf Y, Tang YD, Zheng C, et al
    The Deltacron conundrum: its origin and potential health risks.
    J Med Virol. 2022 Jul 11. doi: 10.1002/jmv.27990.
    >> Share

  114. RANKIN DA, Yanis A, Talj R, Howe HL, et al
    Clinical Presentations of Adult and Pediatric SARS-CoV-2-Positive Cases in a Community Cohort, Nashville, Tennessee.
    J Med Virol. 2022 Jul 11. doi: 10.1002/jmv.27988.
    >> Share

  115. DUMAN N, Tuncel G, Bisgin A, Bozdogan ST, et al
    "Analysis of ACE2 and TMPRSS2 coding variants as a risk factor for SARS-CoV-2 from 946 whole exome sequencing data in the Turkish Population.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27976.
    >> Share

  116. ALMUFTY HB, Mamani MMA, Ali AH, Merza MA, et al
    COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan; a retrospective cohort study.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27985.
    >> Share

  117. TEO KW, Patel D, Sisodia S, Roland D, et al
    Rhinovirus persistence during the COVID-19 pandemic - impact on paediatric acute wheezing admissions.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27986.
    >> Share

  118. QI X, Wang J, Zhang Q, Ai J, et al
    Safety and Immunogenicity of COVID-19 Vaccination in Patients with Hepatocellular Carcinoma (CHESS-NMCID 2101): A Multicenter Prospective Study.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27992.
    >> Share

  119. CARDENOSO DOMINGO L, Roy Vallejo E, Zurita Cruz ND, Chicot Llano M, et al
    Relevant SARS-CoV-2 viremia is associated with COVID-19 severity: prospective cohort study and validation cohort.
    J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27989.
    >> Share

  120. CHENG ZJ, Huang H, Liu Q, Zhong R, et al
    Immunoassay and mass cytometry revealed immunological profiles induced by inactivated BBIBP COVID-19 vaccine.
    J Med Virol. 2022 Jul 8. doi: 10.1002/jmv.27983.
    >> Share

  121. PETRIE JG, Eisenberg MC, Lauring AS, Gilbert J, et al
    Variant-specific burden of SARS-CoV-2 in Michigan: March 2020 through November 2021.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27982.
    >> Share

  122. CHIRUMBOLO S
    Myopericarditis in young subjects after vaccination, clearing the clouds of misunderstanding.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27981.
    >> Share

  123. ZENG G, Wang X
    Ending the COVID-19 pandemic: We still have a long way to go.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27980.
    >> Share

  124. VELAZQUEZ-SALINAS L
    The complex evolutionary dynamics of SARS-CoV-2, a big challenge to control the pandemic of COVID-19.
    J Med Virol. 2022 Jul 7. doi: 10.1002/jmv.27979.
    >> Share

  125. YUASA S, Nakajima J, Takatsuki Y, Takahashi Y, et al
    Viral load of SARS-CoV-2 Omicron is not high despite its high infectivity.
    J Med Virol. 2022 Jul 5. doi: 10.1002/jmv.27974.
    >> Share

  126. AKSAK T, Satar DA, Ridvan B, Gultekin EO, et al
    INVESTIGATION OF THE EFFECT OF COVID-19 ON SPERM COUNT, MOTILITY AND MORPHOLOGY.
    J Med Virol. 2022 Jul 1. doi: 10.1002/jmv.27971.
    >> Share

    June 2022
  127. DESINGU PA, Nagarajan K
    The emergence of Omicron lineages BA.4 and BA.5, and the global spreading trend.
    J Med Virol. 2022 Jun 30. doi: 10.1002/jmv.27967.
    >> Share

  128. HAN L, Zheng Y, Deng J, Nan ML, et al
    SARS-CoV-2 ORF10 antagonizes STING-dependent interferon activation and autophagy.
    J Med Virol. 2022 Jun 28. doi: 10.1002/jmv.27965.
    >> Share

  129. CRUZ CA, Medina PM
    Temporal Changes in the Accessory Protein Mutations of SARS-CoV-2 Variants and Their Predicted Structural and Functional Effects.
    J Med Virol. 2022 Jun 28. doi: 10.1002/jmv.27964.
    >> Share

  130. AKCAY N, Bektas G, Menentoglu ME, Sevketoglu E, et al
    Response to Finsterer on the letter to the editor ''Diagnose SARS-CoV-2 associated Guillain-Barre syndrome upon appropriate criteria and after exclusion of differentials''.
    J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27960.
    >> Share

  131. TAVAKOLI N, Nafissi N, Shokri S, Fallahpour M, et al
    Pediatric and Adolescent COVID-19 Vaccination Side Effects: A Retrospective Cohort Study of Iranian Teenage group in 2021.
    J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27962.
    >> Share

  132. CIMOLAI N
    Disinfection and Decontamination in the Context of SARS-CoV-2 Specific Data.
    J Med Virol. 2022 Jun 27. doi: 10.1002/jmv.27959.
    >> Share

  133. LI D, Xiong L, Pan G, Wang T, et al
    Molecular Imaging on ACE2-dependent Transocular Infection of Coronavirus.
    J Med Virol. 2022 Jun 26. doi: 10.1002/jmv.27958.
    >> Share

  134. UMAIR M, Ikram A, Rehman Z, Haider SA, et al
    Genomic diversity of SARS-CoV-2 in Pakistan during the fourth wave of pandemic.
    J Med Virol. 2022 Jun 26. doi: 10.1002/jmv.27957.
    >> Share

  135. TANG K, Wei Z, Wu X
    Impaired serological response to COVID-19 vaccination following anti-cancer therapy: a systematic review and meta-analysis.
    J Med Virol. 2022 Jun 24. doi: 10.1002/jmv.27956.
    >> Share

  136. KONTOPOULOU K, Nakas CT, Belai C, Papazisis G, et al
    Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in immunocompromised adults in Greece: is a fourth dose necessary?
    J Med Virol. 2022 Jun 23. doi: 10.1002/jmv.27954.
    >> Share

  137. MIAO G, Peng H, Tang H, Liu Y, et al
    Antiviral efficacy of selective estrogen receptor modulators against SARS-CoV-2 infection in vitro and in vivo reveals bazedoxifene acetate as an entry inhibitor.
    J Med Virol. 2022 Jun 22. doi: 10.1002/jmv.27951.
    >> Share

  138. TASEEN S, Nasir F, Abbas M, Altaf M, et al
    Post-pandemic World at the Mercy of Monkeypox Virus Outbreak: Time to worry or not?
    J Med Virol. 2022 Jun 22. doi: 10.1002/jmv.27948.
    >> Share

  139. CHEN JM, Li GH, Ji YF, Sun MH, et al
    A highly powerful non-specific strategy to reduce COVID-19 deaths.
    J Med Virol. 2022 Jun 21. doi: 10.1002/jmv.27949.
    >> Share

  140. PHAN T, Boes S, McCullough M, Gribschaw J, et al
    Emergence of SARS-CoV-2 Omicron BA.5 variant of concern in Western Pennsylvania, United States.
    J Med Virol. 2022 Jun 17. doi: 10.1002/jmv.27945.
    >> Share

  141. STAERK-OSTERGAARD J, Kirkeby C, Christiansen LE, Andersen MA, et al
    Evaluation of diagnostic test procedures for SARS-CoV-2 using latent class models.
    J Med Virol. 2022 Jun 17. doi: 10.1002/jmv.27943.
    >> Share

  142. WOLF JM, Petek H, Maccari JG, Nasi LA, et al
    COVID-19 pandemic in Southern Brazil: Hospitalizations, intensive care unit admissions, lethality rates, and length of stay between March 2020 and April 2022.
    J Med Virol. 2022 Jun 16. doi: 10.1002/jmv.27942.
    >> Share

  143. CEYLAN MR, Kankilic N, Oz O
    Are H1 and H3 haplotypes of endothelial protein C receptor (PROCR) an important factor in contracting COVID-19?
    J Med Virol. 2022 Jun 16. doi: 10.1002/jmv.27938.
    >> Share

  144. TIAN F, Yang R
    Safety and Efficacy of COVID-19 Vaccines in Children and Adolescents: a Systematic Review of Randomized Controlled Trials.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27940.
    >> Share

  145. WANG L, Zhou HY, Li JY, Cheng YX, et al
    Potential Inter-variant and Intra-variant Recombination of Delta and Omicron Variants.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27939.
    >> Share

  146. WELLS DA, Cantoni D, Mayora-Neto M, Di Genova C, et al
    Human seasonal coronavirus neutralisation and COVID-19 severity.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27937.
    >> Share

  147. AKASH K, Sharma A, Kumar D, Singh SK, et al
    MOLECULAR ASPECTS OF OMICRON, VACCINE DEVELOPMENT AND RECOMBINANT STRAIN XE: A REVIEW.
    J Med Virol. 2022 Jun 15. doi: 10.1002/jmv.27936.
    >> Share

  148. LYTRAS T, Kontopidou F, Lambrou A, Tsiodras S, et al
    Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign.
    J Med Virol. 2022 Jun 14. doi: 10.1002/jmv.27934.
    >> Share

  149. ATLURI VL, Stalter RM, McGuffin SA, Johnson L, et al
    Patient Characteristics Associated with Conversion from Negative to Positive SARS-CoV2 PCR Test Results: Implications for Clinical False-Negativity from a Single-Center: A Case-Control Study.
    J Med Virol. 2022 Jun 14. doi: 10.1002/jmv.27932.
    >> Share

  150. RUDIANSYAH M, Jasim SA, Mohammad Pour ZG, Athar SS, et al
    Coronavirus disease 2019 (COVID-19) update: From metabolic reprogramming to immunometabolism.
    J Med Virol. 2022 Jun 10. doi: 10.1002/jmv.27929.
    >> Share

  151. KUMAR S, Karuppanan K, Subramaniam G
    Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.
    J Med Virol. 2022 Jun 9. doi: 10.1002/jmv.27927.
    >> Share

  152. GIRAY BG, Acik GG
    SARS-CoV-2and Mutation RT-qPCR Test Positivity Correlation with ABO and Rh Blood Types.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27923.
    >> Share

  153. CHEN YQ, Ji YF, Chen JM
    Dual impacts of the COVID-19 non-pharmaceutical interventions on other infectious diseases.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27922.
    >> Share

  154. LI H, Chen Z, Liu X, Hu P, et al
    T cell epitopes are largely conserved in the SARS-CoV-2 Omicron subvariant (BA.1, BA.2, BA.3 and GKA).
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27925.
    >> Share

  155. CHEUNG CL, Ho SC, Krishnamoorthy S, Li GH, et al
    COVID-19 and Platelet Traits: A Bi-directional Mendelian Randomization Study.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27920.
    >> Share

  156. MERCIER J, Osman M, Bouiller K, Tipirdamaz C, et al
    Olfactory dysfunction in COVID-19, new insights from a cohort of 353 patients: the ANOSVID study.
    J Med Virol. 2022 Jun 7. doi: 10.1002/jmv.27918.
    >> Share

  157. IDIZ UO, Yurttas TT, Degirmencioglu S, Orhan B, et al
    Immunophenotyping of lymphocytes and monocytes and the status of cytokines in the clinical course of Covid-19 patients.
    J Med Virol. 2022 Jun 6. doi: 10.1002/jmv.27917.
    >> Share

  158. TSAGKARIS C, Eleftheriades A, Laubscher L, Vladyckuk V, et al
    Viruses monkeying around with surgical safety: Monkeypox preparedness in surgical settings.
    J Med Virol. 2022 Jun 3. doi: 10.1002/jmv.27915.
    >> Share

  159. BREHM TT, Pfefferle S, von Possel R, Karolyi M, et al
    Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for SARS-CoV-2 delta and omicron variants.
    J Med Virol. 2022 Jun 3. doi: 10.1002/jmv.27916.
    >> Share

  160. ZHAO L, Li Y, Yi W, Yan K, et al
    The clinical and bioinformatics analysis for the role of anti-hypertension drugs on mortality among patients with hypertension hospitalized with COVID-19.
    J Med Virol. 2022 Jun 3. doi: 10.1002/jmv.27914.
    >> Share

  161. AU TY, Assavarittirong C
    The potential rationale of COVID-19 vaccine-induced myopericarditis.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27910.
    >> Share

  162. SAIED AA, Nascimento MSL, Rangel AHDN, Skowron K, et al
    Transchromosomic bovines (TcB)-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1 and Influenza A virus.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27907.
    >> Share

  163. MAK GCK, Lau SSY, Wong KKY, Lau CS, et al
    Analytical sensitivity of the Rapid Antigen Test kits for detection of SARS-CoV-2 Omicron variant BA.2 sublineage.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27908.
    >> Share

  164. NAH EH, Cho S, Park H, Kim S, et al
    Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: a prospective observational study.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27911.
    >> Share

  165. OKTAY GULTEKIN E, Gultekin O, Coskun A, Aksak T, et al
    Antibody response three months after SARS-CoV-2 infection.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27909.
    >> Share

  166. URSIC T, Kogoj R, Sikonja J, Roskaric D, et al
    Performance of nasopharyngeal swab and saliva in detecting Delta and Omicron SARS-CoV-2 variants.
    J Med Virol. 2022 Jun 1. doi: 10.1002/jmv.27898.
    >> Share

    May 2022
  167. LIU P, Xu M, Lu L, Ma A, et al
    The changing pattern of common respiratory and enteric viruses among outpatient children in Shanghai, China: Two years of the COVID-19 pandemic.
    J Med Virol. 2022 May 31. doi: 10.1002/jmv.27896.
    >> Share

  168. KOZAWA K, Miura H, Kawamura Y, Higashimoto Y, et al
    Unremarkable antibody responses against various infectious agents after inoculation with the BNT162b2 COVID-19 vaccine.
    J Med Virol. 2022 May 31. doi: 10.1002/jmv.27895.
    >> Share

  169. MESTANZA O, Lizarraga W, Padilla-Rojas C, Jimenez-Vasquez V, et al
    GENOMIC SURVEILLANCE OF LAMBDA SARS-COV-2 VARIANT IN A GLOBAL PHYLOGENETIC CONTEXT.
    J Med Virol. 2022 May 29. doi: 10.1002/jmv.27889.
    >> Share

  170. KHORATTANAKULCHAI N, Manopwisedjaroen S, Rattanapisit K, Panapitakkul C, et al
    Receptor Binding Domain Proteins of SARS-CoV-2 Variants Produced in Nicotiana benthamiana Elicit Neutralizing Antibodies Against Variants of Concern.
    J Med Virol. 2022 May 26. doi: 10.1002/jmv.27881.
    >> Share

  171. FLEISCHER B, Olum R, Nakwagala FN, Nassozi DR, et al
    Higher intensive care unit consultations for COVID-19 patients living with HIV compared to those without HIV coinfection in Uganda.
    J Med Virol. 2022 May 26. doi: 10.1002/jmv.27887.
    >> Share

  172. GAO X, Hao J, Yu L, Cao Y, et al
    Evaluation of enterovirus nucleic acids detection method based on ultra-fast real-time fluorescence RT-PCR technology - A pilot study.
    J Med Virol. 2022 May 26. doi: 10.1002/jmv.27886.
    >> Share

  173. NGUYEN-KIM H, Beckmann C, Redondo M, Ziliox J, et al
    COVID Salivary diagnostics: a comparative technical study.
    J Med Virol. 2022 May 25. doi: 10.1002/jmv.27883.
    >> Share

  174. DU P, Li N, Xiong X, Tang S, et al
    A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    J Med Virol. 2022 May 25. doi: 10.1002/jmv.27885.
    >> Share

  175. JIANG Y, Zhang H, Yu J, Huang D, et al
    Humoral immune response to authentic circulating SARS-CoV-2 variants elicited by booster vaccination with distinct RBD subunits in mice.
    J Med Virol. 2022 May 25. doi: 10.1002/jmv.27882.
    >> Share

  176. SIVAN M, Preston N, Parkin A, Makower S, et al
    The modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) patient-reported outcome measure for Long Covid or Post-COVID-19 syndrome.
    J Med Virol. 2022 May 23. doi: 10.1002/jmv.27878.
    >> Share

  177. LIU S, Li W, Jiang S
    Disease of influenza virus and SARS-CoV-2 coinfection: Flurona or Flucovid?
    J Med Virol. 2022 May 19. doi: 10.1002/jmv.27874.
    >> Share

  178. LEE CJ, Woo W, Kim AY, Yon DK, et al
    Clinical Manifestations of COVID-19 Breakthrough Infections: A Systematic Review and Meta-Analysis.
    J Med Virol. 2022 May 19. doi: 10.1002/jmv.27871.
    >> Share

  179. TORRES I, Gimenez E, Albert E, Zulaica J, et al
    SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty(R) COVID-19 vaccine: Looking for correlates of protection.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27867.
    >> Share

  180. VILLACRES B, Paz E, Burbano MJ, Villacres-Granda I, et al
    Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma samples of COVID-19: a transversal surrogate in vitro study performed in Quito-Ecuador.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27866.
    >> Share

  181. CAI S, Liao G, Yu T, Gao Q, et al
    Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27872.
    >> Share

  182. CHIRUMBOLO S
    May the concurrent use of indomethacin and an anti-oxidant in the SARS-CoV2 infection treatment induce an exacerbation of COVID-19?
    J Med Virol. 2022 May 18. doi: 10.1002/jmv.27868.
    >> Share

  183. YE Y, Ye Z, Yang L, Xiang B, et al
    Unignorable public health risk of avian influenza virus during COVID-19 pandemic.
    J Med Virol. 2022 May 17. doi: 10.1002/jmv.27864.
    >> Share

  184. NILGIRIWALA K, Kadam P, Patel G, Shaikh A, et al
    Genomics of Post-Vaccination SARS-CoV-2 Infections During the Delta Dominated Second Wave of COVID-19 Pandemic, from Mumbai Metropolitan Region (MMR), India.
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27861.
    >> Share

  185. KUITUNEN I, Artama M, Haapanen M, Renko M, et al
    Respiratory virus circulation in children after relaxation of COVID-19 restrictions in fall 2021 - a nationwide register study in Finland.
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27857.
    >> Share

  186. BEAUDOIN CA, Pandurangan AP, Kim SY, Hamaia SW, et al
    In silico analysis of mutations near S1/S2 cleavage site in SARS-CoV-2 spike protein reveals increased propensity of glycosylation in Omicron strain.
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27845.
    >> Share

  187. YU T, Ling Q, Xu M, Wang N, et al
    ORF8 protein of SARS-CoV-2 reduces male fertility in mice.
    J Med Virol. 2022 May 15. doi: 10.1002/jmv.27855.
    >> Share

  188. CHO K, Park S, Kim EY, Koyanagi A, et al
    Immunogenicity of COVID-19 Vaccines in Patients with Diverse Health Conditions: a Comprehensive Systematic Review.
    J Med Virol. 2022 May 13. doi: 10.1002/jmv.27828.
    >> Share

  189. VAKIL MK, Mansoori Y, Al-Awsi GRL, Hosseinipour A, et al
    Individual Genetic Variability Mainly of Proinflammatory Cytokines, Cytokine Receptors and Toll-like receptors Dictates Pathophysiology of COVID-19 Disease.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27849.
    >> Share

  190. CLEMENTINO M, Cavalcante KF, Viana VAF, Silva DO, et al
    Detection of SARS-CoV-2 in Different Human Biofluids Using the Loop-Mediated Isothermal Amplification Assay: A Prospective Diagnostic Study in Fortaleza, Brazil.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27842.
    >> Share

  191. LEVESQUE S, Beauchemin S, Vallee M, Longtin J, et al
    Evaluation of water gargle samples for SARS-CoV-2 detection using Abbott ID NOW COVID-19 assay.
    J Med Virol. 2022 May 9. doi: 10.1002/jmv.27847.
    >> Share

  192. PHAN T, Boes S, McCullough M, Gribschaw J, et al
    First detection of SARS-CoV-2 Omicron BA.4 variant in Western Pennsylvania, United States.
    J Med Virol. 2022 May 9. doi: 10.1002/jmv.27846.
    >> Share

  193. ZERBINATI RM, Palmieri M, Schwab G, Felix AC, et al
    Use of Saliva and RT-PCR Screening for SARS-CoV-2 Variants of Concern: Surveillance and Monitoring.
    J Med Virol. 2022 May 6. doi: 10.1002/jmv.27839.
    >> Share

  194. WENG Y, Yi GY
    Estimation of the COVID-19 Mean Incubation Time: Systematic Review, Meta-analysis, and Sensitivity Analysis.
    J Med Virol. 2022 May 6. doi: 10.1002/jmv.27841.
    >> Share

  195. LIN Z, Cheng M, Zhu F, Yang X, et al
    Immunogenicity and safety of different platforms of COVID-19 vaccines given as a 3rd (booster) dose in healthy adults.
    J Med Virol. 2022 May 6. doi: 10.1002/jmv.27836.
    >> Share

  196. DAI Y, Zhong J, Lan Y
    Virus-virus interactions of febrile respiratory syndrome among patients in China based on surveillance data from February 2011 to December 2020.
    J Med Virol. 2022 May 5. doi: 10.1002/jmv.27833.
    >> Share

  197. SIMSEK M, Yasin AI, Besiroglu M, Topcu A, et al
    The Efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac Vaccines in Patients with Cancer.
    J Med Virol. 2022 May 5. doi: 10.1002/jmv.27835.
    >> Share

  198. KIM KW, Wang X, Adhikari A, Yeang M, et al
    Persistent high-level shedding of cultivable SARS-CoV-2 Delta virus 33 days after onset of COVID-19 in a hospitalized patient with pneumonia.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27832.
    >> Share

  199. KEIJSERS CJPW, Broeders MEAC, Baptista Lopes V, Klinkert AF, et al
    Memory impairment and concentration problems in COVID-19 survivors eight weeks after non-ICU hospitalization: a retrospective cohort study.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27831.
    >> Share

  200. ISLAM F, Dhawan M, Mitra S, Bin Emran T, et al
    Assessing the risks associated with the emergence of Florona and possible preventive measures.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27830.
    >> Share

  201. PEIXOTO SG, Wolf JM, Glaeser AB, Maccari JG, et al
    Longer length of stay, days between discharge/first readmission, and pulmonary involvement >/=50% increase prevalence of admissions in ICU in unplanned readmissions after COVID-19 hospitalizations.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27792.
    >> Share

  202. WU F, Yuan Y, Deng Z, Yin D, et al
    Acceptance of COVID-19 Booster Vaccination Based on the Protection Motivation Theory (PMT): A Cross-Sectional Study in China.
    J Med Virol. 2022 May 4. doi: 10.1002/jmv.27825.
    >> Share

  203. FONSECA MHG, Silva MFS, Pinto ACMD, Melo ACL, et al
    Persistently positive SARS-CoV-2 specific IgM during one-year follow-up.
    J Med Virol. 2022 May 3. doi: 10.1002/jmv.27822.
    >> Share

  204. SHAFIEE A, Aghajanian S, Athar MMT, Gargari OK, et al
    Epstein-Barr virus and COVID-19.
    J Med Virol. 2022 May 3. doi: 10.1002/jmv.27823.
    >> Share

  205. KHOKHER W, Beran A, Iftikhar S, Malhas SE, et al
    Pulse versus Non-pulse Steroid Regimens in Patients with Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.
    J Med Virol. 2022 May 3. doi: 10.1002/jmv.27824.
    >> Share

  206. SEDIGHI M, Amanollahi A, Moghaddam OM, Ghafouri HB, et al
    Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid-19 pneumonia.
    J Med Virol. 2022 May 2. doi: 10.1002/jmv.27800.
    >> Share

  207. MAJUMDAR S, Sarkar R
    Mutational and phylogenetic analyses of the two lineages of the Omicron variant.
    J Med Virol. 2022;94:1777-1779.
    >> Share

    April 2022
  208. BANERJEE S, Wang X, Du S, Zhu C, et al
    Comprehensive Role of SARS-CoV-2 Spike Glycoprotein in Regulating Host Signaling Pathway.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27820.
    >> Share

  209. KHAN YH, Mallhi TH, Alanazi AS, Butt MH, et al
    Outbreak of Acute Hepatitis of Unknown etiology in Children; The Critical Role of Healthcare Professionals in Neutralizing Misleading Narratives during the COVID-19 Pandemic.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27819.
    >> Share

  210. TASAR S, Karadag-Oncel E, Yilmaz-Ciftdogan D, Kara-Aksay A, et al
    Influenza is More Severe than Our Newest Enemy (COVID-19) in Hospitalized Children: Experience from a Tertiary Center.
    J Med Virol. 2022 Apr 27. doi: 10.1002/jmv.27817.
    >> Share

  211. QAMAR N, Rukh G, Khan SN
    Vaccines for Covid-19: An Insight on Their Effectiveness and Adverse Effects.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27810.
    >> Share

  212. LI Y, Wang X, Jin J, Ma Z, et al
    T cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27814.
    >> Share

  213. SUN ZP, Yang SY, Cai X, Han WD, et al
    Survival of SARS-CoV-2 in artificial seawater and on the surface of inanimate materials.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27807.
    >> Share

  214. GUPTA N, Wilson W, Ravindra P, Raghu R, et al
    Coinfection of leptospirosis and Coronavirus disease 2019: a retrospective case series from a coastal region in South India.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27816.
    >> Share

  215. PRAZUCK T, Gravier A, Pires-Roteira D, Theillay A, et al
    Evaluation of A NEW "All in One" SARS-CoV-2 antigen-detecting rapid diagnostic test AND self-test: diagnostic performance and usability in child and adult populationS.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27812.
    >> Share

  216. ZHOU B, Song S, Guo H, Zhou X, et al
    A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27811.
    >> Share

  217. RAMIREZ AL, Luna N, Patino LH, Castaneda S, et al
    Impact of SARS-CoV-2 Mu variant on vaccine effectiveness: a comparative genomics study at the peak of the third wave in Bogota, Colombia.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27808.
    >> Share

  218. ZHANG J, Cao J, Ye Q
    Nonpharmaceutical interventions against the COVID-19 pandemic significantly decreased the spread of enterovirus in children.
    J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27806.
    >> Share

  219. JAIN S, Meena R, Kumar V, Kaur R, et al
    Comparison of haematologic abnormalities between hospitalized Coronavirus disease 2019 (COVID-19) positive and negative patients with correlation to disease severity and outcome.
    J Med Virol. 2022 Apr 25. doi: 10.1002/jmv.27793.
    >> Share

  220. COLSON P, Fournier PE, Delerce J, Million M, et al
    Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in southern France.
    J Med Virol. 2022 Apr 25. doi: 10.1002/jmv.27789.
    >> Share

  221. LANZAFAME M, Gibbin E, Lattuada E, Vento S, et al
    Is monoclonal antibody administration necessary in all vaccinated patients with breakthrough COVID-19 infections?
    J Med Virol. 2022 Apr 22. doi: 10.1002/jmv.27802.
    >> Share

  222. PHAN T, Cravener Z, McCullough M, Mays A, et al
    Clinical evaluation of the Cue's COVID-19 diagnostic test to detect.
    J Med Virol. 2022 Apr 22. doi: 10.1002/jmv.27805.
    >> Share

  223. GUO J, Zhang J, Du P, Lu J, et al
    Generation and Characterization of Humanized Synergistic Neutralizing Antibodies against SARS-CoV-2.
    J Med Virol. 2022 Apr 21. doi: 10.1002/jmv.27801.
    >> Share

  224. WANG C, Yang YN, Xi L, Yang LL, et al
    Dynamics of influenza-like illness under urbanization procedure and COVID-19 pandemic in the sub-center of Beijing during 2013-2021.
    J Med Virol. 2022 Apr 21. doi: 10.1002/jmv.27803.
    >> Share

  225. TORRES I, Bellido-Blasco JB, Gimeno C, Burgos JS, et al
    SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at mid-term after Comirnaty(R) COVID-19 vaccination.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27799.
    >> Share

  226. YE Q, Shao W, Meng H
    Performance and Application Evaluation of SARS-CoV-2 Antigen Assay.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27798.
    >> Share


  227. Corrigendum.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27776.
    >> Share

  228. SUBRAMONEY K, Mtileni N, Bharuthram A, Davis A, et al
    Identification of SARS-CoV-2 Omicron variant using spike gene target failure and genotyping assays, Gauteng, South Africa, 2021.
    J Med Virol. 2022 Apr 20. doi: 10.1002/jmv.27797.
    >> Share

  229. KUMAR N, Misra BR, Reddy MM, Deval H, et al
    COVID-19 transmission among vaccinated laboratory workers during the second wave in eastern Uttar Pradesh, India.
    J Med Virol. 2022 Apr 17. doi: 10.1002/jmv.27788.
    >> Share

  230. YAVUZ E, Gunal O, Basbulut E, Sen A, et al
    SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    J Med Virol. 2022 Apr 17. doi: 10.1002/jmv.27794.
    >> Share

  231. LIN-WANG HT, Lemes RC, Farias EDS, Bajgelman MC, et al
    Sequential IgG antibody monitoring for virus-inactivated and adenovirus-vectored COVID-19 vaccine in Brazilian healthcare workers.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27782.
    >> Share

  232. STEPANEK L, Janosikova M, Stepanek L, Nakladalova M, et al
    The kinetics and predictors of anti-SARS-CoV-2 antibodies up to eight months after symptomatic COVID-19: a Czech cross-sectional study.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27784.
    >> Share

  233. LUCIJANIC M, Soric E, Lacko MS, Sabljic A, et al
    Gradual increase in RDW is similarly prognostic for in-hospital mortality in both anemic and non-anemic COVID-19 patients.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27785.
    >> Share

  234. LIN YF, Li Y, Duan Q, Lei H, et al
    Vaccination strategy for preventing the spread of SARS-CoV-2 in the limited supply condition: a mathematical modelling study.
    J Med Virol. 2022 Apr 14. doi: 10.1002/jmv.27783.
    >> Share

  235. OZUDOGRU O, Acer O, Genc Bahce Y
    Risks of catching COVID-19 according to vaccination status of healthcare workers during the SARS COV-2 Delta variant dominant period and their clinical characteristics.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27778.
    >> Share

  236. IN E, Altintop Geckil A, Kavuran G, Sahin M, et al
    Using Artificial Intelligence to Improve the Diagnostic Efficiency of Pulmonologists in Differentiating COVID-19 Pneumonia from Community-Acquired Pneumonia.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27777.
    >> Share

  237. MOHAPATRA RK, Kandi V, Tuli HS, Chakraborty C, et al
    The recombinant variants of SARS-CoV-2: concerns continues amid COVID-19 pandemic.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27780.
    >> Share

  238. ALLEN RA, Williams CL, Penrod Y, McCloskey C, et al
    A pyrosequencing protocol for rapid identification of SARS-CoV-2 variants.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27770.
    >> Share

  239. AHMED KAHM, Hasabo EA, Haroun MS, Eljack MMF, et al
    Clinical Characteristics, Complications and Predictors of Outcome of Hospitalized Adult Sudanese Patients with COVID-19 and Malaria Co-Infection in Sudan: A Multi-Center Retrospective Cross-sectional Study.
    J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27771.
    >> Share

  240. ZHAI SL, Li CL, Sun MF, Zhang JF, et al
    Natural infections of SARS-CoV-2 increased in animals: How should humans get along with animals?
    J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27772.
    >> Share

  241. LAPIC I, Antolic MR, Horvat I, Premuzic V, et al
    Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVID-19 patients: a pilot study.
    J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27774.
    >> Share

  242. BOGLIONE L, Dodaro V, Meli G, Rostagno R, et al
    Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: a case-control study.
    J Med Virol. 2022 Apr 11. doi: 10.1002/jmv.27768.
    >> Share

  243. MEHRAEEN E, SeyedAlinaghi S, Karimi A
    The Post-Omicron Situation: The End of the Pandemic or a Bigger Challenge?
    J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27765.
    >> Share

  244. GAMA S
    RDW shows prognostic potential in hospitalised patients with COVID-19.
    J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27764.
    >> Share

  245. AL-BASSAM WW, Al-Karaawi IA, Sharquie IK, Ad'hiah AH, et al
    Evaluation of interleukin-38 levels in serum of patients with coronavirus disease 2019.
    J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27762.
    >> Share

  246. ABORODE AT, Awuah WA, Mehta A, Abdul-Rahman T, et al
    Concern over Nipah Virus Cases Amidst the COVID-19 Pandemic in India.
    J Med Virol. 2022 Apr 5. doi: 10.1002/jmv.27745.
    >> Share

  247. ELIE B, Roquebert B, Sofonea MT, Trombert-Paolantoni S, et al
    Variant-specific SARS-CoV-2 within-host kinetics.
    J Med Virol. 2022 Apr 4. doi: 10.1002/jmv.27757.
    >> Share


  248. Dominant clade-featured SARS-CoV-2 co-occurring mutations reveal plausible epistasis: An in silico based hypothetical model.
    J Med Virol. 2022 Apr 4. doi: 10.1002/jmv.27733.
    >> Share

  249. YE C, Lv Y, Kuang W, Yang L, et al
    Inactivated vaccines prevent severe COVID-19 in patients infected with the Delta variant: a comparative study of the Delta and Alpha variants from China.
    J Med Virol. 2022 Apr 2. doi: 10.1002/jmv.27759.
    >> Share

  250. BHATNAGAR S, Jones K, Montoya A
    COVID-19 Vaccine Side Effects among Nursing Home Residents and Staff.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27756.
    >> Share

  251. KWOK CS, Muntean EA, Mallen CD
    The impact of COVID-19 on the patient, clinician, healthcare services and society: A patient pathway review.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27758.
    >> Share

  252. KAYGUSUZ S, Korukluoglu G, Cosgun Y, Sahin O, et al
    INVESTIGATION AND LONG-TERM MONITORING OF THE PRESENCE OF NEUTRALIZING ANTIBODY IN PATIENTS WITH COVID-19 DISEASE OF DIFFERENT CLINICAL SEVERITY.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27751.
    >> Share

  253. GAUTRET P, Hoang VT, Jimeno MT, Lagier JC, et al
    Severity of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant, in Marseille, France, December, 2021-February, 2022.
    J Med Virol. 2022 Apr 1. doi: 10.1002/jmv.27760.
    >> Share

  254. CHIRUMBOLO S
    Antioxidants associated with NSAIDs might even exacerbate the progress of SARS-CoV2 disease.
    J Med Virol. 2022;94:1264-1266.
    >> Share

    March 2022
  255. CHAI C, Chen K, Li S, Cheng G, et al
    Effect of elevated fasting blood glucose level on the one-year mortality and sequelae in hospitalized COVID-19 patients: a bidirectional cohort study.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27737.
    >> Share

  256. PENNEY J, Jung A, Koethe B, Doron S, et al
    Cycle Threshold Values and SARS-CoV-2: Relationship to Demographic Characteristics and Disease Severity.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27752.
    >> Share

  257. TAMARIZ L, Bast E, Abad M, Klimas N, et al
    Letter to the editor: Post COVID-19 joint pain: Preliminary report of the relationship with antinuclear antibodies and inflammation.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27753.
    >> Share

  258. CHEN C, Feng Y, Chen Z, Xia Y, et al
    SARS-CoV-2 cold-chain transmission: Characteristics, risks and strategies.
    J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27750.
    >> Share

  259. YANG S, Cao L, Xu W, Xu T, et al
    Comparison of model-specific histopathology in mouse models of COVID-19.
    J Med Virol. 2022 Mar 30. doi: 10.1002/jmv.27747.
    >> Share

  260. COTO E, Albaiceta GM, Amado-Rodriguez L, Garcia-Clemente M, et al
    FURIN gene variants (rs6224/rs4702) as potential markers of deat hand cardiovascular traits in severe COVID-19.
    J Med Virol. 2022 Mar 30. doi: 10.1002/jmv.27748.
    >> Share

  261. RAJPAL VR, Sharma S, Kumar A, Chand S, et al
    'Is Omicron mild'? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies.
    J Med Virol. 2022 Mar 30. doi: 10.1002/jmv.27749.
    >> Share

  262. SINGH R, Kaur U, Singh A, Chakrabarti SS, et al
    Refractory hyper-eosinophilia associated with newly diagnosed rheumatoid arthritis following inactivated BBV152 COVID-19 vaccine.
    J Med Virol. 2022 Mar 29. doi: 10.1002/jmv.27742.
    >> Share

  263. REITER RJ, Sharma R, Tan DX, Neel RL, et al
    Melatonin Use for SARS-CoV-2 Infection:Time to Diversify the Treatment Portfolio.
    J Med Virol. 2022 Mar 26. doi: 10.1002/jmv.27740.
    >> Share

  264. WANG W, Peng X, Jin Y, Pan JA, et al
    Reverse genetics systems for SARS-CoV-2.
    J Med Virol. 2022 Mar 24. doi: 10.1002/jmv.27738.
    >> Share

  265. CHEN Q, Huang XY, Liu Y, Sun MX, et al
    Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice.
    J Med Virol. 2022 Mar 23. doi: 10.1002/jmv.27735.
    >> Share

  266. ZHU G, Zhou S, Xu Y, Gao R, et al
    Mendelian randomization study on the causal effects of COVID-19 on childhood intelligence.
    J Med Virol. 2022 Mar 23. doi: 10.1002/jmv.27736.
    >> Share

  267. YANG S, Zhou H, Liu M, Jaijyan D, et al
    SARS-CoV-2, SARS-CoV and MERS-CoV encode circular RNAs of spliceosome-independent origin.
    J Med Virol. 2022 Mar 22. doi: 10.1002/jmv.27734.
    >> Share

  268. OZTAS M, Bektas M, Karacan I, Aliyeva N, et al
    Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27731.
    >> Share

  269. MASYENI S, Iqhrammullah M, Frediansyah A, Nainu F, et al
    Molnupiravir: a lethal mutagenic drug against rapidly mutating SARS-CoV-2 - A narrative review.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27730.
    >> Share

  270. FERNANDEZ-DE-LAS-PENAS C, Martin-Guerrero JD, Navarro-Pardo E, Torres-Macho J, et al
    Exploring the recovery curve for gastrointestinal symptoms from the acute COVID-19 phase to long-term post-COVID: The LONG-COVID-EXP-CM Multicenter Study.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27727.
    >> Share

  271. MAGALIS BR, Mavian C, Tagliamonte M, Rich SN, et al
    Low-frequency variants in mildly symptomatic vaccine breakthrough infections presents a doubled-edged sword.
    J Med Virol. 2022 Mar 20. doi: 10.1002/jmv.27726.
    >> Share

  272. HASSANIAZAD M, Farshidi H, Gharibzadeh A, Bazram A, et al
    Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with covid-19: a randomized clinical trial.
    J Med Virol. 2022 Mar 16. doi: 10.1002/jmv.27724.
    >> Share

  273. TSAGKARIS C, Loudovikou A, Matiashova L, Papadakis M, et al
    Public health concerns over polio in war-torn Ukraine and nearby regions: Four lessons and a warning from the history of epidemics.
    J Med Virol. 2022 Mar 15. doi: 10.1002/jmv.27723.
    >> Share

  274. MISHRA AR, Nayak D, Byrareddy SN
    Are we moving towards ending SARS-CoV-2?
    J Med Virol. 2022 Mar 14. doi: 10.1002/jmv.27722.
    >> Share

  275. YAN Y, Tang YD, Zheng C
    When cyclin-dependent kinases meet viral infections, including SARS-CoV-2.
    J Med Virol. 2022 Mar 14. doi: 10.1002/jmv.27719.
    >> Share

  276. QIN S, Li R, Zheng Z, Zeng X, et al
    Review of selected animal models for respiratory coronavirus infection and its application in drug research.
    J Med Virol. 2022 Mar 13. doi: 10.1002/jmv.27718.
    >> Share

  277. DHEIR H, Tocoglu A, Toptan H, Pinar M, et al
    Short and mid-term SARS-CoV-2 antibody response after inactivated COVID-19 vaccine in hemodialysis and kidney transplant patients.
    J Med Virol. 2022 Mar 12. doi: 10.1002/jmv.27714.
    >> Share

  278. SHEN L, Sun M, Song S, Hu Q, et al
    The impact of anti-COVID-19 non-pharmaceutical interventions on hand, foot, and mouth disease-a spatiotemporal perspective in Xi'an, northwestern China.
    J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27715.
    >> Share

  279. CHAVDA VP, Patel AB, Vaghasiya DD
    SARS-CoV-2 variants and vulnerability at the global level.
    J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27717.
    >> Share

  280. ARCANI R, Cauchois R, Suchon P, Jean R, et al
    Factors associated with dexamethasone efficacy in COVID-19. A retrospective investigative cohort study.
    J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27712.
    >> Share

  281. YOSHIOKA N, Deguchi M, Hagiya H, Kagita M, et al
    Comparison of Extraction-based and Elution-based Polymerase Chain Reaction Testing, and Automated and Rapid Antigen Testing for the Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2.
    J Med Virol. 2022 Mar 10. doi: 10.1002/jmv.27709.
    >> Share

  282. GHAFOURI M, Saadati H, Taghavi MR, Azimian A, et al
    Survival of the hospitalized patients with COVID-19 receiving Atorvastatin: a randomized clinical trial.
    J Med Virol. 2022 Mar 10. doi: 10.1002/jmv.27710.
    >> Share

  283. XIAO F, Wan P, Wei Q, Wei G, et al
    Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: a case report and literature overview.
    J Med Virol. 2022 Mar 10. doi: 10.1002/jmv.27694.
    >> Share

  284. ARORA G, Taneja J, Bhardwaj P, Goyal S, et al
    Adverse events and Breakthrough infections associated with COVID-19 vaccination in the Indian population.
    J Med Virol. 2022 Mar 8. doi: 10.1002/jmv.27708.
    >> Share

  285. DIRICAN E, Savrun ST, Aydin IE, Gulbay G, et al
    ANALYSIS OF MITOCHONDRIAL DNA CYTOCHROME-B (CYB) and ATPase-6 GENE MUTATIONS IN COVID-19 PATIENTS.
    J Med Virol. 2022 Mar 8. doi: 10.1002/jmv.27704.
    >> Share

  286. CAI C, Tang YD, Zheng C
    When RING Finger Family Proteins meet SARS-CoV-2.
    J Med Virol. 2022 Mar 7. doi: 10.1002/jmv.27701.
    >> Share

  287. LIU N, Long H, Sun J, Li H, et al
    New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression.
    J Med Virol. 2022 Mar 5. doi: 10.1002/jmv.27693.
    >> Share

  288. CHENCHULA S, Karunakaran P
    Current Evidence on Efficacy of COVID-19 Booster Dose Vaccination Against the Omicron Variant. A Systematic Review.
    J Med Virol. 2022 Mar 4. doi: 10.1002/jmv.27697.
    >> Share

  289. RAMIREZ JD, Castaneda S, Ballesteros N, Munoz M, et al
    Hotspots for SARS-CoV-2 Omicron Variant Spread: Lessons from New York City.
    J Med Virol. 2022 Mar 3. doi: 10.1002/jmv.27691.
    >> Share

  290. COLSON P, Delerce J, Beye M, Levasseur A, et al
    First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France.
    J Med Virol. 2022 Mar 3. doi: 10.1002/jmv.27695.
    >> Share

  291. TSUCHIDA T, Hirose M, Inoue Y, Kunishima H, et al
    Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID.
    J Med Virol. 2022 Mar 2. doi: 10.1002/jmv.27689.
    >> Share

  292. MARGIOTTI K, Fabiani M, Mesoraca A, Giorlandino C, et al
    Survey of fully vaccinated anti-COVID 19 people from June to November 2021: Single Italian centre study.
    J Med Virol. 2022 Mar 2. doi: 10.1002/jmv.27690.
    >> Share

  293. OLIVEIRA GS, Silva-Flannery L, da Silva JF, Siza C, et al
    Active surveillance and early detection of community transmission of SARS-CoV-2 Mu variant (B.1.621) in the Brazilian Amazon.
    J Med Virol. 2022 Mar 2. doi: 10.1002/jmv.27686.
    >> Share

  294. CICCARESE G, Drago F, Marinaro E, Parodi A, et al
    PITYRIASIS ROSEA DURING COVID-19: PATHOGENESIS, DIAGNOSIS AND TREATMENT.
    J Med Virol. 2022 Mar 1. doi: 10.1002/jmv.27672.
    >> Share

  295. LIMA ARJ, Ribeiro G, Viala VL, Lima LPO, et al
    SARS-COV-2 GENOMIC MONITORING IN THE STATE OF SAO PAULO UNVEILS TWO EMERGING AY.43 SUBLINEAGES.
    J Med Virol. 2022 Mar 1. doi: 10.1002/jmv.27674.
    >> Share

    February 2022
  296. GIANNOS P, Prokopidis K
    Gut Dysbiosis and Long COVID-19: Feeling Gutted.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27684.
    >> Share

  297. NOTARTE KI, Guerrero-Arguero I, Velasco JV, Ver AT, et al
    Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27688.
    >> Share

  298. LETAFATI A, Aghamirmohammadali FS, Rahimi-Foroushani A, Hasani SA, et al
    No Human Respiratory Syncytial Virus but SARS-CoV-2 in children under 5 years old referred to Children Medical Center in 2021, Tehran, Iran.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27685.
    >> Share

  299. CHIU W, Verschueren L, Eynde CVD, Buyck C, et al
    Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27683.
    >> Share

  300. HAUSLER M, Kleines M
    The SARS-CoV-2 pandemic in Germany may represent the sum of a large number of local but independent epidemics each initiated by individuals aged 10 - 19 years, middle aged males, or elderly individuals.
    J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27682.
    >> Share

  301. ZENG L, Zang F, Song N, Li Z, et al
    Analysis of influenza trend and impact of COVID-19 in Kezhou, Xinjiang for 8 consecutive years.
    J Med Virol. 2022 Feb 25. doi: 10.1002/jmv.27678.
    >> Share

  302. LINSSEN J, Schapendonk C, Munster M, Daemen P, et al
    A method comparison study of the high throughput automated HISCL((R)) SARS-CoV-2 antigen assay using nasopharyngeal swab samples from symptomatic and asymptomatic subjects against conventional RT-PCR.
    J Med Virol. 2022 Feb 25. doi: 10.1002/jmv.27679.
    >> Share

  303. BORDINO V, Marengo N, Garlasco J, Cornio AR, et al
    Cross-sectional study of SARS-CoV-2 seropositivity among health-care workers and residents of long-term facilities in Italy, January 2021.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27670.
    >> Share

  304. ACER O, Bahce YG, Ozudogru O
    Association of viral load with age, gender, disease severity and death in SARS-CoV-2 variants.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27677.
    >> Share

  305. LEFEUVRE C, Pivert A, Przyrowski E, Bouthry E, et al
    Comparison of performance between three SARS-CoV-2 molecular assays (Aptima, Laboratory developed test-Fusion and R-GENE(R)) with a special attention on turn-around time, key point in the laboratory management.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27675.
    >> Share

  306. DUAN Y, Yuan C, Suo X, Cao L, et al
    TET2 is Required for Type I IFN-mediated Inhibition of Bat-Origin Swine Acute Diarrhea Syndrome Coronavirus.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27673.
    >> Share

  307. YADAV PD, Nyayanit DA, Gupta N, Shastri J, et al
    Detection and isolation of SARS-CoV-2 Eta variant from the international travelers and local residents of India.
    J Med Virol. 2022 Feb 24. doi: 10.1002/jmv.27676.
    >> Share

  308. SOBOLEWSKI KA, Smoke SM, Brophy A, Vassallo AV, et al
    Real world evaluation of the impact of two Anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults.
    J Med Virol. 2022 Feb 23. doi: 10.1002/jmv.27668.
    >> Share

  309. PAPPA S, Haidopoulou K, Zarras C, Theodorakou E, et al
    Early initiation of the respiratory syncytial virus season in 2021-2022, Greece.
    J Med Virol. 2022 Feb 23. doi: 10.1002/jmv.27671.
    >> Share

  310. BUSIC N, Lucijanic T, Barsic B, Luksic I, et al
    Vaccination provides protection from respiratory deterioration and death among hospitalized COVID-19 patients: differences between vector and mRNA vaccines.
    J Med Virol. 2022 Feb 20. doi: 10.1002/jmv.27666.
    >> Share

  311. ATA S, Cil T, Duman BB, Unal N, et al
    EVALUATION OF ANTIBODY RESPONSE AFTER TWO DOSES OF THE SINOVAC VACCINE AND THE POTENTIAL NEED FOR BOOSTER DOSES IN CANCER PATIENTS.
    J Med Virol. 2022 Feb 18. doi: 10.1002/jmv.27665.
    >> Share

  312. DESINGU PA, Nagarajan K
    Omicron variant losing its critical mutations in the receptor-binding domain.
    J Med Virol. 2022 Feb 18. doi: 10.1002/jmv.27667.
    >> Share

  313. PASCARELLA S, Bianchi M, Giovanetti M, Narzi D, et al
    The SARS-CoV-2 mu variant shouldn't be left aside: it warrants attention for its immuo-escaping ability.
    J Med Virol. 2022 Feb 16. doi: 10.1002/jmv.27663.
    >> Share

  314. ZHOU JQ, Liu GX, Huang XL, Gan HT, et al
    The importance of fecal nucleic acid detection in patients with coronavirus disease(COVID-19):a systematic review and meta-analysis.
    J Med Virol. 2022 Feb 16. doi: 10.1002/jmv.27652.
    >> Share

  315. HERNANDEZ MM, Riollano-Cruz M, Boyle MC, Banu R, et al
    Food for thought: Eating before saliva collection and interference with SARS-CoV-2 detection.
    J Med Virol. 2022 Feb 16. doi: 10.1002/jmv.27660.
    >> Share

  316. CROSS GB, Naftalin CM, Ngiam JN, Bagdasarian N, et al
    Discrepant serological findings in SARS-CoV-2 PCR negative, hospitalised patients with fever and acute respiratory symptoms during the pandemic.
    J Med Virol. 2022 Feb 16. doi: 10.1002/jmv.27656.
    >> Share

  317. CHEN JM
    Novel statistics predict the COVID-19 pandemic could terminate in 2022.
    J Med Virol. 2022 Feb 11. doi: 10.1002/jmv.27661.
    >> Share

  318. DESINGU PA, Nagarajan K
    Omicron BA.2 lineage spreads in clusters and is concentrated in Denmark.
    J Med Virol. 2022 Feb 11. doi: 10.1002/jmv.27659.
    >> Share

  319. PARIDA SP, Sahu DP, Singh AK, Alekhya G, et al
    Adverse Events Following Immunization of COVID-19 (Covaxin) vaccine at a Tertiary Care Center of India.
    J Med Virol. 2022 Feb 11. doi: 10.1002/jmv.27655.
    >> Share

  320. LAMPEJO DT
    The impact of the COVID-19 pandemic on the global burden of influenza.
    J Med Virol. 2022 Feb 10. doi: 10.1002/jmv.27653.
    >> Share

  321. ZHANG H, Fischer DK, Shuda M, Moore PS, et al
    Construction and characterization of two SARS-CoV-2 minigenome replicon systems.
    J Med Virol. 2022 Feb 9. doi: 10.1002/jmv.27650.
    >> Share

  322. PARK J, Il Shin J, Kim DH, Park J, et al
    Association of atrial fibrillation with infectivity and severe complications of COVID-19: A nationwide cohort study.
    J Med Virol. 2022 Feb 7. doi: 10.1002/jmv.27647.
    >> Share

  323. GUMUS H, Erat T, Ozturk I, Demir A, et al
    Oxidative Stress and Decreased Nrf2 Level in Paediatric Patients with COVID-19.
    J Med Virol. 2022 Feb 6. doi: 10.1002/jmv.27640.
    >> Share

  324. DUNDAR B, Karahangil K, Elgormus CS, Topsakal HNH, et al
    Efficacy of Antibody Response Following the Vaccination of SARS-CoV-2 Infected and Non-Infected Healthcare Workers by Two-Dose Inactive Vaccine against COVID-19.
    J Med Virol. 2022 Feb 6. doi: 10.1002/jmv.27649.
    >> Share

  325. STAUFT CB, Selvaraj P, Lien CZ, Starost MF, et al
    Long-Term Immunity in Convalescent Syrian Hamsters Provides Protection against New-Variant SARS-CoV-2 Infection of the Lower but not Upper Respiratory Tract.
    J Med Virol. 2022 Feb 6. doi: 10.1002/jmv.27641.
    >> Share

  326. TIAN D, Sun Y, Xu H, Ye Q, et al
    The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant.
    J Med Virol. 2022 Feb 3. doi: 10.1002/jmv.27643.
    >> Share

  327. PETRELLI F, Luciani A, Borgonovo K, Ghilardi M, et al
    Third Dose of SARS-CoV-2 Vaccine: A Systematic Review of 30 Published Studies.
    J Med Virol. 2022 Feb 3. doi: 10.1002/jmv.27644.
    >> Share

  328. MOHAPATRA RK, Tiwari R, Sarangi AK, Islam DR, et al
    COMMENTARYOmicron (B.1.1.529) variant of SARS-CoV-2- Concerns, challenges and recent updates.
    J Med Virol. 2022 Feb 3. doi: 10.1002/jmv.27633.
    >> Share

  329. R M, K S
    An exploratory study on the propagation of SARS-CoV-2 variants: Omicron is the most predominant variant.
    J Med Virol. 2022 Feb 3. doi: 10.1002/jmv.27634.
    >> Share

  330. CHIRUMBOLO S, Pandolfi S
    Escaping from COVID-19 emergency accounting on previously infected subjects?
    J Med Virol. 2022 Feb 2. doi: 10.1002/jmv.27645.
    >> Share

  331. TIAN D, Song Y, Zhang M, Pan Y, et al
    Genomic, immunological and clinical analysis of COVID-19 vaccine breakthrough infections in Beijing, China.
    J Med Virol. 2022 Feb 2. doi: 10.1002/jmv.27636.
    >> Share

  332. LUAN N, Wang Y, Cao H, Lin K, et al
    Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS-CoV-2 vaccine in mice.
    J Med Virol. 2022 Feb 2. doi: 10.1002/jmv.27637.
    >> Share

  333. DESINGU PA, Nagarajan K
    SARS-CoV-2 Omicron variant is spreading in different parts of the world in three different trends.
    J Med Virol. 2022 Feb 2. doi: 10.1002/jmv.27646.
    >> Share

  334. WALKER GJ, Stelzer-Braid S, Shorter C, Honeywill C, et al
    Viruses associated with acute respiratory infection in a community-based cohort of healthy New Zealand children.
    J Med Virol. 2022;94:454-460.
    >> Share

  335. BARBOSA G, Cunha Chaves AP, Kleber de Souza Luna L, Bellei N, et al
    SARS-CoV-2 breakthrough infection and viral load among health care workers after COVID-19 vaccines.
    J Med Virol. 2022 Feb 1. doi: 10.1002/jmv.27639.
    >> Share

  336. MILANO E, Ricciardi A, Casciaro R, Pallara E, et al
    Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: a monocentric study in Bari, Italy.
    J Med Virol. 2022 Feb 1. doi: 10.1002/jmv.27629.
    >> Share

    January 2022
  337. YADAV PD, Niyas VKM, Arjun R, Sahay RR, et al
    Detection of Zika virus disease in Thiruvananthapuram, Kerala, India 2021 during second wave of COVID-19 pandemic.
    J Med Virol. 2022 Jan 31. doi: 10.1002/jmv.27638.
    >> Share

  338. GHAYDA RA, Lee KH, Han YJ, Ryu S, et al
    Global case fatality rate of coronavirus disease 2019 (COVID-19) by continents and national income: a meta-analysis.
    J Med Virol. 2022 Jan 31. doi: 10.1002/jmv.27610.
    >> Share

  339. DARIA S, Islam MR
    The SARS-CoV-2 omicron wave is indicating the end of the pandemic phase but the COVID-19 will continue.
    J Med Virol. 2022 Jan 30. doi: 10.1002/jmv.27635.
    >> Share

  340. SILVA SJRD
    Comparing studies of SARS-CoV-2 viral loads requires caution.
    J Med Virol. 2022 Jan 28. doi: 10.1002/jmv.27631.
    >> Share

  341. NUNES PR, Romao-Veiga M, Ribeiro VR, Peracoli JC, et al
    COVID-19: a new risk factor or just a new imitator of preeclampsia? NLRP3 activation: a possible commom mechanism.
    J Med Virol. 2022 Jan 28. doi: 10.1002/jmv.27632.
    >> Share

  342. LIN WT, Hung SH, Lai CC, Wang CY, et al
    The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials.
    J Med Virol. 2022 Jan 27. doi: 10.1002/jmv.27623.
    >> Share

  343. ZHAO W, Li H, Li J, Xu B, et al
    The mechanism of multiple organ dyfunction syndrome in patients with COVID-19.
    J Med Virol. 2022 Jan 27. doi: 10.1002/jmv.27627.
    >> Share

  344. SHARMA V, Rai H, Gautam DNS, Prajapati PK, et al
    Emerging evidence on Omicron (B.1.1.529) SARS-CoV-2 variant.
    J Med Virol. 2022 Jan 26. doi: 10.1002/jmv.27626.
    >> Share

  345. XIANYU Y, Wang M, Yue F, Xu X, et al
    One year follow-up of 18 women who infected COVID-19 while pregnant.
    J Med Virol. 2022 Jan 26. doi: 10.1002/jmv.27628.
    >> Share

  346. HU Y, Jo H, DeGrado WF, Wang J, et al
    Brilacidin, a COVID-19 Drug Candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E and NL63 through targeting both the virus and the host cell.
    J Med Virol. 2022 Jan 25. doi: 10.1002/jmv.27616.
    >> Share

  347. YE Q, Lu D, Zhang T, Mao J, et al
    Recent advances and clinical application in point-of-care testing of SARS-CoV-2.
    J Med Virol. 2022 Jan 25. doi: 10.1002/jmv.27617.
    >> Share

  348. CAGLAYAN D, Suner AF, Siyve N, Guzel I, et al
    An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey.
    J Med Virol. 2022 Jan 25. doi: 10.1002/jmv.27620.
    >> Share

  349. ADLI A, Rahimi M, Khodaie R, Hashemzaei N, et al
    Role of Genetic Variants and Host Polymorphisms on COVID-19: From Viral Entrance Mechanisms to Immunological Reactions.
    J Med Virol. 2022 Jan 24. doi: 10.1002/jmv.27615.
    >> Share

  350. HUANG C, Yang L, Pan J, Xu X, et al
    Correlation between vaccine coverage and the COVID-19 pandemic throughout the world: based on real-world data.
    J Med Virol. 2022 Jan 24. doi: 10.1002/jmv.27609.
    >> Share

  351. WANG L, Guo X, Zhao N, Ouyang Y, et al
    Effects of the Enhanced Public Health Intervention during the COVID-19 Epidemic on Respiratory and Gastrointestinal Infectious Diseases in China.
    J Med Virol. 2022 Jan 23. doi: 10.1002/jmv.27619.
    >> Share

  352. LEON FJF, Silva LLD, Santos AC, Duarte da Costa V, et al
    Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
    J Med Virol. 2022 Jan 22. doi: 10.1002/jmv.27614.
    >> Share

  353. FILIPPATOS F, Tatsi EB, Dellis C, Efthymiou V, et al
    Seroepidemiology of SARS-CoV-2 in pediatric population during a 16-month period prior to vaccination.
    J Med Virol. 2022 Jan 21. doi: 10.1002/jmv.27608.
    >> Share

  354. SCHMITT G, Labdouni S, Soulimani R, Delamare C, et al
    Oxidative stress status and vitamin D levels of asymptomatic to mild symptomatic COVID-19 infections during the third trimester of pregnancy: A retrospective study in Metz, France.
    J Med Virol. 2022 Jan 21. doi: 10.1002/jmv.27606.
    >> Share

  355. SAXENA SK, Kumar S, Ansari S, Paweska JT, et al
    Transmission dynamics and mutational prevalence of the novel SARS-CoV-2 Omicron Variant of Concern.
    J Med Virol. 2022 Jan 20. doi: 10.1002/jmv.27611.
    >> Share

  356. FONSECA MHG, de Souza TFG, de Carvalho Araujo FM, de Andrade LOM, et al
    Dynamics of antibody response to CoronaVac vaccine.
    J Med Virol. 2022 Jan 20. doi: 10.1002/jmv.27604.
    >> Share

  357. BSHESH K, Khan W, Vattoth AL, Janjua E, et al
    Lymphadenopathy Post-COVID-19 Vaccination with Increased FDG Uptake May Be Falsely Attributed to Oncological Disorders: A Systematic Review.
    J Med Virol. 2022 Jan 20. doi: 10.1002/jmv.27599.
    >> Share

  358. ETEROVIC A, Speranca MA, Campos IB, Colpas DR, et al
    SARS-CoV-2 intralineage variation and temporal patterns of COVID-19 risk factors in three cities of Southeastern Brazil: age, sex, and race.
    J Med Virol. 2022 Jan 20. doi: 10.1002/jmv.27607.
    >> Share

  359. HOUHAMDI L, Gautret P, Hoang VT, Fournier PE, et al
    Characteristics of the first 1,119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December 2021.
    J Med Virol. 2022 Jan 20. doi: 10.1002/jmv.27613.
    >> Share

  360. WANG ZH, Fu BQ, Lin YW, Wei XB, et al
    Red Blood Cell Distribution Width: a severity indicator in patients with COVID-19.
    J Med Virol. 2022 Jan 19. doi: 10.1002/jmv.27602.
    >> Share

  361. BIANCOFIORE A, Mirijello A, Puteo MA, Viesti MPD, et al
    Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospitalized patients with COVID-19: a retrospective case-control study.
    J Med Virol. 2022 Jan 18. doi: 10.1002/jmv.27598.
    >> Share

  362. DESINGU PA, Nagarajan K, Dhama K
    Emergence of Omicron third lineage BA.3 and its importance.
    J Med Virol. 2022 Jan 18. doi: 10.1002/jmv.27601.
    >> Share

  363. MARUOTTI A, Giovanetti M, Divino F, Broccolo F, et al
    Prisoners of variants, or free to act as prisoners of swabs? The case of Italy.
    J Med Virol. 2022 Jan 17. doi: 10.1002/jmv.27597.
    >> Share

  364. ESMAEILI ED, Fakhari A, Naghili B, Khodamoradi F, et al
    Case fatality, mortality, socio-demographic, and screening of COVID-19 in the elderly population: A population-based registry study in Iran.
    J Med Virol. 2022 Jan 15. doi: 10.1002/jmv.27594.
    >> Share

  365. SIMSEK A, Kizmaz MA, Cagan E, Dombaz F, et al
    Assessment of CD39 expression in regulatory T cell subsets by disease severity in adult and juvenile COVID -19 cases.
    J Med Virol. 2022 Jan 14. doi: 10.1002/jmv.27593.
    >> Share

  366. LI T, Cui Z, Jia Y, Liang Z, et al
    Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift.
    J Med Virol. 2022 Jan 14. doi: 10.1002/jmv.27596.
    >> Share

  367. LAN SH, Lee HZ, Chao CM, Chang SP, et al
    Efficacy of Melatonin in the Treatment of Patients With COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Med Virol. 2022 Jan 14. doi: 10.1002/jmv.27595.
    >> Share

  368. ALI MA, Hu C, Zhang F, Jahan S, et al
    N protein-based ultrasensitive SARS-CoV-2 antibody detection in seconds via 3D nanoprinted, microarchitected array electrodes.
    J Med Virol. 2022 Jan 14. doi: 10.1002/jmv.27591.
    >> Share

  369. DUGGAL P, Penson T, Manley HN, Vergara C, et al
    Post-sequelae symptoms and comorbidities after COVID-19.
    J Med Virol. 2022 Jan 14. doi: 10.1002/jmv.27586.
    >> Share

  370. NETO AS, Landoni G, Ostermann M, Lumlertgul N, et al
    Angiotensin II Infusion in COVID-19: An International, Multicenter, Registry-based Study.
    J Med Virol. 2022 Jan 14. doi: 10.1002/jmv.27592.
    >> Share

  371. MENG H, Mao J, Ye Q
    Booster vaccination strategy: Necessity, Immunization Objectives, Immunization Strategy and Safety.
    J Med Virol. 2022 Jan 13. doi: 10.1002/jmv.27590.
    >> Share

  372. ARAF Y, Akter F, Tang YD, Fatemi R, et al
    Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines.
    J Med Virol. 2022 Jan 12. doi: 10.1002/jmv.27588.
    >> Share

  373. DEVRIM I, Boncuoglu E, Kiymet E, Sahinkaya S, et al
    Comparison of the pediatric hospitalizations due to COVID-19 and H1N1pdm09 virus infections during the pandemic period.
    J Med Virol. 2022 Jan 12. doi: 10.1002/jmv.27589.
    >> Share

  374. CELEBI MY, Kiymet E, Boncuoglu E, Sahinkaya S, et al
    Evaluation of childhood hospitalization rates and degree of severity of SARS-CoV-2 variants including of the B.1.1.7 (Alpha), B.1.315/P.1 (Beta/Gamma), and B.1.617.2 (Delta).
    J Med Virol. 2022 Jan 11. doi: 10.1002/jmv.27587.
    >> Share

  375. MOHAPATRA RK, Tiwari R, Sarangi AK, Sharma SK, et al
    Twin combination of Omicron and Delta variant triggering a Tsunami wave of ever high surges in COVID-19 cases: a challenging global threat with a special focus on Indian sub-continent.
    J Med Virol. 2022 Jan 10. doi: 10.1002/jmv.27585.
    >> Share

  376. CHEN Y, Li S, Wu W, Geng S, et al
    Distinct mutations and lineages of SARS-CoV-2 virus in the early phase of COVID-19 pandemic and subsequent one-year global expansion.
    J Med Virol. 2022 Jan 9. doi: 10.1002/jmv.27580.
    >> Share

  377. KERGET B, Celik E, Kerget F, Aksakal A, et al
    Evaluation of 3-month follow-up of patients with post-acute COVID-19 syndrome.
    J Med Virol. 2022 Jan 9. doi: 10.1002/jmv.27579.
    >> Share

  378. FANTINI J, Yahi N, Colson P, Chahinian H, et al
    The puzzling mutational landscape of the SARS-2-variant Omicron.
    J Med Virol. 2022 Jan 8. doi: 10.1002/jmv.27577.
    >> Share

  379. YUAN S, Jiang SC, Zhang ZW, Fu YF, et al
    Arrhythmia May Contribute to Neuropsychiatric Symptoms in COVID-19 Patients.
    J Med Virol. 2022 Jan 8. doi: 10.1002/jmv.27583.
    >> Share

  380. NIKOLOVA M, Todorova Y, Emilova R, Trifonova I, et al
    INDUCTION OF HUMORAL AND CELLULAR IMMUNE RESPONSES TO COVID-19 mRNA AND VECTOR VACCINES: A PROSPECTIVE COHORT STUDY IN BULGARIAN HEALTHCARE WORKERS.
    J Med Virol. 2022 Jan 7. doi: 10.1002/jmv.27572.
    >> Share

  381. ARTIK Y, Cosgun AB, Cesur NP, Hizel N, et al
    COMPARISON OF COVID-19 LABORATORY DIAGNOSIS BY COMMERCIAL KITS: EFFECTIVITY OF RT-PCR TO THE RT-LAMP.
    J Med Virol. 2022 Jan 7. doi: 10.1002/jmv.27559.
    >> Share

  382. FERRAVANTE C, Sanna G, Melone V, Fromentier A, et al
    Nasopharyngeal virome analysis of COVID-19 patients during three different waves in Campania Region of Italy.
    J Med Virol. 2022 Jan 6. doi: 10.1002/jmv.27571.
    >> Share

  383. SOHAN M, Hossain MJ, Islam MR
    The SARS-CoV-2 Omicron (B.1.1.529) variant and effectiveness of existing vaccines: What we know so far.
    J Med Virol. 2022 Jan 6. doi: 10.1002/jmv.27574.
    >> Share

  384. LIPPI G, Mattiuzzi C, Henry BM
    Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variant.
    J Med Virol. 2022 Jan 5. doi: 10.1002/jmv.27575.
    >> Share

  385. EVANGELOU K, Rozani S, Tsagkaris C
    Monoclonal antibodies as a trick or treat for COVID-19? The example of abciximab.
    J Med Virol. 2022 Jan 4. doi: 10.1002/jmv.27573.
    >> Share

  386. YE Q, Wang D
    Epidemiological changes of common respiratory viruses in children during the COVID-19 pandemic.
    J Med Virol. 2022 Jan 4. doi: 10.1002/jmv.27570.
    >> Share

  387. KHAN YH, Salman M, Butt MH, Mallhi TH, et al
    Viral Fever of unknown Origin during COVID-19 and Dengue Outbreaks in Pakistan; Is Media spreading panic during pandemic?
    J Med Virol. 2022 Jan 4. doi: 10.1002/jmv.27569.
    >> Share

  388. KOW CS, Ramachandram DS, Hasan SS
    The effectiveness of mRNA-1273 vaccine against COVID-19 caused by delta variant: A systematic review and meta-analysis.
    J Med Virol. 2022 Jan 3. doi: 10.1002/jmv.27568.
    >> Share

  389. MOUSAVI SH, Qaderi S, Ahmadi A, Arman SI, et al
    The daunting task of fighting HIV in Afghanistan: Current evidence and future recommendationsThe daunting task of fighting HIV in Afghanistan: Current evidence and future recommendations.
    J Med Virol. 2022 Jan 3. doi: 10.1002/jmv.27566.
    >> Share

  390. ANDREATA-SANTOS R, Janini LMR, Duraes-Carvalho R
    From Alpha to Omicron SARS-CoV-2 variants: What their evolutionary signatures can tell us?
    J Med Virol. 2022 Jan 3. doi: 10.1002/jmv.27555.
    >> Share

  391. ADACHI E, Saito M, Nagai H, Ikeuchi K, et al
    Transient depletion of T cells during COVID-19 and seasonal influenza in people living with HIV.
    J Med Virol. 2022 Jan 2. doi: 10.1002/jmv.27543.
    >> Share

    December 2021
  392. YAKOOT M
    Non-significant Trends in COVID-19 Trials: Is There a Significance?
    J Med Virol. 2021 Dec 31. doi: 10.1002/jmv.27565.
    >> Share

  393. ITO K, Piantham C, Nishiura H
    Relative Instantaneous Reproduction Number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark.
    J Med Virol. 2021 Dec 30. doi: 10.1002/jmv.27560.
    >> Share

  394. BASTUG A, Bodur H, Aydos O, Filazi N, et al
    The changing dynamics of neutralizing antibody response within ten months of SARS-CoV-2 infections.
    J Med Virol. 2021 Dec 30. doi: 10.1002/jmv.27544.
    >> Share

  395. LIU W, Long X, Wan K, Yin M, et al
    The endogenous factors affecting the detection of serum SARS-CoV-2 IgG/IgM antibodies by ELISA.
    J Med Virol. 2021 Dec 29. doi: 10.1002/jmv.27557.
    >> Share

  396. XIAO F, Zhou Y, Zhang M, Chen D, et al
    Hyperglycemia and blood glucose deterioration are risk factors for severe COVID-19 with diabetes: a two-center cohort study.
    J Med Virol. 2021 Dec 29. doi: 10.1002/jmv.27556.
    >> Share

  397. WU K, Wu X, Wang W, Hong L, et al
    Epidemiology of influenza under the coronavirus disease 2019 pandemic in Nanjing, China.
    J Med Virol. 2021 Dec 29. doi: 10.1002/jmv.27553.
    >> Share

  398. MOHAPATRA RK, Sarangi AK, Kandi V, Azam M, et al
    Omicron (B.1.1.529 variant of SARS-CoV-2); an emerging threat: current global scenario.
    J Med Virol. 2021 Dec 29. doi: 10.1002/jmv.27561.
    >> Share

  399. LI A, Maier A, Carter M, Hugh Guan T, et al
    Omicron and S-Gene Target Failure Cases in the Highest COVID-19 Case Rate Region in Canada - December 2021.
    J Med Virol. 2021 Dec 29. doi: 10.1002/jmv.27562.
    >> Share

  400. RAHMANI S, Rezaei N
    Omicron (B.1.1.529) Variant: Development, Dissemination, and Dominance.
    J Med Virol. 2021 Dec 29. doi: 10.1002/jmv.27563.
    >> Share

  401. DRAGIOTI E, Li H, Tsitsas G, Lee KH, et al
    A large scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic.
    J Med Virol. 2021 Dec 27. doi: 10.1002/jmv.27549.
    >> Share

  402. KERGET B, Kerget F, Aydin M, Karasahin O, et al
    Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19.
    J Med Virol. 2021 Dec 27. doi: 10.1002/jmv.27552.
    >> Share

  403. HE L, Zeng C, Zeng Y, Xu W, et al
    Antibody Responses of the First Wave of Survivors infected with SARS-CoV-2 One Year Ago.
    J Med Virol. 2021 Dec 25. doi: 10.1002/jmv.27551.
    >> Share

  404. NEMR WA, Radwan NK
    TYPING OF ALPHA AND BETA CORONAVIRUSES BY DNA BAR CODING OF NSP12 GENE.
    J Med Virol. 2021 Dec 24. doi: 10.1002/jmv.27550.
    >> Share

  405. PAPAROUPA M, Aldemyati R, Roggenkamp H, Berinson B, et al
    The Prevalence of Early- and Late-Onset Bacterial, Viral and Fungal Respiratory Superinfections in Invasively Ventilated COVID-19 Patients.
    J Med Virol. 2021 Dec 24. doi: 10.1002/jmv.27548.
    >> Share

  406. ISLAM R, Hossain J
    Detection of Omicron (B.1.1.529) variant has created panic among the people across the world: What should we do right now?
    J Med Virol. 2021 Dec 23. doi: 10.1002/jmv.27546.
    >> Share

  407. RAHAMAN MM, Sarkar MMH, Rahman MS, Islam MR, et al
    Genomic characterization of the dominating Beta variant carrying vaccinated (Oxford-AstraZeneca) and non-vaccinated COVID-19 patient samples in Bangladesh: A metagenomics and whole genome approach.
    J Med Virol. 2021 Dec 23. doi: 10.1002/jmv.27537.
    >> Share

  408. SHAH NN, Dar KA, Quibtiya S, Din Azad AMU, et al
    Repurposing of Mycobacterium indicus pranii for the severe form of COVID -19 patients in India: A cohort study.
    J Med Virol. 2021 Dec 23. doi: 10.1002/jmv.27547.
    >> Share

  409. HOSSAIN G, Tang YD, Akter S, Zheng C, et al
    Roles of the polybasic furin cleavage site of spike protein in SARS-CoV-2 replication, pathogenesis, and host immune responses and vaccination.
    J Med Virol. 2021 Dec 22. doi: 10.1002/jmv.27539.
    >> Share

  410. XIANG HR, He B, Li Y, Cheng X, et al
    Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis.
    J Med Virol. 2021 Dec 22. doi: 10.1002/jmv.27542.
    >> Share

  411. THAKUR V, Kanta Ratho R
    OMICRON (B.1.1.529): A new SARS-CoV-2 Variant of Concern mounting worldwide fear.
    J Med Virol. 2021 Dec 22. doi: 10.1002/jmv.27541.
    >> Share

  412. WANG Z, Yang L
    In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery.
    J Med Virol. 2021 Dec 22. doi: 10.1002/jmv.27540.
    >> Share

  413. WU J, Tang J, Zhang T, Chen YC, et al
    Follow-up CT of "Reversed Halo Sign" in SARS-CoV-2 Delta VOC pneumonia: A report of two cases.
    J Med Virol. 2021 Dec 21. doi: 10.1002/jmv.27533.
    >> Share

  414. YE Q, Wang B, Liu H
    Influence of the COVID-19 pandemic on the incidence and exacerbation of childhood allergic diseases.
    J Med Virol. 2021 Dec 21. doi: 10.1002/jmv.27536.
    >> Share

  415. HUSSAIN N, Agarwala P, Iqbal K, Omar HMS, et al
    A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation.
    J Med Virol. 2021 Dec 20. doi: 10.1002/jmv.27534.
    >> Share

  416. MARTORA F, Picone V, Fornaro L, Fabbrocini G, et al
    Can COVID 19 cause atypical forms of Pityriasis Rosea refractory to conventional therapies?
    J Med Virol. 2021 Dec 20. doi: 10.1002/jmv.27535.
    >> Share

  417. LI X
    Omicron: call for updated vaccines.
    J Med Virol. 2021 Dec 20. doi: 10.1002/jmv.27530.
    >> Share

  418. SHANMUGARAJ B, Malla A, Khorattanakulchai N, Phoolcharoen W, et al
    SARS-CoV-2 Omicron Variant: Could it be Another Threat?
    J Med Virol. 2021 Dec 19. doi: 10.1002/jmv.27532.
    >> Share

  419. SOYTAS RB, Cengiz M, Islamoglu MS, Uysal BB, et al
    Antibody responses to COVID-19 vaccines in older adults.
    J Med Virol. 2021 Dec 17. doi: 10.1002/jmv.27531.
    >> Share

  420. PASCARELLA S, Ciccozzi M, Bianchi M, Benvenuto D, et al
    The Electrostatic Potential of the Omicron Variant Spike is Higher than in Delta and Delta-plus Variants: a Hint to Higher Transmissibility?
    J Med Virol. 2021 Dec 16. doi: 10.1002/jmv.27528.
    >> Share

  421. DIVINO F, Maruotti A, Farcomeni A, Jona-Lasinio G, et al
    On the severity of COVID-19 infections in 2021 in Italy.
    J Med Virol. 2021 Dec 16. doi: 10.1002/jmv.27529.
    >> Share

  422. NESR G, Saleem Z, Arami S
    Outcome of COVID-19 in patients with chronic myeloid leukemia: A single centre UK experience.
    J Med Virol. 2021 Dec 15. doi: 10.1002/jmv.27527.
    >> Share

  423. KUMAR S, Thambiraja TS, Karuppanan K, Subramaniam G, et al
    Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike Protein.
    J Med Virol. 2021 Dec 15. doi: 10.1002/jmv.27526.
    >> Share

  424. JIANG P, Wu SH, Zhu T, Guo Y, et al
    A rare case of drug-induced bradycardia associated with the just low dose use of methylprednisolone in a child with COVID-19.
    J Med Virol. 2021 Dec 15. doi: 10.1002/jmv.27525.
    >> Share

  425. SAXENA SK, Kumar S, Ansari S, Paweska JT, et al
    Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) Variant of Concern and its global perspective.
    J Med Virol. 2021 Dec 14. doi: 10.1002/jmv.27524.
    >> Share

  426. KUMAR A
    Mucormycosis in COVID-19 recovered patients.
    J Med Virol. 2021 Dec 14. doi: 10.1002/jmv.27522.
    >> Share

  427. XIE C, Ding H, Ding J, Xue Y, et al
    Preparation of highly specific monoclonal antibodies against SARS-CoV-2 nucleocapsid protein and the preliminary development of antigen detection test strips.
    J Med Virol. 2021 Dec 13. doi: 10.1002/jmv.27520.
    >> Share

  428. WANG L, Cheng G
    Sequence analysis of the Emerging Sars-CoV-2 Variant Omicron in South Africa.
    J Med Virol. 2021 Dec 12. doi: 10.1002/jmv.27516.
    >> Share

  429. BORSETTI A, Scarpa F, Maruotti A, Divino F, et al
    The unresolved question on COVID-19 virus origin: The three cards game?
    J Med Virol. 2021 Dec 12. doi: 10.1002/jmv.27519.
    >> Share

  430. SIM AYC, Naffi AA, Fai TS, Kori N, et al
    Bilateral intermediate uveitis in a healthy teenager with the multisystem inflammatory syndrome in children secondary to COVID-19 infection.
    J Med Virol. 2021 Dec 12. doi: 10.1002/jmv.27521.
    >> Share

  431. OUOBA S, Okimoto M, Nagashima S, Kitahara Y, et al
    Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients.
    J Med Virol. 2021 Dec 12. doi: 10.1002/jmv.27518.
    >> Share

  432. WANG Z, Yang L
    Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges.
    J Med Virol. 2021 Dec 12. doi: 10.1002/jmv.27517.
    >> Share

  433. KANDEEL M, Mohamed MEM, Abd El-Lateef HM, Venugopala KN, et al
    Omicron variant genome evolution and phylogenetics.
    J Med Virol. 2021 Dec 10. doi: 10.1002/jmv.27515.
    >> Share

  434. HAN X, Ye Q
    The variants of SARS-CoV-2 and the challenges of vaccines.
    J Med Virol. 2021 Dec 9. doi: 10.1002/jmv.27513.
    >> Share

  435. CHENG Q, Zhao G, Chen J, Jia Q, et al
    Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: A network meta-analysis of randomized controlled trials.
    J Med Virol. 2021 Dec 9. doi: 10.1002/jmv.27512.
    >> Share

  436. KHAN N, Arshad A, Azam M, Al-Marshadi AH, et al
    Modelling and Forecasting the Total Number of Cases and Deaths Due to Pandemic.
    J Med Virol. 2021 Dec 8. doi: 10.1002/jmv.27506.
    >> Share

  437. HERNANDEZ MM, Banu R, Gonzalez-Reiche AS, van de Guchte A, et al
    Robust clinical detection of SARS-CoV-2 variants by RT-PCR/MALDI-TOF multi-target approach.
    J Med Virol. 2021 Dec 7. doi: 10.1002/jmv.27510.
    >> Share

  438. ROGER S, Lefeuvre C, Pivert A, Ducancelle A, et al
    What is the true place of the SARS-CoV-2 rapid point-of-care antigen test in the hospital setting? Lessons learned from real life.
    J Med Virol. 2021 Dec 6. doi: 10.1002/jmv.27505.
    >> Share

  439. PARK AK, Rhee JE, Kim IH, Kim HM, et al
    Genomic evidence of SARS-CoV-2 reinfection in the Republic of Korea.
    J Med Virol. 2021 Dec 4. doi: 10.1002/jmv.27499.
    >> Share

  440. DARIA S, Bhuiyan MA, Islam MR
    Detection of highly muted coronavirus variant Omicron (B.1.1.529) is triggering the alarm for South Asian countries: Associated risk factors and preventive actions.
    J Med Virol. 2021 Dec 4. doi: 10.1002/jmv.27503.
    >> Share

  441. GAO X, Li G, Wang J, Xu T, et al
    Spatiotemporal evolution, pattern of diffusion and influencing factors of the COVID-19 epidemic in Hainan Province, China.
    J Med Virol. 2021 Dec 4. doi: 10.1002/jmv.27502.
    >> Share

  442. WOO W, Kim AY, Yon DK, Lee SW, et al
    Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine.
    J Med Virol. 2021 Dec 4. doi: 10.1002/jmv.27501.
    >> Share

  443. YAGHOUBI N, Youssefi M, Jabbari Azad F, Farzad F, et al
    Total antioxidant capacity (TAC) as a marker of severity of COVID-19 infection; possible prognostic and therapeutic clinical application.
    J Med Virol. 2021 Dec 4. doi: 10.1002/jmv.27500.
    >> Share

  444. ZHANG X, Meng H, Liu H, Ye Q, et al
    Advances in laboratory detection methods and technology application of SARS-CoV-2.
    J Med Virol. 2021 Dec 2. doi: 10.1002/jmv.27494.
    >> Share

  445. SHANG Y, Liang Y, Liu T, Li J, et al
    Public screening for COVID-19 in Wuhan, China and beware of the antibody positive in women and tumor patients.
    J Med Virol. 2021 Dec 1. doi: 10.1002/jmv.27483.
    >> Share

  446. KOBAYASHI S, Taniguchi Y, Kida I, Tamura N, et al
    SARS-CoV2-triggered acute arthritis: Viral arthritis rather than reactive arthritis.
    J Med Virol. 2021;93:6458-6459.
    >> Share

    November 2021
  447. GAO SJ, Guo H, Luo G
    Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert!
    J Med Virol. 2021 Nov 30. doi: 10.1002/jmv.27491.
    >> Share

  448. SCHAEFER JW, Riley JM, Li M, Cheney-Peters DR, et al
    Comparing Reliability of ICD-10-Based COVID-19 Comorbidity Data to Manual Chart Review, a Retrospective Cross-Sectional Study.
    J Med Virol. 2021 Nov 30. doi: 10.1002/jmv.27492.
    >> Share

  449. MOOSAZADEH M, Mousavi T
    Combination therapy of tocilizumab and steroid for COVID-19 patients: A meta-analysis.
    J Med Virol. 2021 Nov 30. doi: 10.1002/jmv.27489.
    >> Share

  450. LIN Z, Niu J, Xu Y, Qin L, et al
    Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.
    J Med Virol. 2021 Nov 30. doi: 10.1002/jmv.27482.
    >> Share

  451. MILLAN MAD, Plaza NM, Santillan MG, Ortega AM, et al
    Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients.
    J Med Virol. 2021 Nov 29. doi: 10.1002/jmv.27488.
    >> Share

  452. LEVRING MB, Holm DK, Nilsson AC, Bauer JM, et al
    SARS-CoV-2 antibody kinetics in blood donors with a previously positive SARS-CoV-2 antibody test within a seroprevalence survey.
    J Med Virol. 2021 Nov 29. doi: 10.1002/jmv.27486.
    >> Share

  453. MOHAMED K, Rzymski P, Islam MS, Makuku R, et al
    COVID-19 vaccinations: The unknowns, challenges, and hopes.
    J Med Virol. 2021 Nov 29. doi: 10.1002/jmv.27487.
    >> Share

  454. FALAHI S, Kenarkoohi A
    Host Factors and Vaccine Efficacy: Implications for COVID- 19 Vaccines.
    J Med Virol. 2021 Nov 29. doi: 10.1002/jmv.27485.
    >> Share

  455. YU M, Wang DC, Li S, Lei YH, et al
    Meta-analysis of arbidol versuslopinavir/ritonavir in the treatment of coronavirus disease 2019.
    J Med Virol. 2021 Nov 27. doi: 10.1002/jmv.27481.
    >> Share

  456. TANI-SASSA C, Iwasaki Y, Ichimura N, Nagano K, et al
    Viral loads and profile of the patients infected with SARS-CoV-2 Delta, Alpha or R.1 variants in Tokyo.
    J Med Virol. 2021 Nov 26. doi: 10.1002/jmv.27479.
    >> Share

  457. MAAN HS, Chaurasia D, Kapoor G, Dave L, et al
    Intestinal viral infections of nSARS-CoV2 in the Indian community; Risk of virus spread in India.
    J Med Virol. 2021 Nov 26. doi: 10.1002/jmv.27480.
    >> Share

  458. FALLAHZADEH M, Pourhoseingholi MA, Boroujeni MG, Besharati S, et al
    Study of the Effects of Interferon beta-1a on Hospitalized Patients with COVID-19; SBMU Taskforce on the COVIFERON Study.
    J Med Virol. 2021 Nov 25. doi: 10.1002/jmv.27475.
    >> Share

  459. NIA MH, Rokni M, Mirinejad S, Kargar M, et al
    Association of polymorphisms in tumor necrosis factors with SARS-CoV-2 infection and mortality rate: a case-control study and in silico analyses.
    J Med Virol. 2021 Nov 25. doi: 10.1002/jmv.27477.
    >> Share

  460. YU J, Sun S, Tang Q, Wang C, et al
    Establish reference sequences for each clade of SARS-CoV-2 to provide a basis for virus variation and function research.
    J Med Virol. 2021 Nov 25. doi: 10.1002/jmv.27476.
    >> Share

  461. MARSICO C, Capretti MG, Aceti A, Vocale C, et al
    Severe neonatal COVID-19: challenges in management and therapeutic approach.
    J Med Virol. 2021 Nov 23. doi: 10.1002/jmv.27472.
    >> Share

  462. MALTEZOU HC, Krumbholz B, Mavrouli M, Tseroni M, et al
    A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021.
    J Med Virol. 2021 Nov 23. doi: 10.1002/jmv.27465.
    >> Share

  463. KUMAR A, Parashar R, Kumar S, Faiq MA, et al
    Emerging SARS-CoV-2 variants can potentially break set epidemiological barriers in COVID-19.
    J Med Virol. 2021 Nov 23. doi: 10.1002/jmv.27467.
    >> Share

  464. LABRIOLA L, Ruelle J, Scohy A, Seghers F, et al
    Dynamics of spreading of SARS-CoV-2 in a Belgian hemodialysis facility: the importance of the analysis of viral strains.
    J Med Virol. 2021 Nov 23. doi: 10.1002/jmv.27471.
    >> Share

  465. OZER M, Goksu SY, Conception R, Ulker E, et al
    Effectiveness and Safety of Ivermectin in COVID-19 Patients: A Prospective Study at A Safety-Net Hospital.
    J Med Virol. 2021 Nov 23. doi: 10.1002/jmv.27469.
    >> Share

  466. NAGHASHPOUR M, Ghiassian H, Mobarak S, Adelipour M, et al
    Profiling serum levels of glutathione reductase and interleukin-10 in positive and negative-PCR COVID-19 outpatients: a comparative study from southwestern Iran.
    J Med Virol. 2021 Nov 20. doi: 10.1002/jmv.27464.
    >> Share

  467. RASHEDI R, Samieefar N, Masoumi N, Mohseni S, et al
    COVID-19 vaccines Mix-and-Match: The Concept, the Efficacy and the Doubts.
    J Med Virol. 2021 Nov 19. doi: 10.1002/jmv.27463.
    >> Share

  468. GARCIA-SALGUERO C, Culebras E, Merino P, Baos E, et al
    Usefulness of SARS-CoV-2 Antigen Test Sample as input for SARS-CoV-2 RT-PCR analysis.
    J Med Virol. 2021 Nov 16. doi: 10.1002/jmv.27459.
    >> Share

  469. VALIAN NK, Pourakbari B, Ashari KA, Sadeghi RH, et al
    Evaluation of human coronavirus OC43 and SARS-COV-2 in children with respiratory tract infection during the COVID-19 pandemic.
    J Med Virol. 2021 Nov 16. doi: 10.1002/jmv.27460.
    >> Share

  470. SINGH UB, Rophina M, Chaudhry R, Senthivel V, et al
    Variants of Concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.
    J Med Virol. 2021 Nov 16. doi: 10.1002/jmv.27461.
    >> Share

  471. CHANDAN S, Khan SR, Deliwala S, Mohan BP, et al
    Postvaccination SARS-CoV-2 infection among healthcare workers - A Systematic Review and meta-analysis.
    J Med Virol. 2021 Nov 15. doi: 10.1002/jmv.27457.
    >> Share

  472. SIVAN M, Parkin A, Makower S, Greenwood DC, et al
    Post-COVID Syndrome symptoms, functional disability and clinical severity phenotypes in hospitalised and non-hospitalised individuals: a cross-sectional evaluation from a community COVID rehabilitation service.
    J Med Virol. 2021 Nov 15. doi: 10.1002/jmv.27456.
    >> Share

  473. BENJAMANUKUL S, Traiyan S, Yorsaeng R, Vichaiwattana P, et al
    Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
    J Med Virol. 2021 Nov 15. doi: 10.1002/jmv.27458.
    >> Share

  474. LIU K, Yang X, Feng C, Chen M, et al
    Clinical features and independent predictors for recurrence of positive SARS-CoV-2 RNA: A propensity score-matched analysis.
    J Med Virol. 2021 Nov 12. doi: 10.1002/jmv.27450.
    >> Share

  475. ANGELETTI S, Giovanetti M, Fogolari M, Cella E, et al
    SARS-CoV-2 AY.4.2 variant circulating in Italy: Genomic preliminary insight.
    J Med Virol. 2021 Nov 12. doi: 10.1002/jmv.27451.
    >> Share

  476. OZGOCER T, Dagli SN, Ceylan MR, Disli F, et al
    Analysis of long-term antibody response in COVID-19 patients by symptoms grade, gender, age, BMI, and medication.
    J Med Virol. 2021 Nov 12. doi: 10.1002/jmv.27452.
    >> Share

  477. SONG J, Li C, Rivailler P, Wang H, et al
    Molecular evolution and genomic characteristics of genotype H1 of measles virus.
    J Med Virol. 2021 Nov 11. doi: 10.1002/jmv.27448.
    >> Share

  478. FORERO-PENA DA, Carrion-Nessi FS, Mendoza-Millan DL, Omana-Avila OD, et al
    First wave of COVID-19 in Venezuela: Epidemiological, clinical, and paraclinical characteristics of first cases.
    J Med Virol. 2021 Nov 11. doi: 10.1002/jmv.27449.
    >> Share

  479. SAM IC, Chong YM, Abdullah A, Fu JYL, et al
    Changing predominant SARS-CoV-2 lineages drive successive COVID-19 waves in Malaysia, February 2020 to March 2021.
    J Med Virol. 2021 Nov 10. doi: 10.1002/jmv.27441.
    >> Share

  480. LEROUX X, Schock M, Augereau O, Lessire H, et al
    Factors associated with mechanical ventilation in SARS-CoV-2 patients treated with high flow nasal cannula oxygen and outcomes.
    J Med Virol. 2021 Nov 9. doi: 10.1002/jmv.27442.
    >> Share

  481. BRONSTEIN Y, Adler A, Katash H, Halutz O, et al
    Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.
    J Med Virol. 2021 Nov 9. doi: 10.1002/jmv.27445.
    >> Share

  482. BARRERA-AVALOS C, Luraschi R, Vallejos-Vidal E, Figueroa M, et al
    ANALYSIS BY REAL-TIME PCR OF FIVE TRANSPORT AND CONSERVATION MEDIUM OF NASOPHARYNGEAL SWAB SAMPLES TO COVID-19 DIAGNOSIS IN SANTIAGO OF CHILE.
    J Med Virol. 2021 Nov 9. doi: 10.1002/jmv.27446.
    >> Share

  483. KERBAGE A, Haddad S, Nasr L, Riachy A, et al
    Impact of ABO and Rhesus Blood Groups on COVID-19 Susceptibility and Severity: A Case-control Study.
    J Med Virol. 2021 Nov 9. doi: 10.1002/jmv.27444.
    >> Share

  484. FORERO-PENA DA, Hernandez MM, Herrera IPM, Espinal IBC, et al
    Remitting Neuropsychiatric Symptoms in COVID-19 Patients: Viral Cause or Drug Effect?
    J Med Virol. 2021 Nov 9. doi: 10.1002/jmv.27443.
    >> Share

  485. FENG R, Wang B, Ma Z, Guo X, et al
    ALB level and COVID-19Dynamic change of serum albumin level can predict the prognosis of COVID-19 patients with hypoalbuminemia.
    J Med Virol. 2021 Nov 9. doi: 10.1002/jmv.27439.
    >> Share

  486. ALBAYAT SS, Arshad S, Arshad MA, Jabbar A, et al
    Precautionary measures for more transmissible C.1.2 COVID-19 variant: A caution for Qatar and the rest of the world.
    J Med Virol. 2021 Nov 9. doi: 10.1002/jmv.27438.
    >> Share

  487. SKOREK A, Jazwinska-Curyllo A, Romanowicz A, Kwasniewski K, et al
    Assessment of anti-SARS-CoV-2 antibodies level in convalescents plasma.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27433.
    >> Share

  488. KIM HJ, Park MS, Il Shin J, Park J, et al
    Associations of heart failure with susceptibility and severe complications of COVID-19: A nationwide cohort study.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27435.
    >> Share

  489. UMAIR M, Ikram A, Salman M, Haider SA, et al
    Genomic surveillance reveals the detection of SARS-CoV-2 Delta, Beta and Gamma VOCs during the third wave in Pakistan.
    J Med Virol. 2021 Nov 2. doi: 10.1002/jmv.27429.
    >> Share

    October 2021
  490. ADAMS O, Andree M, Rabl D, Ostermann PN, et al
    Humoral response to SARS-CoV-2 and seasonal coronaviruses in COVID-19 patients.
    J Med Virol. 2021 Oct 30. doi: 10.1002/jmv.27427.
    >> Share

  491. CHEN W, Yao M, Hu L, Zhang Y, et al
    Development and Validation of clinical prediction model to estimate the risk of critical patients with COVID-19.
    J Med Virol. 2021 Oct 30. doi: 10.1002/jmv.27428.
    >> Share

  492. FARAH Y, Syed Hasan A, Irfan U
    Norovirus Outbreak amid COVID-19 in the United Kingdom; Priorities for Achieving Control.
    J Med Virol. 2021 Oct 29. doi: 10.1002/jmv.27426.
    >> Share

  493. SAHIN D, Tanacan A, Erol SA, Yetiskin FDY, et al
    Management of Pregnant Women with COVID-19: A Tertiary Pandemic Center Experience on 1416 Cases.
    J Med Virol. 2021 Oct 29. doi: 10.1002/jmv.27423.
    >> Share

  494. CATTEL L, Giordano S, Traina S, Lupia T, et al
    Vaccine development and technology for SARS-CoV-2: current insights.
    J Med Virol. 2021 Oct 29. doi: 10.1002/jmv.27425.
    >> Share

  495. KIM MS, Jung SY, Ahn JG, Park SJ, et al
    Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: a pharmacovigilance analysis of WHO international database.
    J Med Virol. 2021 Oct 28. doi: 10.1002/jmv.27424.
    >> Share

  496. YAMAMOTO Y, Shiroyama T, Hirata H, Kuge T, et al
    Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID-19.
    J Med Virol. 2021 Oct 28. doi: 10.1002/jmv.27421.
    >> Share

  497. PAPADOPOULOU A, Fragkou PC, Maratou E, Dimopoulou D, et al
    "Angiotensin-Converting-Enzyme Insertion/Deletion (I/D) polymorphism, ACE activity and COVID-19: a rather controversial hypothesis. A case - control study".
    J Med Virol. 2021 Oct 28. doi: 10.1002/jmv.27417.
    >> Share

  498. UYSAL EB, Gumus S, Bektore B, Bozkurt H, et al
    EVALUATION OF ANTIBODY RESPONSE AFTER COVID-19 VACCINATION OF HEALTHCARE WORKERS.
    J Med Virol. 2021 Oct 27. doi: 10.1002/jmv.27420.
    >> Share

  499. LAINE P, Nihtila H, Mustanoja E, Lyyski A, et al
    SARS-CoV-2 variant with mutations in N gene affecting detection by widely used PCR primers.
    J Med Virol. 2021 Oct 26. doi: 10.1002/jmv.27418.
    >> Share

  500. RUBAYET UL ALAM ASM, Islam OK, Hasan MS, Islam MR, et al
    Dominant Clade-featured SARS-CoV-2 Co-occurring Mutations Reveals Plausible Epistasis: An in silico based Hypothetical Model.
    J Med Virol. 2021 Oct 22. doi: 10.1002/jmv.27416.
    >> Share

  501. MONTALVO VILLALBA MC, Sosa Glaria E, Rodriguez Lay LLA, Valdes Ramirez O, et al
    Performance evaluation of Elecsys SARS-CoV-2 Antigen immunoassay for diagnostic of COVID-19.
    J Med Virol. 2021 Oct 21. doi: 10.1002/jmv.27412.
    >> Share

  502. ARSLAN GULEN T, Bayraktar M, Yaksi N, Kayabas U, et al
    Is the course of COVID-19 associated with tuberculin skin test diameter? A retrospective study.
    J Med Virol. 2021 Oct 21. doi: 10.1002/jmv.27414.
    >> Share

  503. O'CONNOR RJ, Preston N, Parkin A, Makower S, et al
    The COVID-19 Yorkshire Rehabilitation Scale (C19-YRS): application and psychometric analysis in a post-COVID-19 syndrome cohort.
    J Med Virol. 2021 Oct 21. doi: 10.1002/jmv.27415.
    >> Share

  504. KOMURCU SZM, Artik Y, Cesur NP, Tanriverdi A, et al
    THE EVALUATION POTENTIAL GLOBAL IMPACT OF THE N501Y MUTATION IN SARS-COV-2 POSITIVE PATIENTS.
    J Med Virol. 2021 Oct 21. doi: 10.1002/jmv.27413.
    >> Share

  505. BARROS-LEITE BRAF, Lima MRO, Caminha M, Santos K, et al
    Short-term functional changes after hospital discharge by COVID-19 through teleconsultation at a reference service in Northeast Brazil: a cross-sectional study.
    J Med Virol. 2021 Oct 21. doi: 10.1002/jmv.27410.
    >> Share

  506. ASADI-POOYA AA, Akbari A, Emami A, Lotfi M, et al
    Long COVID syndrome-associated brain fog.
    J Med Virol. 2021 Oct 21. doi: 10.1002/jmv.27404.
    >> Share

  507. MANIK M, Singh RK
    Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19.
    J Med Virol. 2021 Oct 21. doi: 10.1002/jmv.27405.
    >> Share

  508. GOBEILLE PARE S, Bestman-Smith J, Fafard J, Doualla-Bell F, et al
    Natural spring water gargle samples as an alternative to nasopharyngeal swabs for SARS-CoV-2 detection using a laboratory-developed test.
    J Med Virol. 2021 Oct 21. doi: 10.1002/jmv.27407.
    >> Share

  509. LI X
    Concerns on the multiple nomenclature systems for SARS-CoV-2.
    J Med Virol. 2021 Oct 21. doi: 10.1002/jmv.27406.
    >> Share

  510. KAYA H, Usuda D
    Duration from onset to discharge is longer in COVID-19 patients with low blood regulatory T-cell counts.
    J Med Virol. 2021 Oct 18. doi: 10.1002/jmv.27401.
    >> Share

  511. D'ETTORRE G, Gentilini Cacciola E, Santinelli L, De Girolamo G, et al
    Covid-19 sequelae in working age patients: A systematic review.
    J Med Virol. 2021 Oct 16. doi: 10.1002/jmv.27399.
    >> Share

  512. ISLAM K, Molla MA, Hasan P, Sharif M, et al
    Title: Persistence of Sleep Disturbance among Post-Covid Patients: Findings from a two-month follow-up study in a Bangladeshi cohort.
    J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27397.
    >> Share

  513. QUINCOZES-SANTOS A, Rosa RLD, Bobermin LD, Tureta EF, et al
    Association between molecular markers of COVID-19 and Alzheimer's disease.
    J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27391.
    >> Share

  514. KASHIMA S, Slavov SN, Giovanetti M, Rodrigues ES, et al
    INTRODUCTION OF SARS-COV-2 C.37 (WHO VOI LAMBDA) IN THE SAO PAULO STATE, SOUTHEAST BRAZIL.
    J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27389.
    >> Share

  515. LINO K, Alves LS, Raposo JV, Medeiros T, et al
    Presence and clinical impact of human Herpesvirus-6 infection in patients with moderate to critical Coronavirus disease-19.
    J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27392.
    >> Share

  516. ULHAQ ZS, Soraya GV, Indriana K, Devitasari R, et al
    The level of Ig anti-RBD SARS-CoV-2 after two doses of CoronaVac vaccine.
    J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27390.
    >> Share

  517. ALEXIEV I, Ivanov I, Philipova I, Korsun N, et al
    Postvaccination SARS-CoV-2 Alpha (B.1.1.7) Lineage Infection among Healthcare Workers on the Background of IgG Antibodies.
    J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27394.
    >> Share

  518. TONG L, Ji L, Li D, Xu H, et al
    The occurrence of COVID-19 is associated with air quality and relative humidity.
    J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27395.
    >> Share

  519. SILVA VO, Yamashiro R, Ahagon CM, Campos IB, et al
    Inhibition of Receptor-Binding Domain - ACE2 interaction after two doses of Sinovac's CoronaVac or AstraZeneca/Oxford's AZD1222 SARS-CoV-2 vaccines.
    J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27396.
    >> Share

  520. KUNO T, Sahashi Y, Kawahito S, Takahashi M, et al
    Prediction of in-hospital mortality with machine learning for COVID-19 patients treated with steroid and Remdesivir.
    J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27393.
    >> Share

  521. DEHNEN D, Dehnen K, Trilling M, Fiedler M, et al
    Discrepancy between frequent occurrence of COVID-19-like symptoms and low seroconversion rates among healthcare workers.
    J Med Virol. 2021 Oct 11. doi: 10.1002/jmv.27385.
    >> Share

  522. NANCHAL R, Patel D, Guddati AK, Sakhuja A, et al
    Outcomes of Covid 19 Patients - Are Hispanics at greater risk?
    J Med Virol. 2021 Oct 11. doi: 10.1002/jmv.27384.
    >> Share

  523. DASH GC, Subhadra S, Turuk J, Parai D, et al
    Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN(R)) and AZD1222 (COVISHIELDT(M) ) recipients: Report from eastern state of India.
    J Med Virol. 2021 Oct 8. doi: 10.1002/jmv.27382.
    >> Share

  524. DUMONT S, Balduyck J, Reynders M, Vanwalleghem L, et al
    Acute SARS-CoV-2 Alpha variant infection leading to placental insufficiency and fetal distress.
    J Med Virol. 2021 Oct 7. doi: 10.1002/jmv.27379.
    >> Share

  525. TREGGIARI D, Piubelli C, Caldrer S, Mistretta M, et al
    SARS-CoV-2 rapid antigen test in comparison to RT-PCR targeting different genes: a real-life evaluation among unselected patients in a regional hospital of Italy.
    J Med Virol. 2021 Oct 7. doi: 10.1002/jmv.27378.
    >> Share

  526. BORETTI A, Banik B
    Modulation of Covid-19 cytokine storm by Tocilizumab.
    J Med Virol. 2021 Oct 7. doi: 10.1002/jmv.27380.
    >> Share

  527. TIAN D, Sun Y, Zhou J, Ye Q, et al
    The global epidemic of SARS-CoV-2 variants and their mutational immune escape.
    J Med Virol. 2021 Oct 5. doi: 10.1002/jmv.27376.
    >> Share

  528. KUNO T, So M, Takahashi M, Egorova NN, et al
    The association between famotidine and in-hospital mortality of patients with COVID-19.
    J Med Virol. 2021 Oct 5. doi: 10.1002/jmv.27375.
    >> Share

  529. WOLF JM, Kipper D, Borges GR, Streck AF, et al
    Temporal spread and evolution of SARS-CoV-2 in the second pandemic wave in Brazil.
    J Med Virol. 2021 Oct 1. doi: 10.1002/jmv.27371.
    >> Share

  530. MUTNAL MB, Johnson S, Mohamed N, Abddelgader R, et al
    Surveillance genome sequencing reveal multiple SARS-CoV-2 variants circulating in the central Texas, USA with a predominance of Delta variant and review of vaccine breakthrough cases.
    J Med Virol. 2021 Oct 1. doi: 10.1002/jmv.27373.
    >> Share

  531. LI H, Liu T, Wang L, Wang M, et al
    SARS-CoV-2 Delta Variant infects ACE2(low) primary human bronchial epithelial cells more efficiently than other variants.
    J Med Virol. 2021 Oct 1. doi: 10.1002/jmv.27372.
    >> Share

    September 2021
  532. MAK GCK, Au SSM, Yeung MCW, Lau DMW, et al
    Evaluation of rapid antigen detection test for individuals at risk of SARS-CoV-2 under quarantine.
    J Med Virol. 2021 Sep 30. doi: 10.1002/jmv.27369.
    >> Share

  533. MORELAND A, Gillezeau C, Alpert N, Taioli E, et al
    Assessing influenza vaccination success to inform COVID-19 vaccination campaign.
    J Med Virol. 2021 Sep 30. doi: 10.1002/jmv.27368.
    >> Share

  534. BERNARDINI N, Skroza N, Mambrin A, Proietti I, et al
    Herpes Zoster Ophthalmicus in two women after Pfizer-Biontech(BNT162b2) vaccine.
    J Med Virol. 2021 Sep 29. doi: 10.1002/jmv.27366.
    >> Share

  535. CHENEY-PETERS DR, Crystal Y Lee M P H, Mitsuhashi S, Zaret DS, et al
    Association of race/ethnicity and socioeconomic status with COVID-19 30-day mortality at a Philadelphia medical center using a retrospective cohort study.
    J Med Virol. 2021 Sep 29. doi: 10.1002/jmv.27365.
    >> Share

  536. BIRD PW, Riff R, Folwell A, Holmes CW, et al
    Increased incidence of COVID-19 in younger patients (May-July 2021) - an argument for extending vaccination?
    J Med Virol. 2021 Sep 29. doi: 10.1002/jmv.27363.
    >> Share

  537. BOSTAN E, Jarbou A
    Atypical Pityriasis Rosea Associated with mRNA Covid-19 Vaccine.
    J Med Virol. 2021 Sep 29. doi: 10.1002/jmv.27364.
    >> Share

  538. GULHAN PY, Eroz R, Ataoglu O, Ince N, et al
    Can Caspase-3 Gene Expression Levels Show the Degree of Injury in Cells in SARS-CoV-2 Infection?
    J Med Virol. 2021 Sep 29. doi: 10.1002/jmv.27362.
    >> Share

  539. GOLBETS E, Kaplan A, Shafat T, Yagel Y, et al
    Secondary Organizing Pneumonia After Recovery of Mild COVID-19 Infection.
    J Med Virol. 2021 Sep 28. doi: 10.1002/jmv.27360.
    >> Share

  540. WU J, Tang J, Zhang T, Chen YC, et al
    SARS-CoV-2 Delta VOC pneumonia with CT follow-ups: a case report.
    J Med Virol. 2021 Sep 28. doi: 10.1002/jmv.27361.
    >> Share

  541. SONI S, Pudake RN, Jain U, Chauhan N, et al
    A systematic review on SARS-CoV-2 Associated Fungal Co-Infections.
    J Med Virol. 2021 Sep 27. doi: 10.1002/jmv.27358.
    >> Share

  542. KUMAR G, Patel D, Hererra M, Jefferies D, et al
    Do High Dose Corticosteroids Improve Outcomes in Hospitalized COVID-19 Patients?
    J Med Virol. 2021 Sep 24. doi: 10.1002/jmv.27357.
    >> Share

  543. MESQUITA JR, Barradas P, Silva PGD, Ferreira AS, et al
    SARS-CoV-2 and blood donations in Portugal, June-July 2020.
    J Med Virol. 2021 Sep 21. doi: 10.1002/jmv.27353.
    >> Share

  544. SEBASTIAO CS, Gaston C, Paixao JP, Sacomboio ENM, et al
    Coinfection between SARS-CoV-2 and vector-borne diseases in Luanda, Angola.
    J Med Virol. 2021 Sep 21. doi: 10.1002/jmv.27354.
    >> Share

  545. ZHANG RK, Xiao Q, Zhu SL, Lin HY, et al
    Using Different Machine Learning Models to Classify Patients with Mild and Severe Cases of COVID-19 Based on Multivariate Blood Testing.
    J Med Virol. 2021 Sep 20. doi: 10.1002/jmv.27352.
    >> Share

  546. YAQOOB H, Greenberg D, Hwang F, Lee C, et al
    COMPARISON OF PULSE-DOSE AND HIGH-DOSE CORTICOSTEROIDS WITH NO CORTICOSTEROID TREATMENT FOR COVID-19 PNEUMONIA IN THE INTENSIVE CARE UNIT.
    J Med Virol. 2021 Sep 20. doi: 10.1002/jmv.27351.
    >> Share

  547. KESKIN AU, Bolukcu S, Ciragil P, Topkaya AE, et al
    SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
    J Med Virol. 2021 Sep 18. doi: 10.1002/jmv.27350.
    >> Share

  548. LI D, Liu Y, Lu Y, Gao S, et al
    Palmitoylation of SARS-CoV-2 S protein is critical for S-mediated syncytia formation and virus entry.
    J Med Virol. 2021 Sep 16. doi: 10.1002/jmv.27339.
    >> Share

  549. BANO I, Sharif M, Alam S
    Genetic drift in the genome of SARS COV-2 and its global health concern.
    J Med Virol. 2021 Sep 15. doi: 10.1002/jmv.27337.
    >> Share

  550. KITAGAWA Y, Imai K, Matsuoka M, Fukada A, et al
    Evaluation of the correlation between the Access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    J Med Virol. 2021 Sep 15. doi: 10.1002/jmv.27338.
    >> Share

  551. LIU H, Li J, Lin Y, Bo X, et al
    Assessment of two-pool multiplex long-amplicon nanopore sequencing of SARS-CoV-2.
    J Med Virol. 2021 Sep 15. doi: 10.1002/jmv.27336.
    >> Share

  552. CHEN JM
    Should the world collaborate imminently to develop neglected live attenuated vaccines for COVID-19?
    J Med Virol. 2021 Sep 15. doi: 10.1002/jmv.27335.
    >> Share

  553. YUE L, Xie T, Yang T, Zhou J, et al
    A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
    J Med Virol. 2021 Sep 13. doi: 10.1002/jmv.27334.
    >> Share

  554. PHILLIPS MC, Sarff L, Banerjee J, Coffey C, et al
    Effect of Mortality from COVID-19 on Inpatient Outcomes.
    J Med Virol. 2021 Sep 13. doi: 10.1002/jmv.27332.
    >> Share

  555. MESSALI S, Campisi G, Giovanetti M, Ciccozzi M, et al
    The first Italian outbreak of SARS-CoV-2 B.1.1.7 lineage in Corzano, Lombardy.
    J Med Virol. 2021 Sep 13. doi: 10.1002/jmv.27333.
    >> Share

  556. WANG S, Xu X, Wei C, Li S, et al
    Molecular evolutionary characteristics of SARS-CoV-2 emerging in the United States.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27331.
    >> Share

  557. KAZMI SK, Khan FMA, Natoli V, Hunain R, et al
    Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27330.
    >> Share

  558. UMAIR M, Ikram A, Badar N, Haider SA, et al
    Tracking down B.1.351 SARS-CoV-2 variant in Pakistan through genomic surveillance.
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27328.
    >> Share

  559. TSANG AKL, Mak GCK, Leung PKL, Cheng PKC, et al
    Emergence of SARS-CoV-2 lineage B.1.617.2 in the local community of Hong Kong.
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27326.
    >> Share

  560. DIVINO F, Ciccozzi M, Farcomeni A, Lasinio GJ, et al
    Unreliable predictions about COVID-19 infections and hospitalizations make people worry: the case of Italy.
    J Med Virol. 2021 Sep 8. doi: 10.1002/jmv.27325.
    >> Share

  561. CHAUDHRY R, Sreenath K, Batra P, Vinayaraj EV, et al
    Atypical bacterial co-infections among patients with COVID-19: a study from India.
    J Med Virol. 2021 Sep 7. doi: 10.1002/jmv.27324.
    >> Share

  562. PANDOLFI S, Chirumbolo S
    On reaching herd immunity during COVID-19 pandemic and further issues.
    J Med Virol. 2021 Sep 7. doi: 10.1002/jmv.27322.
    >> Share

  563. TANISLAV C, Kostev K
    Fewer non-Covid-19 respiratory tract infections and gastro-intestinal infections during the Covid-19 pandemic.
    J Med Virol. 2021 Sep 7. doi: 10.1002/jmv.27321.
    >> Share

  564. SARGIN ALTUNOK E, Satici C, Dinc V, Kamat S, et al
    Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave vs the second wave.
    J Med Virol. 2021 Sep 7. doi: 10.1002/jmv.27319.
    >> Share

  565. KAUR U, Bala S, Mbbs BO, Mbbs SJ, et al
    Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): a preliminary analysis from north India.
    J Med Virol. 2021 Sep 7. doi: 10.1002/jmv.27320.
    >> Share

  566. YIGIT M, Ozkaya-Parlakay A, Cosgun Y, Ince YE, et al
    SHOULD A THIRD BOOSTER DOSE BE SCHEDULED AFTER TWO DOSES OF CORONAVAC? A SINGLE CENTER EXPERIENCE.
    J Med Virol. 2021 Sep 6. doi: 10.1002/jmv.27318.
    >> Share

  567. FINSTERER J, Almas T
    Guillain-Barre syndrome is immunogenic in SARS-CoV-2 infected.
    J Med Virol. 2021 Sep 1. doi: 10.1002/jmv.27314.
    >> Share

  568. SODEIFIAN F, Nikfarjam M, Kian N, Mohamed K, et al
    The Role of Type I Interferon in the Treatment of COVID-19.
    J Med Virol. 2021 Sep 1. doi: 10.1002/jmv.27317.
    >> Share

  569. PANDA S, Roy S, Garg RK, Hui G, et al
    COVID-19 Disease in Hospitalised Young Adults in India and China: Evaluation of Risk Factors Predicting Progression Across Two Major Ethnic Groups.
    J Med Virol. 2021 Sep 1. doi: 10.1002/jmv.27315.
    >> Share

  570. YALCIN TY, Topcu DI, Dogan O, Aydin S, et al
    Immunogenicity After Two Doses of Inactivated Virus Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: Prospective Observational Study.
    J Med Virol. 2021 Sep 1. doi: 10.1002/jmv.27316.
    >> Share

    August 2021
  571. MALIK P, Patel K, Pinto C, Jaiswal R, et al
    Post-acute COVID-19 syndrome (PCS) and Health related Quality of life (HRQoL)- A systematic review and Meta-analysis.
    J Med Virol. 2021 Aug 31. doi: 10.1002/jmv.27309.
    >> Share

  572. MOUSAVI SA, Heydari K, Mehravaran H, Saeedi M, et al
    Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, Randomized, Controlled Trial.
    J Med Virol. 2021 Aug 30. doi: 10.1002/jmv.27312.
    >> Share

  573. AKINOSOGLOU K, Delastic AL, Dimakopoulou V, Marangos M, et al
    Elements of Th1 / Th2 response and disease severity in COVID-19 patients: A short report.
    J Med Virol. 2021 Aug 30. doi: 10.1002/jmv.27313.
    >> Share

  574. FERNANDEZ J, Bruneau N, Fasce R, Martin HS, et al
    Neutralization of Alpha, Gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    J Med Virol. 2021 Aug 30. doi: 10.1002/jmv.27310.
    >> Share

  575. XIE XP, Sheng LP, Han CQ, Jin Y, et al
    Features of capsule endoscopy in COVID-19 patients with a six-month follow up: a prospective observational study.
    J Med Virol. 2021 Aug 30. doi: 10.1002/jmv.27308.
    >> Share

  576. MISHRA B, Ranjan J, Purushotham P, Saha S, et al
    High proportion of low cycle threshold value as an early indicator of COVID-19 surge.
    J Med Virol. 2021 Aug 30. doi: 10.1002/jmv.27307.
    >> Share

  577. WASIM U, Tahir MJ, Siddiqi AR, Jabbar A, et al
    The impact of the COVID-19 pandemic on impending cancer deaths due to delays in diagnosis in the UK.
    J Med Virol. 2021 Aug 28. doi: 10.1002/jmv.27305.
    >> Share

  578. RATHORE SS, Hussain N, Manju AH, Wen Q, et al
    Prevalence and clinical outcomes of pleural effusion in COVID-19 patients: A systematic review and meta-analysis.
    J Med Virol. 2021 Aug 27. doi: 10.1002/jmv.27301.
    >> Share

  579. OLEA B, Albert E, Torres I, Gozalbo-Rovira R, et al
    SARS-CoV-2 N-antigenemia in critically ill adult COVID-19 patients: frequency and association with inflammatory and tissue-damage biomarkers.
    J Med Virol. 2021 Aug 27. doi: 10.1002/jmv.27300.
    >> Share

  580. PLASENCIA-DUENAS R, Failoc-Rojas VE, Rodriguez-Morales AJ
    Impact of the COVID-19 pandemic on the incidence of dengue fever in Peru.
    J Med Virol. 2021 Aug 26. doi: 10.1002/jmv.27298.
    >> Share

  581. SARKAR S, Kannan S, Khanna P, Singh AK, et al
    Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis.
    J Med Virol. 2021 Aug 26. doi: 10.1002/jmv.27297.
    >> Share

  582. CATALAN IP, Marti CR, Sota DP, Alvarez AC, et al
    "Corticosteroids for COVID-19 symptoms and quality of life at one year from admission".
    J Med Virol. 2021 Aug 26. doi: 10.1002/jmv.27296.
    >> Share

  583. CABRELLE G, Zanon C, Crimi F, Quaia E, et al
    Can rapid antibody tests and chest computed tomography really substitute real-time polymerase chain reaction in COVID-19?
    J Med Virol. 2021 Aug 26. doi: 10.1002/jmv.27295.
    >> Share

  584. PORTILHO AI, Silva VO, Ahagon CM, Matsuda EM, et al
    Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection.
    J Med Virol. 2021 Aug 24. doi: 10.1002/jmv.27290.
    >> Share

  585. BAYRAKTAR N, Turan H, Bayraktar M, Ozturk A, et al
    Analysis of serum cytokine and protective vitamin D levels in severe cases of COVID-19.
    J Med Virol. 2021 Aug 24. doi: 10.1002/jmv.27294.
    >> Share

  586. STRUCK F, Schreiner P, Staschik E, Wochinz-Richter K, et al
    Incomplete IgG avidity maturation after seasonal coronavirus infections.
    J Med Virol. 2021 Aug 24. doi: 10.1002/jmv.27291.
    >> Share

  587. YAZDANPANAH N, Rezaei N
    Autoimmune Complications of COVID-19.
    J Med Virol. 2021 Aug 24. doi: 10.1002/jmv.27292.
    >> Share

  588. MURAT K, Ediz TE
    The Effectiveness of Inactivated SARS-CoV-2 Vaccine (CoronaVac) on Antibody Response in Participants Aged 65 Years and Older.
    J Med Virol. 2021 Aug 24. doi: 10.1002/jmv.27289.
    >> Share

  589. ZAWBAA HM, Osama H, El-Gendy A, Saeed H, et al
    Effect of mutation and vaccination on spread, severity, and mortality of COVID-19 disease.
    J Med Virol. 2021 Aug 24. doi: 10.1002/jmv.27293.
    >> Share

  590. OZDEMIR O
    Re-activation or Re-infection of COVID-19 disease?
    J Med Virol. 2021 Aug 20. doi: 10.1002/jmv.27286.
    >> Share

  591. BOSHIER FAT, Pang J, Penner J, Parker M, et al
    Evolution of viral variants in remdesivir treated and untreated SARS-CoV-2 infected paediatrics patients.
    J Med Virol. 2021 Aug 20. doi: 10.1002/jmv.27285.
    >> Share

  592. DOLSCHEID-POMMERICH R, Bartok E, Renn M, Kummerer BM, et al
    Correlation Between a Quantitative Anti-SARS-CoV-2 IgG ELISA and Neutralization Activity.
    J Med Virol. 2021 Aug 20. doi: 10.1002/jmv.27287.
    >> Share

  593. KAWASUJI H, Morinaga Y, Tani H, Yoshida Y, et al
    SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID-19.
    J Med Virol. 2021 Aug 19. doi: 10.1002/jmv.27282.
    >> Share

  594. GHORBANI SS, Taherpour N, Bayat S, Ghajari H, et al
    Epidemiologic characteristics of cases with re-infection, recurrence and hospital readmission due to COVID-19: a systematic review and meta-analysis.
    J Med Virol. 2021 Aug 19. doi: 10.1002/jmv.27281.
    >> Share

  595. SHAKERI H, Azimian A, Ghasemzadeh-Moghaddam H, Safdari M, et al
    Evaluation of the Relationship Between Serum levels of Zinc, Vitamin B12, Vitamin D and Clinical outcomes in Patients with COVID-19.
    J Med Virol. 2021 Aug 18. doi: 10.1002/jmv.27277.
    >> Share

  596. STOECKLE K, Witting B, Kapadia S, An A, et al
    Elevated Inflammatory Markers Are Associated With Poor Outcomes in COVID-19 Patients Treated With Remdesivir.
    J Med Virol. 2021 Aug 18. doi: 10.1002/jmv.27280.
    >> Share

  597. AI S, Awford A, Roncolato F
    Hemophagocytic lymphohistiocytosis following ChAdOx1 nCov-19 vaccination.
    J Med Virol. 2021 Aug 18. doi: 10.1002/jmv.27279.
    >> Share

  598. HASAN MM, Mohanan P, Emmanuella N, Costa ACDS, et al
    Challenges of HIV amidst COVID-19 in Africa: Can we conquer them?
    J Med Virol. 2021 Aug 17. doi: 10.1002/jmv.27276.
    >> Share

  599. TANG F, Zhang X, Zhang B, Zhu B, et al
    A nomogram prediction of outcome in patients with COVID-19 based on individual characteristics incorporating immune response-related indicators.
    J Med Virol. 2021 Aug 17. doi: 10.1002/jmv.27275.
    >> Share

  600. YAN X, Chen G, Jin Z, Zhang Z, et al
    Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19.
    J Med Virol. 2021 Aug 17. doi: 10.1002/jmv.27274.
    >> Share

  601. EBRAHIMI M, Farhadian N, Amiri AR, Hataminia F, et al
    Evaluating the efficacy of extracted squalene from seed oil in the form of microemulsion for the treatment of COVID-19: A clinical study.
    J Med Virol. 2021 Aug 17. doi: 10.1002/jmv.27273.
    >> Share

  602. YILMAZ G, Ebru O, Ibrahim B, Ulkem C, et al
    ASSESSMENT OF CLINICAL OUTCOMES IN RENAL TRANSPLANT RECIPIENTS WITH COVID-19.
    J Med Virol. 2021 Aug 13. doi: 10.1002/jmv.27271.
    >> Share

  603. FARI G, de Sire A, Giorgio V, Rizzo L, et al
    Impact of COVID-19 on the mental health in a cohort of Italian Rehabilitation health care workers.
    J Med Virol. 2021 Aug 13. doi: 10.1002/jmv.27272.
    >> Share

  604. STRUCK F, Schreiner P, Staschik E, Wochinz-Richter K, et al
    Vaccination versus infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity maturation.
    J Med Virol. 2021 Aug 13. doi: 10.1002/jmv.27270.
    >> Share

  605. DENG J, Heybati K, Zhou F
    Letter to the editor in response to "Safety and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis".
    J Med Virol. 2021 Aug 13. doi: 10.1002/jmv.27269.
    >> Share

  606. ABBASS S, Salama M, Salman T, Sabry A, et al
    fficacy and safety of Sofosbuvir plus Daclatasvir or Ravidasvir in patients with COVID-19, A Randomized Controlled Trial.
    J Med Virol. 2021 Aug 11. doi: 10.1002/jmv.27264.
    >> Share

  607. ZHOU R, Liu L, Wang Y
    Viral Proteins Recognized by Different TLRs.
    J Med Virol. 2021 Aug 10. doi: 10.1002/jmv.27265.
    >> Share

  608. CICCOZZI M, Maruotti A, Ceccarelli G, Divino F, et al
    While we are discussing...the SARS-CoV-2 virus laughs.
    J Med Virol. 2021 Aug 10. doi: 10.1002/jmv.27266.
    >> Share

  609. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Antibody response to SARS-CoV-2 vaccination, previous SARS-CoV-2 infection and change to single dose vaccination.
    J Med Virol. 2021 Aug 10. doi: 10.1002/jmv.27263.
    >> Share

  610. CHI G, Memar Montazerin S, Lee JJ, Kazmi SHA, et al
    Effect of Azithromycin and Hydroxychloroquine in Patients Hospitalized with COVID-19: Network Meta-Analysis of Randomized Controlled Trials.
    J Med Virol. 2021 Aug 9. doi: 10.1002/jmv.27259.
    >> Share

  611. PADILLA-ROJAS C, Jimenez-Vasquez V, Hurtado V, Mestanza O, et al
    Genomic analysis reveals a rapid spread and predominance of Lambda (C.37) SARS-COV-2 lineage in Peru despite circulation of variants of concern.
    J Med Virol. 2021 Aug 9. doi: 10.1002/jmv.27261.
    >> Share

  612. KUNO T, So M, Miyamoto Y, Iwagami M, et al
    The association of COVID-19 antibody with in-hospital outcomes in COVID-19 infected patients.
    J Med Virol. 2021 Aug 9. doi: 10.1002/jmv.27260.
    >> Share

  613. ESSAR MY, Kazmi SK, Hasan MM, Santos Costa ACD, et al
    The rampant use of cow-dung to treat COVID-19: Is India at the brink of a zoonotic disease outbreak?
    J Med Virol. 2021 Aug 5. doi: 10.1002/jmv.27258.
    >> Share

  614. QURESHI QH, Ashraf T, Rehman K, Khosa MK, et al
    Therapeutic interventions of remdesivir in diabetic and non-diabetic COVID-19 patients: A prospective observational study conducted on Pakistani population.
    J Med Virol. 2021 Aug 5. doi: 10.1002/jmv.27256.
    >> Share

  615. GUAN Y, Chen C, Guo A, Wei J, et al
    Prolonged Symptom Onset to Admission Time is Associated with Severe Coronavirus Disease: A Meta combined Propensity-adjusted Analysis.
    J Med Virol. 2021 Aug 4. doi: 10.1002/jmv.27253.
    >> Share

  616. ABDULAH DM
    ABDULAHPrevalence and correlates of COVID-19 vaccine hesitancy in general public in Iraqi Kurdistan: A cross-sectional study.
    J Med Virol. 2021 Aug 4. doi: 10.1002/jmv.27255.
    >> Share

    July 2021
  617. WERFEL S, Jakob CEM, Borgmann S, Schneider J, et al
    Development and Validation of a Simplified Risk Score for the Prediction of Critical COVID-19 Illness in Newly Diagnosed Patients.
    J Med Virol. 2021 Jul 31. doi: 10.1002/jmv.27252.
    >> Share

  618. UNSALER S, Okan A, Tekin S, Hafiz AM, et al
    Comparison of nasopharyngeal swab and nasopharyngeal aspiration in adults for SARS-CoV-2 identification using reverse transcription-polymerase chain reaction.
    J Med Virol. 2021 Jul 31. doi: 10.1002/jmv.27250.
    >> Share

  619. DESHPANDE K, Pt U, Kaduskar O, Vijay N, et al
    Performance assessment of seven SARS-CoV-2 IgG enzyme linked immunosorbent assays.
    J Med Virol. 2021 Jul 31. doi: 10.1002/jmv.27251.
    >> Share

  620. CASSUTO NG, Gravier A, Colin M, Theillay A, et al
    Evaluation of a SARS-CoV-2 antigen-detecting rapid diagnostic test as a self-test: diagnostic performance and usability.
    J Med Virol. 2021 Jul 31. doi: 10.1002/jmv.27249.
    >> Share

  621. MESSALI S, Bertelli A, Campisi G, Zani A, et al
    A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.
    J Med Virol. 2021 Jul 30. doi: 10.1002/jmv.27247.
    >> Share

  622. GHOLIPOUR E, Vizvari B, Babaqi T, Takacs S, et al
    Statistical analysis of the Hungarian COVID-19 victims.
    J Med Virol. 2021 Jul 29. doi: 10.1002/jmv.27242.
    >> Share

  623. BUTT MH, Safdar A, Amir A, Zaman M, et al
    Arboviral Diseases and COVID-19 Coincidence: Challenges for Pakistan's Derelict Healthcare System.
    J Med Virol. 2021 Jul 29. doi: 10.1002/jmv.27241.
    >> Share

  624. BENOIT P, Labbe AC, Lalancette L, Gagnon S, et al
    Comparison of SARS-CoV-2 detection with the cobas(R) 6800/8800 system on gargle samples using two sample processing methods with combined oropharyngeal/nasopharyngeal swab.
    J Med Virol. 2021 Jul 29. doi: 10.1002/jmv.27245.
    >> Share

  625. ZHANG F, Li W, Feng J, Ramos da Silva S, et al
    SARS-CoV-2 pseudovirus infectivity and expression of viral entry-related factors ACE2, TMPRSS2, Kim-1 and NRP-1 in human cells from respiratory, urinary, digestive, reproductive and immune systems.
    J Med Virol. 2021 Jul 29. doi: 10.1002/jmv.27244.
    >> Share

  626. KARA AA, Boncuoglu E, Kiymet E, Arikan KO, et al
    Evaluation of predictors of severe-moderate COVID-19 infections at children: a review of 292 children.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27237.
    >> Share

  627. WAN Z, Zhao Y, Lu R, Dong Y, et al
    Rapid antigen detection alone may not be sufficient for early diagnosis and/or mass screening of COVID-19.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27236.
    >> Share

  628. KERGET F, Kerget B, Kahraman CY, Araz O, et al
    Evaluation of the relationship between pentraxin 3 (PTX3) rs2305619 (281A/G) and rs1840680 (1449A/G) polymorphisms and the clinical course of COVID-19.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27238.
    >> Share

  629. NAGANO K, Tani-Sassa C, Iwasaki Y, Takatsuki Y, et al
    SARS-CoV-2 R.1 lineage variants prevailed in Tokyo in March 2021.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27240.
    >> Share

  630. BAJ A, Novazzi F, Ferrante FD, Genoni A, et al
    Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27235.
    >> Share

  631. WU B, Zhang H, Wang YC, Tang A, et al
    Sequencing on an imported case in China of COVID-19 Delta variant emerging from India in a cargo ship in Zhoushan, China.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27239.
    >> Share

  632. SAADATIAN-ELAHI M, Amour S, Elias C, Henaff L, et al
    Tobacco smoking and severity of COVID-19: Experience from a hospital-based prospective cohort study in Lyon-France.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27233.
    >> Share

  633. LI XQ, Liu H, Yin HY, Gao WY, et al
    Critical roles of cytokine storm and secondary bacterial infection in acute kidney injury development in COVID-19: A multi-center retrospective cohort study.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27234.
    >> Share

  634. KANEKO S, Kurosaki M, Sugiyama T, Takahashi Y, et al
    The dynamics of quantitative SARS-CoV-2 anti-spike IgG response to BNT162b2 vaccination.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27231.
    >> Share

  635. MORENO-ESCOBAR MC, Feizi P, Podury S, Tandon M, et al
    Acute Cerebellitis following SARS-CoV-2 infection: A Case Report and Review of Literature.
    J Med Virol. 2021 Jul 27. doi: 10.1002/jmv.27232.
    >> Share

  636. LIU T, Chen Z, Xu J
    Epidemiological characteristics and incubation period of SARS-CoV-2 during the 2020-2021 winter pandemic wave in north China: an observational study.
    J Med Virol. 2021 Jul 24. doi: 10.1002/jmv.27226.
    >> Share

  637. REICH N, Lowe CF, Puddicombe D, Matic N, et al
    Repeat virological and serological profiles in hospitalized patients initially tested by nasopharyngeal RT-PCR for SARS-CoV-2.
    J Med Virol. 2021 Jul 23. doi: 10.1002/jmv.27227.
    >> Share

  638. LIN Z, Qing H, Li R, Zheng L, et al
    Evolution Trace of SARS-CoV-2 from January 19 to March 12, 2020 in the United States.
    J Med Virol. 2021 Jul 22. doi: 10.1002/jmv.27225.
    >> Share

  639. SPRENGHOLZ P, Betsch C
    Previous SARS-CoV-2 infection is linked to lower vaccination intentions.
    J Med Virol. 2021 Jul 21. doi: 10.1002/jmv.27221.
    >> Share

  640. SUVVARI TK, Kutikuppala LS, Tsagkaris C, Corriero AC, et al
    Post COVID-19 Complications: Multi-Systemic Approach.
    J Med Virol. 2021 Jul 21. doi: 10.1002/jmv.27222.
    >> Share

  641. UWISHEMA O, Nnagha EM, Chalhoub E, Nchasi G, et al
    Dengue fever outbreak in Cook Island: A rising concern, Efforts, Challenges and Future recommendations.
    J Med Virol. 2021 Jul 21. doi: 10.1002/jmv.27223.
    >> Share

  642. NEISES JZ, Hossain MS, Sultana R, Wanniarachchi KN, et al
    Seroprevalence of SARS-CoV-2 Antibodies Among Rural Healthcare Workers.
    J Med Virol. 2021 Jul 21. doi: 10.1002/jmv.27224.
    >> Share

  643. HATTATOGLU DG, Yildiz BP
    Comparison Of Clinical And Biochemical Features Of Hospitalized COVID-19 And Influenza Pneumonia Patients.
    J Med Virol. 2021 Jul 21. doi: 10.1002/jmv.27218.
    >> Share

  644. CARBONELL-SAHUQUILLO S, Lazaro-Carreno MI, Camacho J, Barres-Fernandez A, et al
    Evaluation of a rapid antigen detection test (Panbio COVID-19 Ag Rapid Test Device) as a point-of-care diagnostic tool for COVID-19 in a Pediatric Emergency Department.
    J Med Virol. 2021 Jul 21. doi: 10.1002/jmv.27220.
    >> Share

  645. UWISHEMA O, Alshareif BAA, Yousif MYE, Omer MEA, et al
    Lassa fever amidst the COVID-19 Pandemic in Africa: A rising concern, Efforts, Challenges and Future recommendations.
    J Med Virol. 2021 Jul 21. doi: 10.1002/jmv.27219.
    >> Share

  646. WENBAN C, Heer RS, Baktash V, Kandiah P, et al
    Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalised Covid-19 patients.
    J Med Virol. 2021 Jul 17. doi: 10.1002/jmv.27215.
    >> Share

  647. NICHOLS L, Thompson M, Bentz GL
    Comparison of clinical characteristics of a patient with Epstein-Barr virus-associated seizure and patients with COVID-19-associated seizure.
    J Med Virol. 2021 Jul 16. doi: 10.1002/jmv.27197.
    >> Share

  648. AL KHAMES AGA QA, Alkhaffaf WH, Hatem TH, Nassir KF, et al
    SAFETY OF COVID-19 VACCINES.
    J Med Virol. 2021 Jul 16. doi: 10.1002/jmv.27214.
    >> Share

  649. LING Y, Zhong J, Luo J
    Safety and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis.
    J Med Virol. 2021 Jul 15. doi: 10.1002/jmv.27203.
    >> Share

  650. ARANHA C, Patel V, Bhor V, Gogoi D, et al
    Cycle threshold values in RT-PCR to determine dynamics of SARS-CoV-2 viral load: An approach to reduce isolation period for COVID-19 patients.
    J Med Virol. 2021 Jul 15. doi: 10.1002/jmv.27206.
    >> Share

  651. ABOBAKER A, Darrat M
    The association between biochemically confirmed thyroid gland disorder and morbidity and mortality in patients with COVID-19.
    J Med Virol. 2021 Jul 14. doi: 10.1002/jmv.27213.
    >> Share

  652. UWISHEMA O, Adanur I, Babatunde AO, Hasan MM, et al
    Viral Infections amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Jul 14. doi: 10.1002/jmv.27211.
    >> Share

  653. PASCARELLA S, Ciccozzi M, Zella D, Bianchi M, et al
    SARS-CoV-2 B.1.617 Indian variants: are electrostatic potential changes responsible for a higher transmission rate?
    J Med Virol. 2021 Jul 14. doi: 10.1002/jmv.27210.
    >> Share

  654. GULEC EY, Cesur NP, Fazlioglu GY, Kazezoglu C, et al
    Effect of Different Storage Conditions on Covid-19 RT-PCR Results.
    J Med Virol. 2021 Jul 14. doi: 10.1002/jmv.27204.
    >> Share

  655. AKDEMIR Y, Haciseyitoglu D, Celebi G, Aydemir C, et al
    Probable viremia and positive placental swabs for SARS-CoV-2 in a preterm pregnant woman with mild COVID-19.
    J Med Virol. 2021 Jul 14. doi: 10.1002/jmv.27202.
    >> Share

  656. OZTURK A, Bozok T, Bozok TS
    Evaluation of Rapid Antibody Test and Chest Computed Tomography Results of COVID-19 Patients: A Retrospective Study.
    J Med Virol. 2021 Jul 14. doi: 10.1002/jmv.27209.
    >> Share

  657. RAHMAN FI, Islam MR, Bhuiyan MA
    Mucormycosis or black fungus infection is a new scare in South Asian countries during COVID-19 pandemic: Associated risk factors and preventive measures.
    J Med Virol. 2021 Jul 14. doi: 10.1002/jmv.27207.
    >> Share

  658. BORGOGNA C, De Andrea M, Griffante G, Lai A, et al
    SARS-CoV-2 re-infection in a cancer patient with a defective neutralizing humoral response.
    J Med Virol. 2021 Jul 14. doi: 10.1002/jmv.27200.
    >> Share

  659. ZHANG S, Ning Y, Rong Y, Nie Y, et al
    Rapid immunoassay and clinical evaluation of the SARS-CoV-2 antibody assay on the Real Express-6 analyzer.
    J Med Virol. 2021 Jul 13. doi: 10.1002/jmv.27201.
    >> Share

  660. KALANTARI S, Fard SR, Maleki D, Taher MT, et al
    Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
    J Med Virol. 2021 Jul 13. doi: 10.1002/jmv.27195.
    >> Share

  661. KAYAASLAN B, Eser F, Kalem AK, Kaya G, et al
    Post-covid Syndrome: A Single-Center Questionnaire Study On 1007 Participants Recovered from COVID-19.
    J Med Virol. 2021 Jul 13. doi: 10.1002/jmv.27198.
    >> Share

  662. ZELLA D, Giovanetti M, Benedetti F, Unali F, et al
    The variants question: what is the problem?
    J Med Virol. 2021 Jul 13. doi: 10.1002/jmv.27196.
    >> Share

  663. ELGENDY MO, Abdelrahim MEA
    Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy.
    J Med Virol. 2021 Jul 13. doi: 10.1002/jmv.27199.
    >> Share

  664. CONTICINI E, D'Alessandro M, Bergantini L, Bargagli E, et al
    Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report.
    J Med Virol. 2021 Jul 12. doi: 10.1002/jmv.27192.
    >> Share

  665. FANG S, Liu S, Shen J, Lu AZ, et al
    Updated SARS-CoV-2 Single Nucleotide Variants and Mortality Association.
    J Med Virol. 2021 Jul 10. doi: 10.1002/jmv.27191.
    >> Share

  666. ABUSREWIL Z, Alhudiri IM, Kaal HH, Meshri SEE, et al
    Time scale performance of rapid antigen testing for SARS-COV-2: evaluation of ten rapid antigen assays.
    J Med Virol. 2021 Jul 9. doi: 10.1002/jmv.27186.
    >> Share

  667. SAHIN E, Bozdayi G, Yigit S, Muftah H, et al
    Genomic Characterization of SARS-CoV-2 Isolates from Patients in Turkey Reveals the Presence of Novel Mutations in Spike and nsp12 Proteins.
    J Med Virol. 2021 Jul 9. doi: 10.1002/jmv.27188.
    >> Share

  668. AFSHAR ZM, Babazadeh A, Hasanpour A, Barary M, et al
    Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge.
    J Med Virol. 2021 Jul 9. doi: 10.1002/jmv.27187.
    >> Share

  669. AKSAKAL A, Kerget B, Kerget F, Askin S, et al
    Evaluation of the relationship between macrophage migration inhibitory factor level and clinical course in patients with COVID-19 pneumonia.
    J Med Virol. 2021 Jul 9. doi: 10.1002/jmv.27189.
    >> Share

  670. SLAVOV SN, Patane JSL, Bezerra RDS, Giovanetti M, et al
    GENOMIC MONITORING UNVEIL THE EARLY DETECTION OF THE SARS-COV-2 B.1.351 (BETA) VARIANT (20H/501Y.V2) IN BRAZIL.
    J Med Virol. 2021 Jul 9. doi: 10.1002/jmv.27190.
    >> Share

  671. ALAY H, Laloglu E
    The Role of Angiopoietin-2 and Surfactant Protein-D Levels in SARS-CoV-2-related lung injury: A prospective, observational, cohort study.
    J Med Virol. 2021 Jul 7. doi: 10.1002/jmv.27184.
    >> Share

  672. TANBOGA IH
    Statistical modelling, dichotomization and non-linearity.
    J Med Virol. 2021 Jul 7. doi: 10.1002/jmv.27183.
    >> Share

  673. SUVVARI TK, Rajesh E, D Silva RG, Corriero AC, et al
    SARS-CoV-2 Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT): Promoting Awareness to Improve Patient-Doctor Trust.
    J Med Virol. 2021 Jul 7. doi: 10.1002/jmv.27176.
    >> Share

  674. SINGH Y, Fuloria NK, Fuloria S, Subramaniyan V, et al
    N-terminal domain of SARS CoV-2 spike protein mutation associated reduction in effectivity of neutralizing antibody with vaccinated individuals.
    J Med Virol. 2021 Jul 7. doi: 10.1002/jmv.27181.
    >> Share

  675. BISTROVIC P, Lucijanic M
    Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with Coronavirus disease 2019 (COVID-19) - the pilot study.
    J Med Virol. 2021 Jul 7. doi: 10.1002/jmv.27177.
    >> Share

  676. YU JL, Hou S, Feng YT, Bu G, et al
    Emergence of a young case infected with avian influenza A (H5N6) in Anhui Province, East China during the COVID-19 pandemic.
    J Med Virol. 2021 Jul 7. doi: 10.1002/jmv.27179.
    >> Share

  677. KUITUNEN I, Artama M, Haapanen M, Renko M, et al
    Rhinovirus spread in children during the COVID-19 pandemic despite social restrictions-a nationwide register study in Finland.
    J Med Virol. 2021 Jul 6. doi: 10.1002/jmv.27180.
    >> Share

  678. SHAHID S, Raza M, Junejo S, Maqsood S, et al
    Clinical Features and Outcome of COVID-19 positive children from a tertiary healthcare Hospital in Karachi.
    J Med Virol. 2021 Jul 6. doi: 10.1002/jmv.27178.
    >> Share

  679. MOUSAVI-ROKNABADI RS, Haddad F, Fazlzadeh A, Kheirabadi D, et al
    Investigation of plasma exchange and hemoperfusion effects and complications for the treatment of patients with severe COVID-19 (SARS-CoV-2) disease: a systematic scoping review.
    J Med Virol. 2021 Jul 6. doi: 10.1002/jmv.27182.
    >> Share

  680. RASHKI A, Hoseinpour Dehkordi A, Nemati R, Tavousi P, et al
    What does COVID-19 Testing Results Really Say? The Real Statistics Concealed Behind the Accessible Data.
    J Med Virol. 2021 Jul 5. doi: 10.1002/jmv.27173.
    >> Share

  681. MARCO C, Sheyda K, Angelo C, Riccardo C, et al
    AstraZeneca (AZD1222) Covid 19 vaccine-associated adverse drug event: a case report.
    J Med Virol. 2021 Jul 2. doi: 10.1002/jmv.27175.
    >> Share

  682. ASGHAR MS, Yasmin F, Dapke K, Phadke R, et al
    Derangements of Biochemical Markers and Thyroid Function Analysis Among COVID-19 Positive Patients: A Developing Country Single-Center Experience.
    J Med Virol. 2021 Jul 2. doi: 10.1002/jmv.27174.
    >> Share

  683. RAMIREZ-HINOJOSA JP, Rodriguez-Sanchez Y, Romero-Gonzalez AK, Chavez-Gutierrez M, et al
    Association between cycle threshold (Ct) values and clinical and laboratory data in inpatients with COVID-19 and asymptomatic health workers.
    J Med Virol. 2021 Jul 1. doi: 10.1002/jmv.27170.
    >> Share

  684. LUKASZEWICZ AC, Venet F, Faure A, Vignot E, et al
    Immunostimulation with Interferon-gamma in protracted SARS-Cov-2 pneumonia.
    J Med Virol. 2021 Jul 1. doi: 10.1002/jmv.27172.
    >> Share

  685. CAMARGO JF, Lin RY, Komanduri KV
    Lack of correlation between the SARS-CoV-2 cycle threshold (Ct) value and clinical outcomes in patients with COVID-19.
    J Med Virol. 2021 Jul 1. doi: 10.1002/jmv.27171.
    >> Share

    June 2021
  686. HASAN MM, Costa ACDS, Xenophontos E, Mohanan P, et al
    Lassa Fever and COVID-19 in Africa: A double crisis on the fragile health system.
    J Med Virol. 2021 Jun 30. doi: 10.1002/jmv.27169.
    >> Share

  687. ABE H, Ushijima Y, Bikangui R, Zoa-Assoumou S, et al
    Unrecognized introduction of SARS-CoV-2 variants of concern to Central Africa: Import and local transmission of B.1.1.7 in Gabon in the very early stage of the variant spread to the African continent.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27164.
    >> Share

  688. IVANOV A, Semenova E
    Long-term monitoring of the development and extinction of IgA and IgG responses to SARS-CoV-2 infection.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27166.
    >> Share

  689. JUSCAMAYTA-LOPEZ E, Carhuaricra D, Tarazona D, Valdivia F, et al
    Phylogenomics reveals multiple introductions and early spread of SARS-CoV-2 into Peru.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27167.
    >> Share

  690. UWISHEMA O, Adriano LF, Torbati T, Onyeaka H, et al
    Measles crisis in Africa amidst the COVID-19 pandemic: Delayed measles vaccine administration may cause a measles outbreak in Africa.
    J Med Virol. 2021 Jun 28. doi: 10.1002/jmv.27150.
    >> Share

  691. BIRD PW, Sandhu K, Fletcher O, Ames B, et al
    Retrospective SARS-CoV-2 IgG screening during the first wave (March-June 2020) of the COVID-19 pandemic in the UK.
    J Med Virol. 2021 Jun 26. doi: 10.1002/jmv.27162.
    >> Share

  692. ABDELRAHMAN MM, Abd-Elrahman NM, Bakheet TM
    Persistence of symptoms after improvement of acute COVID19 infection, a longitudinal study.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27156.
    >> Share

  693. CELIK SK, Genc GC, Piskin N, Acikgoz B, et al
    Polymorphisms of ACE (I/D) and ACE2 Receptor Gene (Rs2106809, Rs2285666) are not Related to the Clinical Course of COVID-19; A Case Study.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27160.
    >> Share

  694. PANDOLFI S, Simonetti V, Ricevuti G, Chirumbolo S, et al
    Paracetamol in the home treatment of early COVID-19 symptoms: A possible foe rather than a friend for elderly patients?
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27158.
    >> Share

  695. MATSUZAKI N, Orihara Y, Kodana M, Kitagawa Y, et al
    Evaluation of a chemiluminescent enzyme immunoassay-based high-throughput SARS-CoV-2 antigen assay for the diagnosis of COVID-19: The VITROS((R)) SARS-CoV-2 Antigen Test.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27153.
    >> Share

  696. KHAN F, Sharma P, Pandey S, Sharma D, et al
    COVID-19-associated Guillain Barre syndrome: Post-infectious alone or neuroinvasive too?
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27159.
    >> Share

  697. TANG CY, Wang Y, McElroy JA, Li T, et al
    Reinfection with two genetically distinct SARS-CoV-2 viruses within 19 days.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27154.
    >> Share

  698. PERCHETTI GA, Zhu H, Mills MG, Shrestha L, et al
    Specific allelic discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B.1.1.7 lineage in Washington State.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27155.
    >> Share

  699. ZENG F, Wu M, Wang J, Li J, et al
    Over one-year duration and age difference of SARS-CoV-2 antibody in convalescent COVID-19 patients.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27152.
    >> Share

  700. DURMAZ B, Abdulmajed O, Durmaz R, Koroglu M, et al
    RESPIRATORY VIRUSES IN HEALTHY MIDDLE EAR AND MIDDLE EAR WITH OTITIS MEDIA WITH EFFUSION.
    J Med Virol. 2021 Jun 23. doi: 10.1002/jmv.27151.
    >> Share

  701. ELEFTHERIOU I, Dasoula F, Dimopoulou D, Lebessi E, et al
    Real-life evaluation of a COVID-19 rapid antigen detection test in hospitalized children.
    J Med Virol. 2021 Jun 22. doi: 10.1002/jmv.27149.
    >> Share

  702. ANGELETTI S, Travaglino F, Spoto S, Pascarella MC, et al
    COVID-19 Sniffer Dog experimental training: which protocol and which implications for reliable identification?
    J Med Virol. 2021 Jun 21. doi: 10.1002/jmv.27147.
    >> Share

  703. POURHOSEINGHOLI MA, Jafari R, Jafari NJ, Rahimi-Bashar F, et al
    Predicting One-year post-COVID-19 mortality based on chest computed tomography scan.
    J Med Virol. 2021 Jun 21. doi: 10.1002/jmv.27146.
    >> Share

  704. ULLAH I, Hassan W, Tahir MJ, Ahmed A, et al
    Antiretrovirals shortage in Kenya amid COVID-19.
    J Med Virol. 2021 Jun 18. doi: 10.1002/jmv.27134.
    >> Share

  705. HIROI S, Kubota-Koketsu R, Sasaki T, Morikawa S, et al
    Infectivity Assay for Detection of SARS-CoV-2 in Samples from Patients with COVID-19.
    J Med Virol. 2021 Jun 17. doi: 10.1002/jmv.27145.
    >> Share

  706. LEI J, Li M, Wang X
    Predicting the development trend of the second wave of COVID-19 in five European countries.
    J Med Virol. 2021 Jun 17. doi: 10.1002/jmv.27143.
    >> Share

  707. PICCHI G, Di Norcia M, Cofini V, Sinatti G, et al
    Laboratory Parameters related to Severe Disease and Death in SARS-CoV-2 Pneumonia: Retrospective Analysis.
    J Med Virol. 2021 Jun 17. doi: 10.1002/jmv.27141.
    >> Share

  708. LUNDSTROM A, Ziegler L, Havervall S, Rudberg AS, et al
    Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.
    J Med Virol. 2021 Jun 17. doi: 10.1002/jmv.27144.
    >> Share

  709. MOHAN A, Temitope RA, Cavdaroglu S, Hasan MM, et al
    Measles returns to the Democratic Republic of Congo: A new predicament amid the COVID-19 crisis.
    J Med Virol. 2021 Jun 17. doi: 10.1002/jmv.27137.
    >> Share

  710. BARUA S, Hoque M, Kelly PJ, Bai J, et al
    High-resolution melting curve FRET-PCR rapidly identifies SARS-CoV-2 mutations.
    J Med Virol. 2021 Jun 17. doi: 10.1002/jmv.27139.
    >> Share

  711. MORENO-PEREZ O, Ramos JM, Gimeno A, Rodriguez JC, et al
    Medium-term serostatus in Spanish case series recovered from SARS-CoV-2 infection.
    J Med Virol. 2021 Jun 17. doi: 10.1002/jmv.27135.
    >> Share

  712. ZHU C, He G, Yin Q, Zeng L, et al
    Molecular biology of the SARs-CoV-2 spike protein: A review of current knowledge.
    J Med Virol. 2021 Jun 14. doi: 10.1002/jmv.27132.
    >> Share

  713. NAKHLBAND A, Fakhari A, Azizi H
    Interferon-alpha position in combating with COVID-19: A systematic review.
    J Med Virol. 2021 Jun 8. doi: 10.1002/jmv.27072.
    >> Share

  714. POON KS, Tee NW
    Detecting SARS-CoV-2 RNA in fecal specimens: The practical challenges.
    J Med Virol. 2021 Jun 8. doi: 10.1002/jmv.27071.
    >> Share

  715. AL-JARALLAH M, Rajan R, Dashti R, Saber AA, et al
    In-hospital Mortality in SARS-CoV-2 stratified by serum 25-Hydroxy-Vitamin D levels: A Retrospective Study.
    J Med Virol. 2021 Jun 7. doi: 10.1002/jmv.27133.
    >> Share

  716. RODRIGUEZ-VIDALES EP, Garza-Carrillo D, Perez-Trujillo JJ, Robles-Rodriguez OA, et al
    PREVALENCE OF IgG ANTIBODIES INDUCED BY THE SARS-COV-2 VIRUS IN ASYMPTOMATIC ADULTS IN NUEVO LEON, MEXICO.
    J Med Virol. 2021 Jun 7. doi: 10.1002/jmv.27131.
    >> Share

  717. KARCIOGLU BATUR L, Hekim N
    Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries.
    J Med Virol. 2021 Jun 3. doi: 10.1002/jmv.27127.
    >> Share

  718. UWISHEMA O, Adriano LF, Chalhoub E, Onyeaka H, et al
    Bird Flu Outbreak Amidst COVID-19 Pandemic in South Africa: Efforts and Challenges at Hand.
    J Med Virol. 2021 Jun 3. doi: 10.1002/jmv.27124.
    >> Share

  719. DEGERLI E, Derin S, Oruc K, Samanci NS, et al
    The Demographic Characteristic, Prognosis and the Relationship with Cancer Subtypes of Hospitalised Covid-19 Patients with Malignancy: A Single-Center Experience.
    J Med Virol. 2021 Jun 3. doi: 10.1002/jmv.27123.
    >> Share

  720. FINSTERER J
    Diagnose SARS-CoV-2 associated Guillain-Barre syndrome upon appropriate criteria and after exclusion of differentials.
    J Med Virol. 2021 Jun 3. doi: 10.1002/jmv.27129.
    >> Share

  721. SINACI S, Ocal DF, Seven B, Anuk AT, et al
    Vertical Transmission of SARS-CoV-2: a prospective cross-sectional study from a tertiary center.
    J Med Virol. 2021 Jun 3. doi: 10.1002/jmv.27128.
    >> Share

  722. BARCHUK A, Shirokov D, Sergeeva M, Tursun Zade R, et al
    Evaluation of the performance of SARS-CoV-2 antibody assays for the longitudinal population-based study of COVID-19 spread in St. Petersburg, Russia: Interpretation.
    J Med Virol. 2021 Jun 3. doi: 10.1002/jmv.27126.
    >> Share

  723. ABD-ELSALAM S, Noor RA, Badawi R, Khalaf M, et al
    Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.
    J Med Virol. 2021 Jun 2. doi: 10.1002/jmv.27122.
    >> Share

  724. NIGAR S, Tanjil Shah SM, Setu MAA, Dip SD, et al
    Relative expression of pro-inflammatory molecules in COVID-19 patients manifested disease severities.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27112.
    >> Share

  725. MOHAN A, Fakhor H, Nimavat N, Wara UU, et al
    Dengue and COVID-19: A risk of coepidemic in Ethiopia.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27116.
    >> Share

  726. YANG Y, Yang P, Huang C, Wu Y, et al
    Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca(2+) -dependent membrane fusion.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27117.
    >> Share

  727. WANG Y, Feng R, Xu J, Hou H, et al
    An updated meta-analysis on the association between tuberculosis and COVID-19 severity and mortality.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27119.
    >> Share

  728. EMMERICH P, von Possel R, Hemmer CJ, Fritzsche C, et al
    Longitudinal detection of SARS-CoV-2-specific antibody responses with different serological methods.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27113.
    >> Share

    May 2021
  729. KARATAS M, Tatar E, Simsek C, Yildirim AM, et al
    COVID-19 pneumonia in kidney transplant recipients: A promising treatment algorithm in the absence of a disease-specific drug.
    J Med Virol. 2021 May 29. doi: 10.1002/jmv.27110.
    >> Share

  730. WOLTERS F, Grunberg M, Huber M, Kessler HH, et al
    European multicenter evaluation of Xpert(R) Xpress SARS-CoV-2/Flu/RSV test.
    J Med Virol. 2021 May 29. doi: 10.1002/jmv.27111.
    >> Share

  731. ABI ZEID DAOU C, Natout MA, El Hadi N
    Biphasic anaphylaxis after exposure to the first dose of Pfizer-BioNTech COVID-19 mRNA vaccine.
    J Med Virol. 2021 May 29. doi: 10.1002/jmv.27109.
    >> Share

  732. BLAIRON L, Cupaiolo R, Thomas I, Piteus S, et al
    Efficacy comparison of three rapid antigen tests for SARS-CoV-2 and how viral load impact their performance.
    J Med Virol. 2021 May 29. doi: 10.1002/jmv.27108.
    >> Share

  733. AKAMA-GARREN EH, Li JX
    Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: a retrospective study of 835 patients.
    J Med Virol. 2021 May 27. doi: 10.1002/jmv.27105.
    >> Share

  734. SOYTAS RB, Cengiz M, Islamoglu MS, Uysal BB, et al
    Does the COVID-19 seroconversion in older adults resemble the young?
    J Med Virol. 2021 May 27. doi: 10.1002/jmv.27106.
    >> Share

  735. GUARIN G, Lo KB, Bhargav R, Salacup G, et al
    Factors Associated with Hospital Readmissions among Patients with COVID-19: A Single Center Experience.
    J Med Virol. 2021 May 27. doi: 10.1002/jmv.27104.
    >> Share

  736. DAO MH, Phan LT, Cao TM, Luong QC, et al
    Genome-wide analysis of SARS-CoV-2 in VietnamGenome-wide analysis of SARS-CoV-2 strains circulating in Vietnam: understanding the nature of the epidemic and role of the D614G mutation.
    J Med Virol. 2021 May 27. doi: 10.1002/jmv.27103.
    >> Share

  737. AGHBASH PS, Eslami N, Shirvaliloo M, Baghi HB, et al
    Viral Co-infections in COVID-19.
    J Med Virol. 2021 May 25. doi: 10.1002/jmv.27102.
    >> Share

  738. BARDAKCI MI, Ozturk EN, Ozkarafakili MA, Ozkurt H, et al
    EVALUATION of LONG TERM RADIOLOGICAL FINDINGS, PULMONARY FUNCTIONS AND HEALTH-RELATED QUALITY OF LIFE IN SURVIVORS OF SEVERE COVID-19.
    J Med Virol. 2021 May 25. doi: 10.1002/jmv.27101.
    >> Share

  739. BAYRAM A, Demirbakan H, Karadeniz PG, Erdogan M, et al
    Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in health care workers.
    J Med Virol. 2021 May 21. doi: 10.1002/jmv.27098.
    >> Share

  740. KERGET B, Kerget F, Aksakal A, Askin S, et al
    Evaluation of the relationship between KIM-1 and suPAR levels and clinical severity in COVID-19 patients: A different perspective on suPAR.
    J Med Virol. 2021 May 21. doi: 10.1002/jmv.27099.
    >> Share

  741. ERDOGAN A, Can FE, Gonullu H
    Evaluation of the prognostic role of NLR, LMR, PLR and LCR ratio in COVID-19 patients.
    J Med Virol. 2021 May 21. doi: 10.1002/jmv.27097.
    >> Share

  742. GAO X, Liu Y, Zou S, Liu P, et al
    Genome-wide screening of SARS-CoV-2 infection-related genes based on the blood leucocytes sequencing dataset of patients with COVID-19.
    J Med Virol. 2021 May 19. doi: 10.1002/jmv.27093.
    >> Share

  743. ABORODE AT, Olofinsao OA, Osmond E, Batubo AP, et al
    Equal Access of COVID-19 Vaccine distribution in Africa: Challenges and Way Forward.
    J Med Virol. 2021 May 19. doi: 10.1002/jmv.27095.
    >> Share

  744. LAPIC I, Segulja D, Rogic D
    Assessment of salivary antibody response to BNT162b2 mRNA COVID-19 vaccination.
    J Med Virol. 2021 May 19. doi: 10.1002/jmv.27096.
    >> Share

  745. REZA S, Corentin D, Te-Din H, Pierre B, et al
    Rapid COVID-19 antigenic tests: Usefulness of a modified method for diagnosis.
    J Med Virol. 2021 May 19. doi: 10.1002/jmv.27094.
    >> Share

  746. PEREZ-GARCIA F, Romanyk J, Gutierrez HM, Ballestero AL, et al
    Comparative evaluation of Panbio and SD Biosensor antigen rapid diagnostic tests for COVID-19 diagnosis.
    J Med Virol. 2021 May 17. doi: 10.1002/jmv.27089.
    >> Share

  747. HUBERT F, Chessa C, Beby-Defaux A, Bourgoin A, et al
    Emergence of the SARS-CoV-2 B.1.1.7 variant observed at the Poitiers University Hospital.
    J Med Virol. 2021 May 17. doi: 10.1002/jmv.27092.
    >> Share

  748. MAHMOUD SA, Ganesan S, Ibrahim E, Thakre B, et al
    Evaluation of six different rapid methods for nucleic acid detection of SARS-COV-2 virus.
    J Med Virol. 2021 May 17. doi: 10.1002/jmv.27090.
    >> Share

  749. MATIASHOVA L, Isayeva G, Shanker A, Tsagkaris C, et al
    COVID-19 vaccination in Ukraine: An update on the status of vaccination and the challenges at hand.
    J Med Virol. 2021 May 17. doi: 10.1002/jmv.27091.
    >> Share

  750. KHO J, Mandal AKJ, Geraldes R, Tuzlali H, et al
    COVID-19 encephalitis and Wernicke's encephalopathy.
    J Med Virol. 2021 May 15. doi: 10.1002/jmv.27088.
    >> Share

  751. WU D, Rao Q, Zhang W
    The natural course of COVID-19 patients without clinical intervention.
    J Med Virol. 2021 May 15. doi: 10.1002/jmv.27087.
    >> Share

  752. ABBAS M, Verma S, Verma S, Siddiqui S, et al
    Association of GSTM1 and GSTT1 gene polymorphisms with COVID-19 susceptibility and its outcome.
    J Med Virol. 2021 May 15. doi: 10.1002/jmv.27076.
    >> Share

  753. VADAKEDATH S, Kandi V, Mohapatra RK, Pinnelli VBK, et al
    Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease-19 (COVID-19): a scoping review.
    J Med Virol. 2021 May 15. doi: 10.1002/jmv.27081.
    >> Share

  754. FINSTERER J, Scorza FA
    Consider differentials before diagnosing SARS-CoV-2 associated Guillain-Barre syndrome.
    J Med Virol. 2021 May 15. doi: 10.1002/jmv.27084.
    >> Share

  755. PEREIRA F, Tosta S, Lima MM, Reboredo de Oliveira da Silva L, et al
    Genomic surveillance activities unveil the introduction of the SARS-CoV-2 B.1.525 variant of interest in Brazil: Case Report.
    J Med Virol. 2021 May 15. doi: 10.1002/jmv.27086.
    >> Share

  756. VIANA-GARCIA A, Pina-Belmonte A, Salavert-Pamblanco S, Atienza-Garcia A, et al
    Multisystemic inflammatory syndrome in a young adult after SARS-CoV2 infection: case report.
    J Med Virol. 2021 May 15. doi: 10.1002/jmv.27083.
    >> Share

  757. GETACHEW B, Tizabi Y
    Vitamin D and COVID-19: Role of ACE2, Age, Gender and Ethnicity.
    J Med Virol. 2021 May 14. doi: 10.1002/jmv.27075.
    >> Share

  758. PUNEET G, Surender K, Sudhan SS
    SARS-CoV-2 prevalence, maternal and perinatal outcomes among pregnant women admitted for delivery: Experience from Covid-19 dedicated maternity hospital in Jammu, Jammu and Kashmir (India).
    J Med Virol. 2021 May 11. doi: 10.1002/jmv.27074.
    >> Share

  759. HUANG C, Jiang Y, Yan J
    Comparative Analyses of ACE2 and TMPRSS2 gene: Implications for the Risk for Which Vertebrate Animals Are Susceptible to SARS-CoV-2.
    J Med Virol. 2021 May 11. doi: 10.1002/jmv.27073.
    >> Share

  760. HENRY BM, Szergyuk I, Oliveira MHS, Lippi G, et al
    Complement levels at admission as a reflection of Coronavirus Disease 19 (COVID-19) severity state.
    J Med Virol. 2021 May 11. doi: 10.1002/jmv.27077.
    >> Share

  761. POURAKBARI B, Mahmoudi S, Mahmoudieh Y, Eshaghi H, et al
    SARS-CoV-2 RNAaemia in children: An Iranian referral hospital-based study.
    J Med Virol. 2021 May 10. doi: 10.1002/jmv.27065.
    >> Share

  762. KESHAVARZ P, Yazdanpanah F, Azhdari S, Kavandi H, et al
    Coronavirus Disease 2019 (COVID-19): A Systematic Review of 133 Children Presented with Kawasaki-like Multisystem Inflammatory Syndrome.
    J Med Virol. 2021 May 10. doi: 10.1002/jmv.27067.
    >> Share

  763. NOVAZZI F, Baj A, Genoni A, Spezia PG, et al
    SARS-CoV-2 B.1.1.7 reinfection after previous COVID-19 in two immunocompetent Italian patients.
    J Med Virol. 2021 May 10. doi: 10.1002/jmv.27066.
    >> Share

  764. HOLZNER C, Pabst D, Anastasiou OE, Dittmer U, et al
    SARS-CoV-2 rapid antigen test: Fast-safe or dangerous? An analysis in the emergency department of an university hospital.
    J Med Virol. 2021 May 9. doi: 10.1002/jmv.27033.
    >> Share

  765. HERNANDEZ MM, Banu R, Shrestha P, Patel A, et al
    RT-PCR/MALDI-TOF mass spectrometry-based detection of SARS-CoV-2 in saliva specimens.
    J Med Virol. 2021 May 8. doi: 10.1002/jmv.27069.
    >> Share

  766. GURSOY B, Surmeli CD, Alkan M, Satici C, et al
    Cytokine Storm in Severe COVID-19 Pneumonia.
    J Med Virol. 2021 May 8. doi: 10.1002/jmv.27068.
    >> Share

  767. DI GIACOMO S, Mercatelli D, Rakhimov A, Giorgi FM, et al
    Preliminary report on SARS-CoV-2 Spike mutation T478K.
    J Med Virol. 2021 May 5. doi: 10.1002/jmv.27062.
    >> Share

  768. EROL SA, Polat N, Akdas S, Ayral PA, et al
    Maternal Selenium Status has Crucial Role on Clinical Outcomes Of Pregnant Women With COVID-19 Infection.
    J Med Virol. 2021 May 5. doi: 10.1002/jmv.27064.
    >> Share

  769. MAK GC, Lau AW, Chan AM, Lam ET, et al
    The surveillance of spike protein for patients with COVID-19 detected in Hong Kong in 2020.
    J Med Virol. 2021 May 5. doi: 10.1002/jmv.27063.
    >> Share

  770. MANGANOTTI P, Bellavita G, Tommasini V, D'Acunto L, et al
    Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathies patients.
    J Med Virol. 2021 May 5. doi: 10.1002/jmv.27061.
    >> Share

  771. ZABOLI E, Majidi H, Alizadeh-Navaei R, Hedayatizadeh-Omran A, et al
    Lymphopenia and lung complications in patients with coronavirus disease-2019 (COVID-19): A retrospective study based on clinical data.
    J Med Virol. 2021 May 4. doi: 10.1002/jmv.27060.
    >> Share

  772. KUITUNEN I
    Influenza season 2020-2021 did not begin in Finland despite the looser social restrictions during the second wave of COVID-19: A nationwide register study.
    J Med Virol. 2021 May 4. doi: 10.1002/jmv.27048.
    >> Share

  773. DE GREEF J, Scohy A, Zech F, Frank A, et al
    Determinants of IgG antibodies kinetics after severe and critical COVID-19.
    J Med Virol. 2021 May 4. doi: 10.1002/jmv.27059.
    >> Share

  774. TANVEER M, Ahmed A, Siddiqui A, Gudi SK, et al
    The mystery of plummeting cases of measles during COVID-19 pandemic in Pakistan: Hidden impact of collateral damage.
    J Med Virol. 2021 May 3. doi: 10.1002/jmv.27045.
    >> Share

  775. CAMOU F, Tinevez C, Beguet-Yachine M, Bellecave P, et al
    Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia.
    J Med Virol. 2021 May 3. doi: 10.1002/jmv.27032.
    >> Share

  776. SAWAL I, Ahmad S, Tariq W, Tahir MJ, et al
    Unequal distribution of COVID-19 vaccine: A looming crisis.
    J Med Virol. 2021 May 3. doi: 10.1002/jmv.27031.
    >> Share

  777. LOPES EN, Fonseca V, Frias D, Tosta S, et al
    Betacoronaviruses genome analysis reveals evolution toward specific codons usage: implications for SARS-CoV-2 mitigation strategies.
    J Med Virol. 2021 May 2. doi: 10.1002/jmv.27056.
    >> Share

  778. PURUT YE, Giray B, Gurbuz E
    Effect of The Coronavirus Pandemic on Tumor Markers.
    J Med Virol. 2021 May 1. doi: 10.1002/jmv.27057.
    >> Share

  779. ZERVOU FN, Louie P, Stachel A, Zacharioudakis IM, et al
    SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
    J Med Virol. 2021 May 1. doi: 10.1002/jmv.27058.
    >> Share

    April 2021
  780. NIANOGO RA, Emeruwa, Gounder P, Manuel V, et al
    Optimal Uses of Pooled Testing for COVID-19 incorporating imperfect test performance and pool dilution effect: An Application to Congregate Settings in Los Angeles County.
    J Med Virol. 2021 Apr 30. doi: 10.1002/jmv.27054.
    >> Share

  781. LEI G, Meng F, Wang C, Yan J, et al
    The breadth of concomitant virological features in a family cluster outbreak of COVID-19 pneumonia.
    J Med Virol. 2021 Apr 30. doi: 10.1002/jmv.27055.
    >> Share

  782. TORRES I, Qualai J, Albert E, Bueno F, et al
    Real-life evaluation of a rapid extraction-free SARS-CoV-2 RT-PCR assay (COVID-19 PCR Fast-L) for the diagnosis of COVID-19.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27039.
    >> Share

  783. HERNANDEZ C, Florez C, Castaneda S, Ballesteros N, et al
    Evaluation of the diagnostic performance of nine commercial RT-PCR kits for the detection of SARS-CoV-2 in Colombia.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27051.
    >> Share

  784. KANG D, Ellgen C, Kulstad E
    Possible Effects of Air Temperature on COVID-19 Disease Severity and Transmission Rates.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27042.
    >> Share

  785. RUSK DS, Strachan CC, Hunter BR
    Lack of Immune Response After mRNA Vaccination to SARS-CoV-2 in a Solid Organ Transplant Patient.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27044.
    >> Share

  786. HAN L, Zhuang MW, Deng J, Zheng Y, et al
    SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27050.
    >> Share

  787. AGHAJANI MH, Moradi O, Amini H, Tehrani HA, et al
    Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27053.
    >> Share

  788. LEACH S, Harandi AM, Bergstrom T, Andersson LM, et al
    Comparable endemic coronavirus nucleoprotein-specific antibodies in mild and severe Covid-19 patients.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27038.
    >> Share

  789. EID E, Abdullah L, Kurban M, Abbas O, et al
    Herpes Zoster emergence following mRNA COVID-19 Vaccine.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27036.
    >> Share

  790. FENOGLIO D, Dentone C, Parodi A, Di Biagio A, et al
    Characterization of T lymphocytes in severe COVID-19 patients.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27037.
    >> Share

  791. OBANDO-PEREDA G
    Can molecular mimicry explain the cytokine storm of SARS-CoV-2?: an in silico approach.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27040.
    >> Share

  792. GILLEZEAU C, Alpert N, Caltabiano M, Flores R, et al
    Informing the Global COVID-19 Response by Estimating Excess Deaths in Italy During the COVID-19 and 1918 Influenza Pandemics.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27052.
    >> Share

  793. BEST JH, Kong AM, Kaplan-Lewis E, Brawley OW, et al
    Treatment Patterns in US Patients Hospitalized With COVID-19 and Pulmonary Involvement.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27049.
    >> Share

  794. LEE J, Song JU
    Diagnostic accuracy of the Cepheid Xpert Xpress and the Abbott ID NOW assay for rapid detection of SARS-CoV-2: A systematic review and meta-analysis.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.26994.
    >> Share

  795. DUBEY A, Kotnala G, Mandal TK, Sonkar SC, et al
    Evidence of presence of SARS-CoV-2 virus in atmospheric air and surfaces of dedicated COVID hospital.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27029.
    >> Share

  796. CAKIR B
    "Development and Validation of Clinical Prediction Models to Estimate the Probability of Death in Hospitalized Patients with COVID-19: Insights from a Nationwide Database".
    J Med Virol. 2021 Apr 23. doi: 10.1002/jmv.27030.
    >> Share

  797. CAVDAROGLU S, Hasan MM, Mohan A, Xenophontos E, et al
    The spread of Yellow fever amidst the COVID-19 pandemic in Africa and the ongoing efforts to mitigate it.
    J Med Virol. 2021 Apr 19. doi: 10.1002/jmv.27027.
    >> Share

  798. MENDES CORREA MC, Leal FE, Villas Boas LS, Witkin SS, et al
    Prolonged presence of replication-competent SARS-CoV-2 in mildly symptomatic individuals: A Report of 2 Cases.
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27021.
    >> Share

  799. WILSON JM, Platts Mills TAE, Keshavarz B
    Reply to: The antibody response to the glycan alpha-Gal correlates with COVID-19 symptoms.
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27022.
    >> Share

  800. AKCAY N, Menetoglu ME, Bektas G, Sevketoglu E, et al
    Axonal Guillain-Barre syndrome associated with SARS-CoV-2 infection in a child.
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27018.
    >> Share

  801. HEMIDA MG, Alhammadi M, Almathen F, Alnaeem A, et al
    Exploring the potential roles of some rodents in the transmission of the Middle East respiratory syndrome coronavirus.
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27023.
    >> Share

  802. LABBE AC, Benoit P, Pare SG, Coutlee F, et al
    Comparison of saliva with oral and nasopharyngeal swabs for SARS-CoV-2 detection on various commercial and laboratory developed assays.
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27026.
    >> Share

  803. SIDDIQUI A, Ahmed A, Tanveer M, Arshad A, et al
    The crux of Pakistan's prolonged rabies vaccine shortage: a rising mortal threat in the COVID-19 pandemic.
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27024.
    >> Share

  804. ISHACK S, Lipner SR
    Bioinformatics and Immunoinformatics to Support COVID-19 Vaccine Development.
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27017.
    >> Share

  805. MURALIDAR S, Gopal G, Ambi SV
    Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27019.
    >> Share

  806. ALI Z, Sarwar M, Ansar S, Awan UA, et al
    COVID-19 vaccination hesitancy in patients with autoimmune diseases: A mystery that needs an immediate solution!
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27014.
    >> Share

  807. SHENG H, Wu L, Wu T, Peng B, et al
    Network Dynamic Model of Epidemic Transmission Introducing a Heterogeneous Control Factor.
    J Med Virol. 2021 Apr 14. doi: 10.1002/jmv.27025.
    >> Share

  808. GARCIA-CALAVARO C, Paternina-Caicedo A, Smith AD, Harrison LH, et al
    Covid-19 mortality needs age adjusting for international comparisons.
    J Med Virol. 2021 Apr 10. doi: 10.1002/jmv.27007.
    >> Share

  809. COSTA ACDS, Hasan MM, Xenophontos E, Mohanan P, et al
    COVID-19 And Zika: An emerging dilemma for Brazil.
    J Med Virol. 2021 Apr 10. doi: 10.1002/jmv.27006.
    >> Share

  810. TAHIR M
    Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target.
    J Med Virol. 2021 Apr 10. doi: 10.1002/jmv.27009.
    >> Share

  811. RAPP JL, Tremblay D, Alpert N, Lieberman-Cribbin W, et al
    Red Cell Distribution Width is Associated with Mortality in Non-Anemic Patients with COVID-19.
    J Med Virol. 2021 Apr 10. doi: 10.1002/jmv.27011.
    >> Share

  812. ALI KM, Ali AM, Tawfeeq HM, Figueredo G, et al
    Hypoalbuminemia in Patients Following Their Recovery from Severe Coronavirus Disease 2019.
    J Med Virol. 2021 Apr 8. doi: 10.1002/jmv.27002.
    >> Share

  813. NAEMI FMA, Al-Adwani S, Al-Khatabi H, Al-Nazawi A, et al
    Association between the HLA genotype and the severity of COVID-19 infection among South Asians.
    J Med Virol. 2021 Apr 8. doi: 10.1002/jmv.27003.
    >> Share

  814. WAN XF, Tang CY, Ritter D, Wang Y, et al
    SARS-CoV-2 show no infectivity at later stages in a prolonged COVID-19 patient despite positivity in RNA testing.
    J Med Virol. 2021 Apr 8. doi: 10.1002/jmv.27001.
    >> Share

  815. NASIR N, Rehman F, Omair SF
    Article title: Risk factors for bacterial infections in patients with moderate to severe COVID-19: A case control study.
    J Med Virol. 2021 Apr 6. doi: 10.1002/jmv.27000.
    >> Share

  816. KADALI RAK, Janagama R, Peruru S, Gajula V, et al
    Adverse effects of COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.
    J Med Virol. 2021 Apr 6. doi: 10.1002/jmv.26996.
    >> Share

  817. RANI PR, Imran M, Lakshmi JV, Jolly B, et al
    Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26997.
    >> Share

  818. FUKUDA Y, Homma T, Inoue H, Onitsuka C, et al
    Downregulation of type III interferons in patients with severe COVID-19.
    J Med Virol. 2021 Apr 3. doi: 10.1002/jmv.26993.
    >> Share

  819. MOVAHED SMM, Akhavizadegan H, Dolatkhani F, Nejadghaderi SA, et al
    Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: a retrospective study.
    J Med Virol. 2021 Apr 1. doi: 10.1002/jmv.26992.
    >> Share

  820. KUMAR A, Sahu A, Kaushik J, Arora A, et al
    Unilateral sub-macular hemorrhage- novel presentation of COVID-19 infection.
    J Med Virol. 2021 Apr 1. doi: 10.1002/jmv.26991.
    >> Share

    March 2021
  821. CINGOLANI V
    Hypothesis of Zinc Ascorbate as best zinc ionophore for raising anti-viral resistance against Covid-19.
    J Med Virol. 2021 Mar 31. doi: 10.1002/jmv.26989.
    >> Share

  822. PHADKE R, Mohan A, Cavdaroglu S, Dapke K, et al
    Dengue amidst COVID-19 in India: The mystery of plummeting cases.
    J Med Virol. 2021 Mar 31. doi: 10.1002/jmv.26987.
    >> Share

  823. CALLEGARO A, Borleri D, Farina C, Napolitano G, et al
    Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.
    J Med Virol. 2021 Mar 31. doi: 10.1002/jmv.26982.
    >> Share

  824. SEITZ T, Schindler S, Winkelmeyer P, Zach B, et al
    Evaluation of rapid antigen tests based on saliva for the detection of SARS-CoV-2.
    J Med Virol. 2021 Mar 31. doi: 10.1002/jmv.26983.
    >> Share

  825. LAMPEJO DT
    Remdesivir for the treatment of COVID-19 in pregnancy.
    J Med Virol. 2021 Mar 31. doi: 10.1002/jmv.26986.
    >> Share

  826. MATSUDA EM, de Campos IB, de Oliveira IP, Colpas DR, et al
    Field evaluation of COVID-19 antigen tests versus RNA based detection: Potential lower sensitivity compensated by immediate results, technical simplicity and low cost.
    J Med Virol. 2021 Mar 31. doi: 10.1002/jmv.26985.
    >> Share

  827. BOUAYED J, Bohn T
    The link between microglia and the severity of COVID-19: the 'two-hit' hypothesis.
    J Med Virol. 2021 Mar 31. doi: 10.1002/jmv.26984.
    >> Share

  828. GUNDUZ A, Firat M, Turkoglu G
    Comparison of the Simultaneous Conjunctiva and Oropharynx-Nasopharynx Swab Results in Patients Applying to the SARS-CoV-2 Outpatient Clinic for the First Time.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26981.
    >> Share

  829. SPAGNOLELLO O, Pierangeli A, Cedrone MC, Di Biagio V, et al
    Viral Community Acquired Pneumonia at the Emergency Department: Report From the Pre COVID-19 Age.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26980.
    >> Share

  830. CHRISTOS P, Vasiliki V
    A reduction of the number of assays and turnaround time by optimizing Polymerase Chain Reaction (PCR) pooled testing for SARS-CoV-2.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26972.
    >> Share

  831. BERAN A, Zink E, Mhanna M, Abugharbyeh A, et al
    Transmissibility and viral replication of SARS-COV-2 in immunocompromised patients.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26970.
    >> Share

  832. UGINET M, Breville G, Assal F, Lovblad KO, et al
    COVID-19 encephalopathy: clinical and neurobiological features.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26973.
    >> Share

  833. REHMAN HA, Ramzan F, Basharat Z, Shakeel M, et al
    Comprehensive Comparative Genomic and Microsatellite Analysis of SARS, MERS, BAT-SARS and COVID-19 Coronaviruses.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26974.
    >> Share

  834. EISEN AKA, Gularte JS, Demoliner M, de Abreu Goes Pereira VM, et al
    Low circulation of Influenza A and coinfection with SARS-CoV-2 among other respiratory viruses during the COVID-19 pandemic in a region of southern Brazil.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26975.
    >> Share

  835. HAFEEZ S, Din M, Zia F, Ali M, et al
    Emerging concerns regarding COVID-19; second wave and new variant.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26979.
    >> Share

  836. TORTAJADA C, Anon S, Ortiz MM, Andreu-Ballester JC, et al
    Interferon beta-1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26976.
    >> Share

  837. RONAN G, Kumar L, Davey M, O'Leary C, et al
    Factors associated with SARS-CoV-2 infection in patients attending an acute hospital ambulatory assessment unit.
    J Med Virol. 2021 Mar 26. doi: 10.1002/jmv.26966.
    >> Share

  838. WOLF JM, Streck AF, Fonseca A, Ikuta N, et al
    Dissemination and evolution of SARS-CoV-2 in the early pandemic phase in South America.
    J Med Virol. 2021 Mar 25. doi: 10.1002/jmv.26967.
    >> Share

  839. VALDESPINO-VAZQUEZ MY, Helguera-Repetto CA, Leon-Juarez M, Villavicencio-Carrisoza O, et al
    Fetal and placental infection with SARS-CoV-2 in early pregnancy.
    J Med Virol. 2021 Mar 25. doi: 10.1002/jmv.26965.
    >> Share

  840. TANG JW, Bialasiewicz S, Dwyer DE, Dilcher M, et al
    Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic.
    J Med Virol. 2021 Mar 24. doi: 10.1002/jmv.26964.
    >> Share

  841. NAKAMURA A, Ando S, Endo H, Sato R, et al
    Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers in a non-epidemic region, Japan: A hospital-based study on May, 2020.
    J Med Virol. 2021 Mar 24. doi: 10.1002/jmv.26962.
    >> Share

  842. MALHOTRA V, Basu S, Sharma N, Kumar S, et al
    Outcomes among 10,314 hospitalized COVID-19 patients at a tertiary care government hospital in Delhi, India.
    J Med Virol. 2021 Mar 23. doi: 10.1002/jmv.26956.
    >> Share

  843. MANSUY JM, Bourcier M, Tremeaux P, Dimeglio C, et al
    COVID-19 pandemic period, where are the seasonal viruses?
    J Med Virol. 2021 Mar 23. doi: 10.1002/jmv.26959.
    >> Share

  844. CHAKRABARTI S, Chakrabarti SS, Kaur U, Agrawal BK, et al
    Cross-immunity and trained immunity in explaining variable COVID-19 mortality- guidance for future pandemics.
    J Med Virol. 2021 Mar 23. doi: 10.1002/jmv.26958.
    >> Share

  845. RABIU AT, Mohan A, Cavdaroglu S, Xenophontos E, et al
    Dengue and COVID-19: A double burden to Brazil.
    J Med Virol. 2021 Mar 23. doi: 10.1002/jmv.26955.
    >> Share

  846. HANNA HUANG Y, Huang JT
    Use of Chlorhexidine to Eradicate Oropharyngeal SARS-CoV-2 in COVID-19 Patients.
    J Med Virol. 2021 Mar 23. doi: 10.1002/jmv.26954.